

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Potentially inappropriate prescriptions and omissions in pediatrics: detection by POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) in the emergency unit and in the ambulatory setting.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019186
Article Type:	Research
Date Submitted by the Author:	16-Aug-2017
Complete List of Authors:	Berthe-Aucejo, Aurore; Hopital Universitaire Robert Debre, Pharmacy department Nguyen, Phuong Khanh Hoang; Hopital Universitaire Robert Debre, Department of Pharmacy Angoulvant, François; Hopital universitaire Necker-Enfants malades, Emergency unit; INSERM, U1123 Bellettre, Xavier; Hopital Universitaire Robert Debre, Emergency unit Albaret, Patrick; Albaret Pharmacy Weil, Thomas; Hopital Universitaire Robert Debre, Department of Pharmacy Boulkedid, Rym; Hopital Universitaire Robert Debre, Clinical Epidemiology unit; INSERM, U1123 Bourdon, Olivier; Hopital Universitaire Robert Debre, Department of pharmacy; Universite Paris Descartes, Clinical Pharmacy Prot-Labarthe, Sonia; Hopital Universitaire Robert Debre, Department of Pharmacy; INSERM, U1123
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	General practice / Family practice
Keywords:	inappropriate prescription, omission, tool, detection

SCHOLARONE™  
Manuscripts

1  
2  
3 **Potentially inappropriate prescriptions and omissions in pediatrics: detection by POPI**  
4 **(Pediatrics: Omission of Prescription and Inappropriate prescription) in the emergency**  
5 **unit and in the ambulatory setting.**  
6

7  
8 A. Berthe-Aucejo<sup>1</sup>, H.P.K Nguyen<sup>1</sup>, F. Angoulvant<sup>2,3</sup>, X. Bellettre<sup>4</sup>, P. Albaret<sup>5,6</sup>, T. Weil<sup>1</sup>, R.  
9 Boulkedid<sup>3,7</sup>, O. Bourdon<sup>1,6,8,9</sup>, S.Prot-Labarthe<sup>1,3,9</sup>  
10  
11  
12  
13  
14  
15

16 <sup>1</sup> Department of Pharmacy, Robert-Debré Hospital, Paris, France

17  
18 <sup>2</sup> Emergency unit, Necker Hospital, Paris, France

19  
20  
21 <sup>3</sup> U1123, INSERM ECEVE, Paris, France

22  
23  
24 <sup>4</sup> Emergency unit AP-HP, Robert-Debré Hospital, Paris, France

25  
26 <sup>5</sup> Albaret Pharmacy, Cesson, France

27  
28  
29 <sup>6</sup> Clinical Pharmacy, Paris Descartes University, Paris, France

30  
31  
32 <sup>7</sup> Clinical Epidemiology Unit, Robert-Debré Hospital, Paris, France

33  
34  
35 <sup>8</sup> Laboratoire Educations et Pratiques de Santé, Paris XIII University, Bobigny, France

36  
37 <sup>9</sup> Groupe Pédiatrie de la Société Française de Pharmacie Clinique, Paris, France  
38  
39  
40

41 **Word count : 2628**

42  
43  
44 **Corresponding author**

45  
46  
47 Dr Aurore Berthe-Aucejo, Service Pharmacie, AP-HP Hôpital Robert-Debré, 48 Boulevard  
48 Sérurier, 75019 Paris, Fax: 01-40-03-24-81, Tel: 01-40-03-57-41, Email:  
49 [aurore.berthe@aphp.fr](mailto:aurore.berthe@aphp.fr)  
50

51  
52  
53 **Keywords**

54  
55  
56 Inappropriate prescription, omission, tool, detection  
57  
58  
59  
60

## ABSTRACT

**Background and Objective:** POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) is the first tool of detection for potentially inappropriate medicines (PIM) and potentially prescribing omissions (PPO) in pediatrics. The aim of this study was to evaluate the prevalence of PIM and PPO detected by POPI regarding issuing of prescription in hospital and outpatient care. The second objective is to determine the risk factors related to PIM.

**Design:** A retrospective and descriptive study was conducted in the emergency department (ED) and community pharmacy (CP) from 1 October 2014 and 31 March 2015. POPI was used to identify inappropriate prescriptions and omissions.

**Setting:** Robert-Debré Hospital (AP-HP, France) and Albaret community pharmacy (Seine and Marne)

**Participants:** Inclusion criteria included patients who were under 18 years old and who had one medicine prescription between 1<sup>st</sup> October 2014 and 31<sup>st</sup> March 2015. Exclusion criteria consisted of inaccessible medical records for patients consulted in ED and prescription without drugs for outpatients.

**Primary and secondary outcome measures:** PIM and PPO rate, PIM risk factors

**Results:** A total of 18.562 prescriptions for 15.973 patients at the ED and 4.780 prescriptions for 2.225 patients at the CP were analyzed. The PIM rate and PPO rate were respectively 3.3% and 2.6% at the ED and 26.4% and 13.2% at the CP. Respiratory and digestive diseases had the highest rate of PIM in hospital and community pharmacy. Multivariate analysis showed that children aged between 2 and 6 years (OR=2.4; IC 1.9-2.9;  $p<0.001$ ) and prescriptions issued from outpatient care (OR=5.2, 95% confidence interval (CI) 5.0-6.5,  $p<0.001$ ) correlated with a higher risk of PIM.

**Conclusion:** This study is the first to observe the prevalence of PIM and PPO detecting by POPI in a pediatric population. A prospective and multicenter study should be conducted to evaluate its impact and benefit in clinical practice.

### Strengths and limitations of this study

- This study is the first to observe the prevalence of PIM and PPO in a pediatric population. The inappropriate prescription rate and omission rate were respectively 3.3% and 2.6% at the emergency unit and 26.4% and 13.2% at the community pharmacy.
- It is a retrospective and monocentric study. Our result in the hospital could be underestimated.
- Ambulatory prescription and the group age between two and six years were associated with a higher risk of inappropriate prescribing.
- Our study showed that there are many criteria which could be detected without access to clinical information and that they are easy to identify.

## INTRODUCTION

Inappropriate prescribing is a known preventable cause of adverse drug events (ADE) and has an important impact on public health and cost of care.[1,2] Incidence of hospitalization due to ADE was 42.8% according to a French survey in 2009.[3] The World Health Organization estimated that 50% of medications are prescribed and utilized inappropriately.[4] The most recent definition of inappropriate prescription (IP) encompasses potentially inappropriate medicines (PIM) and prescribing omissions (PPO).[5] In a report from the French National Authority for Health, PIMs are defined as “drugs being used in a situation in which the risks involved in treatment potentially outweigh the benefits, lack of indication demonstrated, high risk of ADE, and an unfavorable cost-effect or risk-benefit ratio exists”. PPO or underuse of appropriate medication is defined as the absence of initiation of an effective treatment in subjects with a condition for which one or several drug classes have demonstrated their efficacy [6]. In an elderly population, which presents with age-related physiological changes and high prevalence of polypharmacy, various measures have been developed to detect PIM such as: Beers’ criteria, the Inappropriate Prescribing in the Elderly Tool, The Medication Appropriate Index, and STOPP/START (Screening Tool of Older Person’s prescriptions/Screening Tool to Alert doctor to Right Treatment).[7–11] Only the STOPP/START enables us to detect under-prescribing.[5] Using these tools, many studies have been carried out which have detected that inappropriate prescriptions are issued to between 35% and 51% of this population.[12–16] Omission prescriptions in geriatric population detected by START tool concerned between 58%-61% of patients.[5,17] Negative outcomes related to an IP such as side effects, hospitalization, mortality and utilization of resources were also demonstrated.[1,11,18–20]

1  
2  
3 Prescribing in a pediatric population is always a challenge for physician. It is often empirical  
4 and primarily based on safety and pharmacology information obtained in adults.[21] This is a  
5 worry not only in a hospital or general practitioner setting but also for the community  
6 pharmacists. They may only be able to check information and resources or even dispense  
7 infrequently for this vulnerable population.[22] Medication errors were identical in adults and  
8 children but side effects were three time more common in the pediatric population. This  
9 frequency was explained by the vulnerability of young people, pharmacokinetic changes  
10 during childhood and pediatric off-label drug used.[23,24] In order to improve the correct  
11 drug use and optimize practice, the first tool of detection for PIM and PPO was created by  
12 Prot-Labarthe *et al.* in 2013. The tool was named POPI (Pediatrics: Omission of Prescriptions  
13 and Inappropriate prescriptions) (Appendix1).[25,26] Presently, the complete tool has not  
14 been tested in actual practice and the prevalence of PIM and OP is not known.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30 Our aim is to evaluate the prevalence of PIM and PPO detected by POPI. This was its first  
31 application, regarding issuing of prescriptions in hospital and outpatient care. The second  
32 objective is to determine the risk factors related to PIM.

## 33 34 35 36 37 38 **METHODS**

### 39 40 41 **Population**

42  
43  
44 A retrospective and descriptive study was conducted in the emergency department (ED) of  
45 Robert-Debré hospital (Paris) - the largest French pediatric hospital- and the Albaret  
46 community pharmacy (Seine and Marne). Inclusion criteria included patients who were under  
47 18 years old and who had one medicine prescription between 1<sup>st</sup> October 2014 and 31<sup>st</sup> March  
48 2015. Exclusion criteria consisted of inaccessible medical records for patients consulted in ED  
49 and prescription without drugs for outpatients.

## Data collection

The prescriptions given while leaving emergency department were extracted from the software Urqual V5<sup>®</sup> (\*) (McKesson Corp, Paris, France). Urqual<sup>®</sup> is an emergency prescription software which is used in many French hospitals. Patient information including age, sex, weight, medicine prescription and current diagnosis was collected. Medical histories and clinical examinations were consulted individually when necessary. Due to the significant amount of data, clinical files of ED were analyzed, based on primary diagnosis. Assessable criteria in the retrospective study in hospital were identified by the symbol « \* » in appendix 1.

Data from the community pharmacy were obtained from the pharmacy management software OPUS<sup>®</sup> (Computer PG, France). Patient's age and drugs prescribed were collected. Clinical case records and sex were not available in pharmacy as this was a retrospective analysis, so only drugs that did not require assessment of diagnosis (for example Domperidone, Metoclopramide etc.) were analyzed. These criteria were denoted by the symbol « ° » in appendix 1.

Pathologies analyzed by POPI were the same in emergency department and in community.

## Statistical analysis

Categorical variables comprised percentages and numbers. Quantitative variables (age, number of prescriptions by patient, number of medications per prescription, comprised the mean, minimum and maximum standard deviation (SD) for parametric variables; the median and interquartile range for non-parametric variables. Influence factors for PIM according to POPI were determined by the model of logistic regression: univariate analysis and then multi-



variate analysis (using adolescents as a reference). We presented the results with their odds ratios (OR) and their 95% confidence intervals (CI). Statistical significance was established at  $p < 0.05$ . SPSS-22<sup>®</sup> software (SPSS Inc., Chicago, IL, USA) was used for analysis.

This project was approved by the local research ethics committee (n°2015/218).

## RESULTS

In the emergency department, 18 562 prescriptions for 15 973 patients consulted were analyzed. Among them, 29% had at least two visits in 6 months. In the community pharmacy, 4 780 prescriptions for 2 225 patients were evaluated (Figure 1). In total, 53% of patients had been issued with one prescription, 21% with two and 26% with more than three prescriptions. The population's characteristics and the frequency of pathologies were presented in table 1. Distribution of number of prescriptions by age category was described in the figure 2.

**Table 1. Characteristics of the study population**

Population characteristics	Hospital (N=15 973)		Community (N=2 225)
Age* (years)	4.9 ± 4.5 (0-18)		7.9 ± 5.3 (0-18)
Female gender (%)	54.9%		NA
Number of prescriptions/patient*	1.4 ± 0.9 (1-12)		2.2 ± 1.9 (1-16)
Medications/prescriptions*	NA		2.4 ± 1.6 (1-22)
Number of prescriptions by pathology			
Digestive disorders <sup>°</sup>	2728	(14.7%)	NA
ENT-Pulmonary disorders <sup>°</sup>	8397	(45.2%)	NA
Dermatological disorders <sup>°</sup>	604	(3.3%)	NA

Neuropsychiatric disorders <sup>°</sup>	242	(1.3%)	NA
Various illnesses <sup>°,#</sup>	6591	(35.5%)	NA

NA: Not available; ENT: ear, nose and throat

\* Mean  $\pm$  standard deviation (Minimum – Maximum)

<sup>°</sup> Percentage calculated from 18 562 hospital prescriptions

<sup>#</sup> For example, traumatic injury, pain, sickle cell disease

In hospital, POPI tools identified 541 PIM in 2.9% of the prescriptions analyzed. They were detected in 3.3% of the patients (n=530). In the community, PIM represented 12.3% of all prescriptions, affecting 26.4% patients (Table 2).

**Table 2. Potentially inappropriate medications (PIMs) identified by POPI**

	Hospital		Community	
	N (%)		N (%)	
No. of PIM identified per prescription *				
1	519	(2.8%)	551	(11.5%)
2	11	(0.1%)	37	(0.8%)
No. of prescriptions with at least one PIM *	530	(2.9%)	588	(12.3%)
No. of patients with at least one PIM <sup>°</sup>	530	(3.3%)	588	(26.4%)

\* Percentage calculated from 18 562 prescriptions at hospital and 4 780 prescriptions in the community.

<sup>°</sup> Percentage calculated from 15 793 patients at hospital and 2 225 patients in the community.

No.: Number

Details of PIM detected were presented in Table 3 for ED and in Table 4 for community pharmacy. Respiratory and digestive diseases had the highest rate of PIM in hospital and community pharmacy. For various illnesses, we removed one criterion involving medicines containing codeine because of their new contraindication in children under 12 years old [27]. However, the prescription of codeine was observed in 18 cases. According to our comparison

of PIMs detectable in both settings, out-of-hospital medication always presents with a higher prevalence of PIMs.

**Table 3. Most frequently PIMs and PPO identified by POPI in hospital**

Criteria		No. of PIMs and PPO	No. of case analyzed	%
<b>Potentially inappropriate medications (PIMs)</b>		<b>541</b>	<b>7 304</b>	<b>7.4%</b>
<b>Various illnesses</b>		<b>3</b>	<b>64</b>	<b>4.6%</b>
AI-6	Opiates to treat migraine attacks	3	64	4.6%
<b>Digestives disorders</b>		<b>56</b>	<b>1 977</b>	<b>2.8%</b>
EI-2	Domperidone	28	1 956	1.4%
FI-3	The use of Diosmectite (Smecta <sup>®</sup> ) in combination with another medication	27	1 956	1.4%
EI-1	Metoclopramide	1	1 956	0.05%
<b>ENT-Pulmonary disorders</b>		<b>472</b>	<b>5 163</b>	<b>9.1%</b>
II-4	Antibiotics to treat acute suppurative otitis media etc.	2	7	28.6%
II-2	Antibiotic treatment for a sore throat, without a positive RDT.	23	160	14.4%
II-9	Ear drops in the event of acute otitis media	86	1 083	7.9%
HI-1	Beta2 agonist, corticosteroids to treat an infant's first case of bronchiolitis	25	386	6.4%
II-5	Corticosteroids to treat acute suppurative otitis media etc.	190	3 616	5.2%
II-1	An antibiotic other than amoxicillin as a first-line treatment.	59	1 259	4.7%
JI-1	H1-antagonist to treat asthma	9	802	1.1%
II-8	Tenoate Etanolamine (Rhinotrophy <sup>®</sup> ) and other nasal antiseptics	21	2 455	0.8%
II-3	Antibiotics for nasopharyngitis	26	3 444	0.7%
GI-3	Alimemazine (Theralene <sup>®</sup> ), oxomemazine (Toplexil <sup>®</sup> ) etc.	18	2 585	0.7%
JI-2	Cough suppressants to treat asthma	5	802	0.6%
HI-2	H1-antagonists, cough suppressants etc. to treat bronchiolitis	2	386	0.5%
II-7	H1-antagonists with sedative or atropine-like effects.	4	2 585	0.2%
GI-2	Mucolytics drugs, mucokinetics drugs or helicidine before 2 years of age	1	2 585	< 0.1%
II-6	Nasal or oral decongestant etc.	1	2 455	< 0.1%
<b>Dermatological disorders</b>		<b>10</b>	<b>100</b>	<b>10%</b>
OI-1	A combination of locally applied and orally administered antibiotics	9	32	28.1%
PI-2	Topical agents containing acyclovir administered to a	1	68	1.5%

	child under six years of age			
<b>Potentially Prescribing Omissions (PPO)</b>		<b>425</b>	<b>4 508</b>	<b>9.4%</b>
<b>Digestives disorders</b>		<b>372</b>	<b>1 956</b>	<b>19.0%</b>
EO-1	Oral rehydration solution in the event of vomiting	135	313	43.1%
FO-1	Oral rehydration solution in the event of diarrhea	237	1 643	14.4%
<b>ENT-Pulmonary disorders</b>		<b>52</b>	<b>1 469</b>	<b>3.5%</b>
HO-1	0.9% NaCl to relieve nasal congestion etc.	38	386	9.8%
IO-2	Paracetamol combined with antibiotic treatment for ear infections etc.	14	1 083	1.3%
<b>Dermatological disorders</b>		<b>1</b>	<b>3</b>	<b>33.3%</b>
NO-2	Griseofulvin taken during a meal containing a moderate amount of fat	1	3	33.3%

ENT: ear, nose and throat; No: Number; RDT: Rapid diagnostic test.

% Percentage calculated by the number of PIMs or PPO detected from the total number of analyzable cases

**Table 4. Most frequently occurring PIMs and PPOs identified by POPI in community setting**

Criteria		N	%
<b>Potentially inappropriate medications (PIMs)</b>		<b>591</b>	
<b>Various illnesses</b>		<b>15</b>	<b>2.5%</b>
AI-5	Oral solutions of ibuprofen administered in more than 3 doses etc.	7	1.2%
CI-1	Fluoride supplements prescribed to infants under six months of age	5	0.8%
AI-4	The combined use of two NSAIDs	3	0.5%
<b>Digestives disorders</b>		<b>201</b>	<b>34%</b>
EI-2	Domperidon	152	25.7%
FI-3	The use of Diosmectite (Smecta <sup>®</sup> ) in combination with another medication	35	5.9%
FI-5	Intestinal antiseptics	9	1.5%
EI-1	Metoclopramide	2	0.3%
EI-6	The use of type H2 antihistamines for long periods of treatment	2	0.3%
FI-1	Loperamide before 3 years of age	1	0.2%
<b>ENT-Pulmonary disorders</b>		<b>369</b>	<b>62.4%</b>
GI-3	Alimemazine (Theralene <sup>®</sup> ), oxomemazine (Toplexil <sup>®</sup> )...	202	34.2%
GI-1	Pholcodine	81	13.7%
II-8	Tenoate etanolamine (Rhizophyl <sup>®</sup> ) and other nasal antiseptics	62	10.5%
II-6	Nasal or oral decongestant etc.	20	3.4%
GI-2	Mucolytic drugs, mucokinetic drugs or helcidine prescribed to a child under 2 years of age	3	0.5%
GI-4	Terpene-based suppositories	1	0.2%
<b>Dermatological disorders</b>		<b>1</b>	<b>0.2%</b>
PI-2	Topical agents containing acyclovir prescribed to	1	0.2%

	a child under six years of age		
<b>Neuropsychiatric disorders</b>		<b>5</b>	<b>0.8%</b>
RI-3	Levetiracetam in mL or in mg prescribed without systematically indicating XX mg per Y mL	5	0.8%
<b>Potentially Prescribing Omissions (PPO)</b>		<b>293</b>	
IO-1	Dose in mg for oral (solution of) amoxicillin etc.	293	100%

NSAIDs: Non-steroidal anti-inflammatory drugs; ENT: ear, nose and throat  
% Percentage calculated from the total number of PIMs or PPO detected

Omissions were identified in 425 prescriptions from our hospital (Table 3). The criterion on prescribing amoxicillin in mg (IO-1) was not analyzable due to the fact that this drug is prescribed in great quantity. Nonetheless, one analysis on acute otitis media alone identified a rate of 99.5% (807/811) of prescriptions issued without specification of the doses in mg for oral amoxicillin. In community care, this was observed in 97% prescriptions, in 13.2% of patients (Table 4).

PIMs classed by age were presented in the figure 4. Multivariate analysis showed that children and prescriptions issued from outpatient care correlated with a higher risk of PIM (Table 5).

**Table 5. Univariate and multivariate analysis to determine which factors are related to PIM according to POPI criteria**

Variable	Univariate analysis		Multivariate analysis	
	OR* [CI 95%]	p-value	OR* [CI 95%]	p-value
<b>Model 1 : Hospital</b>				
<b>Sex</b>				
Male	1			
Female	1.0 [0.9-1.3]	0.3		
<b>Age category</b>				
≤ 28 days	0.000	0.9		
28 days - 2 years	2.5 [1.5-3.8]	< 0.001*		
2 - 6 years	3.9 [2.3-6.0]	< 0.001*		
6 - 12 years	2.2 [1.2-3.4]	0.002*		
12 - 18 years	1			
<b>Model 2 : Community</b>				

<b>Age category</b>				
≤ 28 days	0.000	0.9	0.000	0.9
28 days - 2 years	0.9 [0.6-1.1]	0.4	0.9 [0.6-1.1]	0.4
2 - 6 years	2.1 [1.6-2.6]	< 0.001*	2.0 [1.5-2.5]	< 0.001*
6 - 12 years	1.9 [1.5-2.4]	< 0.001*	2.0 [1.5-2.6]	< 0.001*
12 - 18 years	1		1	
<b>Medications/prescription</b>	1.4 [1.3-1.4]	< 0.001*	1.4 [1.3-1.4]	< 0.001*
<b>Model 3 : Hospital and Community</b>				
<b>Age category</b>				
≤ 28 days	0.000	1.0	0.000	
28 days - 2 years	0.7 [0.5-0.8]	0.004*	1.4 [1.0-1.7]	0.005*
2 - 6 years	1.4 [1.2-1.8]	< 0.001*	2.4 [1.9-2.9]	< 0.001*
6 - 12 years	1.4 [1.1-1.7]	<0.001*	1.9 [1.5-2.2]	< 0.001*
12 - 18 years	1		1	
<b>Service</b>				
Hospital	1			
Community	4.8 [4.2-5.4]	< 0.0001*	5.2 [5.0-6.5]	< 0.0001*

OR: Odds ratio, CI: Confidence intervals, \*: statistically significant  $p < 0.05$ .

## DISCUSSION

This study is the first to observe the prevalence of PIM and PPO in a pediatric population. As expected, the rate of IP detected is lower than in the geriatric population (pediatric: 3.3% in hospital, 26.4% in community vs geriatric: 35% in hospital and 51.3% in community). Similarly, the incidence of PPO was higher in older people (57.9% and 59.4%) vs (2.6% and 13.2%).<sup>[5,12,28]</sup> This result could be explained by the comorbidities present in elderly patients. Consequently, polypharmacy is the main factor which leads to PIM (2.4 drugs/prescription observed in our study compared with 6 per prescription).<sup>[12,28]</sup> The majority of PIM are found in respiratory and digestive pathology, in contrast with a geriatric population. Elderly people are frequently concerned by PIM in cardiovascular and nervous central system indications.<sup>[12,28]</sup> Respiratory and digestive pathologies are typical in children. These diseases are the most common reasons to be admitted to the ED.<sup>[29]</sup>

1  
2  
3 Domperidone, which is considered inappropriate by POPI was prescribed more frequently in  
4 the outpatient care. In our hospital, considering its modest effectiveness and adverse events  
5 (serious cardiac disorders – QT prolongation and arrhythmia), this drug was no longer  
6 referenced.[30] Loperamide is not recommended, particularly for infants (contraindicated in  
7 France) due to its adverse effects such as ileus or death.[31,32] It is also considered to  
8 produce PIM in a geriatric population. One case of prescription of loperamide was detected in  
9 a young child (2 years) and we therefore made a phone call to the community pharmacist for  
10 intervention. As they hold no recommendation in gastrointestinal disease, metoclopramide  
11 and intestinal antiseptic were rarely observed in hospital prescription.[33] This could also be  
12 explained by the contraindication of metoclopramide in children < 18 years old, except in the  
13 event of nausea or vomiting associated with antimotile.[33–35] PIM for diosmectite also  
14 occurred frequently. It is important to not administer other drugs at the same time as  
15 diosmectite leaving a time interval to prevent any ADEs via interaction.[36]

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32 In respiratory tract infections, PIM was most frequently found in cases of a sore throat (14%).  
33  
34 Lack of rapid test results is common, although this enables us to avoid excessive prescription  
35 of antibiotics and to reduce the emergence of highly resistant bacteria. As we know, the main  
36 cause of sore throat in children are viruses, and streptococcal infection only presents in 25-  
37 40% of cases.[37] We observed that antibiotics were present for 90% of cases of acute otitis  
38 media (AOM). Amoxicillin was not used as the first-line treatment for 145 cases (13%).  
39  
40 However, only 59 cases were considered noncompliant according to criterion II-1. Indeed, in  
41 the management of conjunctivitis-otitis syndrome caused by *Haemophilus influenzae*, giving  
42 amoxicillin/clavulanic acid as a first-line treatment is recommended.[38] This antibiotic is  
43 also privileged for acute maxillary sinusitis and frontal, ethmoidal and sphenoid sinusitis.[37]  
44  
45 Amoxicillin was used in 77% of cases of AOM, at a higher rate than that observed in a  
46 national study in 2012 (66%). This result shows that the French recommendation for this  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 course of action in 2011, in order to reduce the rate of bacteria resistance, has had a strong  
4 impact.[37,39] Eardrops are considered inappropriate in cases of AOM without other  
5 symptoms. For chronic otitis with otorrhea, perforation of the eardrum or, antibiotic eardrops  
6 are recommended.[40,41] This application showed that some of our criteria need to be more  
7 detailed, in order to avoid mis-detection of PIM. Prevalence of beta2 agonists or  
8 corticosteroids in an infant's first case of bronchiolitis is 6.4% (25/386 cases), lower than that  
9 observed in a study of another French area in 2012 (41%).[42–44] A high frequency of  
10 prescription of antibiotics, corticosteroids or nasal antiseptic medication was detected in case  
11 of nasopharyngitis, although there is no evidence for this.[45] Antiseptics such as tenoate  
12 ethanolamine did not receive a favorable opinion from the ANSM (French National Agency  
13 for Medicines and Health Products Safety) because they exposed patients to potential nasal  
14 irritation and occasionally to serious allergies.[46] Even so, it was frequently present in  
15 prescriptions from outpatient care. Unnecessary exposure to cough suppressants, pholcodine,  
16 nasal or oral decongestants was also observed frequently in this sector.[46]

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34 Less PIM were found in dermatological disorders. In the management of scabies, we had  
35 removed the criterion on Ascabiol<sup>®</sup> (Sulfirame and Benzyl Benzoate) as it was out of stock  
36 since 2012.

37  
38  
39  
40  
41  
42 In comparison to PIM, the rate of PPO observed was lower and centred on specific disorders.  
43  
44 In the management of diarrhea caused by gastroenteritis, in hospital, our study found that it  
45 was common to omit prescription of an oral rehydration solution (ORS): 14% (237/1643  
46 case). Even so, this rate is lower than that found in another national study in 2007 (29%).[47]  
47  
48  
49  
50 It could be that the recommendation of the European Society for Paediatric Gastroenterology,  
51 Hepatology, and Nutrition (ESPGHAN) in 2008 has had a positive impact.[31,33] Thus, this  
52 criterion serves not only to highlight the importance of ORS for the prescriber but also helps  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 to increase the frequency of pharmaceutical recommendation of this drug. Another common  
4  
5 omission was identified in the prescription of oral liquid formulation. A precise dosage of oral  
6  
7 amoxicillin is necessary because many errors occurred when using the dosing spoon.[48] In  
8  
9 62/63 cases, oral acyclovir was not prescribed for herpetic gingivostomatitis. In daily practice,  
10  
11 this occurred because a blood test to screen for the primary infection is not realized. However,  
12  
13 the oral treatment can prevent recurrences, which cannot be attained by using cream.[49]  
14  
15 Once again, the role of the community pharmacist is significant in detecting the omission,  
16  
17 intervening or providing education to the patient when necessary.  
18  
19

20  
21 As estimated, the child group has the highest risk of presenting with a PIM, according to a  
22  
23 multivariate analysis. Certainly, this age group is most frequently affected by respiratory  
24  
25 diseases and is thus exposed to many unnecessary prescriptions such as cough suppressants or  
26  
27 decongestant drugs. As we know, they are also affected by off-label drug prescriptions, which  
28  
29 is consistent with reports from other sources.[50,51] Once again, our study highlights the  
30  
31 importance of appropriate prescription in this age group. As with geriatrics, an increase in  
32  
33 numbers of medications can be associated with PIM.[28] Prescriptions issued from hospitals  
34  
35 elicit fewer IP than those issued by the community. The main reason for this is that many  
36  
37 drugs are not available in this hospital, such as cough suppressants, Rhinotrophyl<sup>®</sup> (tenoate  
38  
39 ethanolamine), domperidone, etc. This shows that many PIM are preventable in a hospital  
40  
41 setting. An efficient method for prevention of PIM could be to focus on the prescribing habits  
42  
43 of physicians and thus have an impact on the selection of drugs, thereby reducing the rate of  
44  
45 PIM.  
46  
47  
48  
49

50  
51 Our study has several limitations. Firstly, it is a retrospective and monocentric study. Our  
52  
53 result in the hospital could be underestimated. In addition, several criteria could not be  
54  
55 analyzed due to the large number of prescriptions (for example, those for fever or pain which  
56  
57  
58  
59  
60

1  
2  
3 are associated with many diseases) or absence of a specific pathology (mosquitos, lice,  
4 hyperactivity etc.). Antibiotic prophylaxis, vitamin supplements, proposition of vaccination  
5 etc. can be analyzed in prospective studies. A lack of clinical information is the main  
6  
7 limitation in detection in a community setting. This also constitutes a challenge for  
8  
9 pharmaceutical care review in elderly patients.[52] However, a certain amount of PIM were  
10  
11 identified using POPI. Our study showed that there are many criteria which could be detected  
12  
13 without access to clinical information and that they are easy to identify. Moreover,  
14  
15 community pharmacists, in their practice, can extrapolate diagnoses from their experience,  
16  
17 from common indications or by interviewing their patient.  
18  
19  
20  
21  
22

23 This is the first study which permits to evaluate prevalence of PIM and PPO in pediatric's  
24  
25 prescription Hereafter, in order to prove the effectiveness of this tool, further investigations  
26  
27 must be carried out on a larger scale, both in hospital and in community care. It is also  
28  
29 necessary to evaluate the impact of this tool on reducing adverse drugs events, both in  
30  
31 consultation or upon hospitalization. The impact of pharmacists in providing appropriate  
32  
33 prescriptions should be also evaluated. Subsequently, this tool may be proposed to several  
34  
35 professional societies such as the French Society for Pediatricians and the French Society of  
36  
37 Clinical Pharmacy to make its use more widespread. The tool should be regularly updated to  
38  
39 reflect recent events and to specify certain criteria.  
40  
41  
42  
43

44 To facilitate its use, this tool can be presented as a mobile app, a small handbook or be  
45  
46 installed into prescription software. In summary, we hope that POPI could be a practical  
47  
48 option used to reduce medication errors and to improve the suitability of prescriptions. It  
49  
50 provides rapid detection of PIM and PPO and can also open up a discussion on the  
51  
52 relationship between the medicine and the pharmacist to remedy the issue at hand.[53]  
53  
54  
55  
56  
57  
58  
59  
60

## CONCLUSION

Our study was carried out in in two sectors, hospital and community, and provides a global view of PIM and PPO in pediatric patients. It highlights the potential role of POPI tools in improving prescription quality in various sectors. POPI should be applied in different services to deepen and reinforce its utilization. A prospective and multicenter study should be conducted to evaluate its impact and benefit in clinical practice.

## ACKNOWLEDGMENTS

We would like to thank the Emergency department of Robert-Debré hospital and the Albaret pharmacy community for their data support.

We would also like to thank the French Society of Clinical Pharmacy (pediatric group) for their support.

## ETHICS

This project was approved by the local research ethics committee (n°2015/218).

## DISCLOSURE OF INTEREST

None Declared

## FUNDING STATEMENT

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

## AUTHOR'S CONTRIBUTION

1  
2  
3 Sonia Prot-Labarthe, Aurore Berthe-Aucejo conceptualised and designed the study, drafted  
4 the initial manuscript, and approved the final manuscript as submitted.  
5

6  
7 Rym Boulkedid and HPK Nguyen carried out analyses, reviewed and revised the manuscript,  
8 and approved the final manuscript as submitted.  
9

10  
11 Xavier Bellettre, Thomas Weil, Olivier Bourdon reviewed and revised the manuscript and  
12 approved the final manuscript as submitted.  
13  
14

15  
16 François Angoulvant and Patrick Albaret supplied data from hospital and community  
17 pharmacy and reviewed and revised the manuscript and approved the final manuscript as  
18 submitted.  
19  
20

## 21 22 **DATA SHARING STATEMENT**

23  
24  
25 We have no additional unpublished data  
26

## 27 28 **REFERENCES**

- 29  
30  
31 1 Chrischilles EA, VanGilder R, Wright K, *et al.* Inappropriate medication use as a risk  
32 factor for self-reported adverse drug effects in older adults. *J Am Geriatr Soc*  
33 2009;**57**:1000–6.  
34  
35 2 Lund BC, Carnahan RM, Egge JA, *et al.* Inappropriate prescribing predicts adverse drug  
36 events in older adults. *Ann Pharmacother* 2010;**44**:957–63. doi:10.1345/aph.1M657  
37  
38 3 Drees - Ministère des Affaires sociales et de la Santé. Enquête Nationale sur les  
39 Événements Indésirables graves associés aux Soins. 2011.  
40 [http://www.drees.sante.gouv.fr/enquete-nationale-sur-les-evenements-indesirables-](http://www.drees.sante.gouv.fr/enquete-nationale-sur-les-evenements-indesirables-graves-associes-aux-soins-description-des-resultats-2009,9499.html)  
41 [graves-associes-aux-soins-description-des-resultats-2009,9499.html](http://www.drees.sante.gouv.fr/enquete-nationale-sur-les-evenements-indesirables-graves-associes-aux-soins-description-des-resultats-2009,9499.html) (accessed 5 Mar  
42 2015).  
43  
44 4 Reidenberg MM. Can the selection and use of essential medicines decrease inappropriate  
45 drug use? *Clin Pharmacol Ther* 2009;**85**:581–3. doi:10.1038/clpt.2009.10  
46  
47 5 Barry PJ, Gallagher P, Ryan C, *et al.* START (screening tool to alert doctors to the right  
48 treatment)--an evidence-based screening tool to detect prescribing omissions in elderly  
49 patients. *Age Ageing* 2007;**36**:632–8. doi:10.1093/ageing/afm118  
50  
51 6 Legrain S others. Consommation médicamenteuse chez le sujet âgé. Consommation,  
52 prescription, iatrogénie et observance. 2005.[http://www.has-](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28_16_44_51_580.pdf)  
53 [sante.fr/portail/upload/docs/application/pdf/pmsa\\_synth\\_biblio\\_2006\\_08\\_28\\_16\\_44\\_51\\_](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28_16_44_51_580.pdf)  
54 [580.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28_16_44_51_580.pdf)  
55  
56  
57  
58  
59

- 1
- 2
- 3 7 Beers MH, Ouslander JG, Rollinger I, *et al.* Explicit criteria for determining  
4 inappropriate medication use in nursing home residents. UCLA Division of Geriatric  
5 Medicine. *Arch Intern Med* 1991;**151**:1825–32.
- 6
- 7 8 Naugler CT, Brymer C, Stolee P, *et al.* Development and validation of an improving  
8 prescribing in the elderly tool. *Can J Clin Pharmacol J Can Pharmacol Clin* 2000;**7**:103–  
9 7.
- 10
- 11 9 Samsa GP, Hanlon JT, Schmader KE, *et al.* A summated score for the medication  
12 appropriateness index: development and assessment of clinimetric properties including  
13 content validity. *J Clin Epidemiol* 1994;**47**:891–6.
- 14
- 15 10 Laroche M-L, Bouthier F, Merle L, *et al.* Médicaments potentiellement inappropriés aux  
16 personnes âgées: intérêt d'une liste adaptée à la pratique médicale française. *Rev*  
17 *Médecine Interne* 2009;**30**:592–601. doi:10.1016/j.revmed.2008.08.010
- 18
- 19 11 Gallagher P, Ryan C, Byrne S, *et al.* STOPP (Screening Tool of Older Person's  
20 Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment).  
21 Consensus validation. *Int J Clin Pharmacol Ther* 2008;**46**:72–83.
- 22
- 23 12 Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially  
24 inappropriate Prescriptions): application to acutely ill elderly patients and comparison  
25 with Beers' criteria. *Age Ageing* 2008;**37**:673–9. doi:10.1093/ageing/afn197
- 26
- 27 13 Gallagher P, Lang PO, Cherubini A, *et al.* Prevalence of potentially inappropriate  
28 prescribing in an acutely ill population of older patients admitted to six European  
29 hospitals. *Eur J Clin Pharmacol* 2011;**67**:1175–88. doi:10.1007/s00228-011-1061-0
- 30
- 31 14 Dalleur O, Boland B, Losseau C, *et al.* Reduction of potentially inappropriate medications  
32 using the STOPP criteria in frail older inpatients: a randomised controlled study. *Drugs*  
33 *Aging* 2014;**31**:291–8. doi:10.1007/s40266-014-0157-5
- 34
- 35 15 Ryan C, O'Mahony D, Kennedy J, *et al.* Potentially inappropriate prescribing in an Irish  
36 elderly population in primary care. *Br J Clin Pharmacol* 2009;**68**:936–47.  
37 doi:10.1111/j.1365-2125.2009.03531.x
- 38
- 39 16 Yayla ME, Bilge U, Binen E, *et al.* The use of START/STOPP criteria for elderly patients  
40 in primary care. *ScientificWorldJournal* 2013;**2013**:165873. doi:10.1155/2013/165873
- 41
- 42 17 Borges EP, Morgado M, Macedo AF. Prescribing omissions in elderly patients admitted  
43 to a stroke unit: descriptive study using START criteria. *Int J Clin Pharm* 2012;**34**:481–9.  
44 doi:10.1007/s11096-012-9635-1
- 45
- 46 18 Dedhiya SD, Hancock E, Craig BA, *et al.* Incident use and outcomes associated with  
47 potentially inappropriate medication use in older adults. *Am J Geriatr Pharmacother*  
48 2010;**8**:562–70. doi:10.1016/S1543-5946(10)80005-4
- 49
- 50 19 Lau DT, Kasper JD, Potter DEB, *et al.* Hospitalization and death associated with  
51 potentially inappropriate medication prescriptions among elderly nursing home residents.  
52 *Arch Intern Med* 2005;**165**:68–74. doi:10.1001/archinte.165.1.68
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 20 Bradley MC, Fahey T, Cahir C, *et al.* Potentially inappropriate prescribing and cost  
4 outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced  
5 Prescribing Database. *Eur J Clin Pharmacol* 2012;**68**:1425–33. doi:10.1007/s00228-012-  
6 1249-y  
7
- 8 21 Hébert G, Prot-Labarthe S, Tremblay M-E, *et al.* La pédiatrie, toujours exclue de  
9 l'innovation pharmaceutique? *Arch Pédiatrie* 2014;**21**:245–50.  
10 doi:10.1016/j.arcped.2013.12.016  
11
- 12 22 Benavides S, Huynh D, Morgan J, *et al.* Approach to the pediatric prescription in a  
13 community pharmacy. *J Pediatr Pharmacol Ther JPPT Off J PPAG* 2011;**16**:298–307.  
14 doi:10.5863/1551-6776-16.4.298  
15
- 16 23 Kaushal R, Bates DW, Goldmann DA. Medication errors and adverse drug events in  
17 pediatric inpatients. *JAMA* 2001;**285**:2114–20.  
18
- 19 24 Mercier J., Morin L, Prot-Labarthe S. Les erreurs de prescription et leurs conséquences.  
20 2010.  
21
- 22 25 Prot-Labarthe S, Vercheval C, Angoulvant F, *et al.* « POPI ; pédiatrie : omissions et  
23 prescriptions inappropriées ». Outil d'identification des prescriptions inappropriées chez  
24 l'enfant. *Arch Pédiatrie* 2011;**18**:1231–2. doi:10.1016/j.arcped.2011.08.019  
25
- 26 26 Prot-Labarthe S, Weil T, Angoulvant F, *et al.* POPI (Pediatrics: Omission of Prescriptions  
27 and Inappropriate Prescriptions): Development of a Tool to Identify Inappropriate  
28 Prescribing. *PLoS ONE* 2014;**9**:e101171. doi:10.1371/journal.pone.0101171  
29
- 30 27 European Medicines Agency. Codeine not to be used in children below 12 years for  
31 cough and cold. 2015.<http://www.ema.europa.eu>  
32  
33
- 34 28 Gallagher P, Lang PO, Cherubini A, *et al.* Prevalence of potentially inappropriate  
35 prescribing in an acutely ill population of older patients admitted to six European  
36 hospitals. *Eur J Clin Pharmacol* 2011;**67**:1175–88. doi:10.1007/s00228-011-1061-0  
37
- 38 29 Nadège Caillère, Céline Caserio-Schonemann. Réseau OSCOUR® (Organisation de la  
39 surveillance coordonnée des urgences) Résultats nationaux 2004/2011. 2011.  
40
- 41 30 European Medicines Agency. PRAC recommends restricting use of domperidone.  
42 2014.<http://www.ema.europa.eu>  
43
- 44 31 Guarino A, Albano F, Ashkenazi S, *et al.* European Society for Paediatric  
45 Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious  
46 Diseases evidence-based guidelines for the management of acute gastroenteritis in  
47 children in Europe: executive summary. *J Pediatr Gastroenterol Nutr* 2008;**46**:619–21.  
48 doi:10.1097/MPG.0b013e31816e219e  
49
- 50 32 Li S-TT, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children:  
51 systematic review and meta-analysis. *PLoS Med* 2007;**4**:e98.  
52 doi:10.1371/journal.pmed.0040098  
53
- 54 33 Guarino A, Ashkenazi S, Gendrel D, *et al.* European Society for Pediatric  
55 Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious  
56  
57  
58  
59

- 1  
2  
3 Diseases evidence-based guidelines for the management of acute gastroenteritis in  
4 children in Europe: update 2014. *J Pediatr Gastroenterol Nutr* 2014;**59**:132–52.  
5 doi:10.1097/MPG.0000000000000375  
6
- 7 34 Agence national de sécurité du médicament et des produits de santé. Contre-indication des  
8 spécialités à base de métopropramide (Primpéran® et génériques) chez l'enfant et  
9 l'adolescent et renforcement des informations sur les risques neurologiques et  
10 cardiovasculaires - Lettre aux professionnels de santé. 2012.  
11
- 12 35 Agence national de sécurité du médicament et des produits de sant. Spécialités à base de  
13 métopropramide : actualisation des indications et de la posologie pour diminuer le risque  
14 (principalement neurologique) d'effets indésirables - Lettre aux professionnels de santé.  
15 2014.  
16
- 17 36 CNHIM. Diosmectite MYL 3G PDR Oral Sachet-Monographie spécialité.  
18 <http://www.theriaque.org>  
19
- 20 37 Société de Pathologie Infectieuse de Langue Française. Antibiothérapie par voie générale  
21 en pratique courante dans les infections respiratoires hautes de l'adulte et l'enfant. 2011.  
22
- 23 38 American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media.  
24 Diagnosis and management of acute otitis media. *Pediatrics* 2004;**113**:1451–65.  
25
- 26 39 Levy C, Pereira M, Guedj R, *et al.* Impact of 2011 French guidelines on antibiotic  
27 prescription for acute otitis media in infants. *Médecine Mal Infect* 2014;**44**:102–6.  
28 doi:10.1016/j.medmal.2014.01.005  
29
- 30 40 Granath A, Rynnel-Dagö B, Backheden M, *et al.* Tube associated otorrhea in children  
31 with recurrent acute otitis media; results of a prospective randomized study on  
32 bacteriology and topical treatment with or without systemic antibiotics. *Int J Pediatr*  
33 *Otorhinolaryngol* 2008;**72**:1225–33. doi:10.1016/j.ijporl.2008.04.015  
34
- 35 41 Antibiothérapie locale en ORL. Argumentaire. *Médecine Mal Infect* 2004;**34**:573–82.  
36 doi:10.1016/j.medmal.2004.10.004  
37
- 38 42 Bronchiolitis in children | 1-recommendations | Guidance and guidelines | NICE.  
39 <http://www.nice.org.uk/guidance/NG9/chapter/1-recommendations> (accessed 22 Jun  
40 2015).  
41
- 42 43 Conférence de Consensus sur la prise en charge de la bronchiolite du nourrisson.  
43 2000.<http://www.has-sante.fr>  
44
- 45 44 Branchereau E, Branger B, Launay E, *et al.* [Management of bronchiolitis in general  
46 practice and determinants of treatment being discordant with guidelines of the HAS].  
47 *Arch Pédiatrie Organe Off Société Fr Pédiatrie* 2013;**20**:1369–75.  
48 doi:10.1016/j.arcped.2013.09.028  
49
- 50 45 Centre for Clinical Practice at NICE (UK). *Respiratory Tract Infections - Antibiotic*  
51 *Prescribing: Prescribing of Antibiotics for Self-Limiting Respiratory Tract Infections in*  
52 *Adults and Children in Primary Care*. London: : National Institute for Health and Clinical  
53 Excellence (UK) 2008. <http://www.ncbi.nlm.nih.gov/books/NBK53632/> (accessed 22 Jun  
54 2015).  
55  
56  
57  
58  
59

- 1  
2  
3 46 *La Revue Prescrire*. 2014. <http://www.prescrire.org/fr/>
- 4  
5 47 Martinot A, Pruvost I, Aurel M, *et al*. [Improvement in the management of acute  
6 diarrhoea in France?]. *Arch Pédiatrie Organe Off Société Fr Pédiatrie* 2007;**14** **Suppl**  
7 **3**:S181-185.
- 8  
9 48 Berthe-Aucejo A, Girard D, Lorrot M, *et al*. Evaluation of frequency of paediatric oral  
10 liquid medication dosing errors by caregivers: amoxicillin and josamycin. *Arch Dis Child*  
11 Published Online First: 4 January 2016. doi:10.1136/archdischild-2015-309426
- 12  
13 49 Société Française de Dermatologie. Prise en charge de l'herpès cutané-muqueux chez le  
14 sujet immuno compétent (manifestations oculaires exclues). 2001. <http://www.has-sante.fr>
- 15  
16 50 Joret P, Prot-Labarthe S, Brion F, *et al*. Caractérisation des indications hors AMM en  
17 pédiatrie : analyse descriptive de 327 lignes de prescriptions dans un hôpital pédiatrique.  
18 *Pharm Hosp Clin* 2014;**49**:e151–2. doi:10.1016/j.phclin.2014.04.306
- 19  
20 51 Shah SS, Hall M, Goodman DM, *et al*. Off-label drug use in hospitalized children. *Arch*  
21 *Pediatr Adolesc Med* 2007;**161**:282–90. doi:10.1001/archpedi.161.3.282
- 22  
23 52 Ryan C, O'Mahony D, O'Donovan DÓ, *et al*. A comparison of the application of  
24 STOPP/START to patients' drug lists with and without clinical information. *Int J Clin*  
25 *Pharm* 2013;**35**:230–5. doi:10.1007/s11096-012-9733-0
- 26  
27 53 Gillespie U, Alassaad A, Hammarlund-Udenaes M, *et al*. Effects of Pharmacists'  
28 Interventions on Appropriateness of Prescribing and Evaluation of the Instruments' (MAI,  
29 STOPP and STARTs') Ability to Predict Hospitalization—Analyses from a Randomized  
30 Controlled Trial. *PLoS ONE* 2013;**8**. doi:10.1371/journal.pone.0062401
- 31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Appendix 1. POPI - Pediatrics: Omission of Prescriptions & Inappropriate prescriptions

### A- PAIN AND FEVER

#### Inappropriate prescriptions

- AI-1.** Prescription of two alternating antipyretics as a first-line treatment. \*
- AI-2.** Prescription of a medication other than paracetamol as a first line treatment (except in the case of migraine).
- AI-3.** Rectal administration of paracetamol as a first-line treatment.
- AI-4.** The combined use of two NSAIDs. \* °
- AI-5.** Oral solutions of ibuprofen administered in more than three doses per day using a graduated pipette of 10mg/kg (other than Advil®). °
- AI-6.** Opiates to treat migraine attacks. \*

#### Omissions

- A0-1.** Failure to give sugar solution to new-born babies and infants under four months old two minutes prior to venipuncture.
- A0-2.** Failure to give an osmotic laxative to patients being treated with morphine for a period of more than 48 hours.

### B- URINARY INFECTIONS

#### Inappropriate prescriptions

- BI-1.** Nitrofurantoin used as a prophylactic.
- BI-2.** Nitrofurantoin used as a curative agent in children under six years of age, or indeed any other antibiotic if avoidable.
- BI-3.** Antibiotic prophylaxis following an initial infection without complications (except in the case of uropathy).
- BI-4.** Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of uropathy).

### C- VITAMIN SUPPLEMENTS AND ANTIBIOTIC PROPHYLAXIS

#### Inappropriate prescriptions

- CI-1.** Fluoride supplements prior to six months of age.

#### Omissions

- CO-1.** Insufficient intake of vitamin D. Minimum vitamin D intake:
- Breastfed baby = 1 000 to 1 200 IU/day
  - Infant < 18 months of age (milk enriched in vitamin D) = 600 to 800 IU/day
  - Child aged between 18 months and five years, and adolescents aged between 10 and 18 years: two quarterly loading doses of 80 000 to 100 000 IU/day in winter (adolescents can take this dose in one go).
- CO-2.** Antibiotic prophylaxis with phenoxymethylpenicillin (Oracilline) starting from two months of age and lasting until five years of age for children with sickle-cell anemia: 100 000 IU/kg/day (in two doses) for children weighing 10kg or less and 50 000 IU/kg/day for children weighing over 10kg (also in two doses).

### D- MOSQUITOS

#### Inappropriate prescriptions

- DI-1.** The use of skin repellents in infants less than six months old and picardin in children less than 24 months old.
- DI-2.** Citronella (lemon grass) oil (essential oil).
- DI-3.** Anti-insect bracelets to protect against mosquitos and ticks.
- DI-4.** Ultrasonic pest control devices, vitamin B1, homeopathy, electric bug zappers, sticky tapes without insecticide.

#### Omissions

- DO-1. DEET** "30%" (max) before 12 years old  
"50%" (max) after 12 years old.
- DO-2. IR3535** "20%" (max) before 24 months old  
"35%" (max) after 24 months old.
- DO-3.** Mosquito nets and clothes treated with pyrethroids.

**E- NAUSEA, VOMITTING, OR GASTROESOPHAGEAL REFLUX****Inappropriate prescriptions**

- EI-1.** Metoclopramide.\* °
- EI-2.** Domperidone.\* °
- EI-3.** Gastric antisecretory drugs to treat gastroesophageal reflux, dyspepsia, the crying of new-born babies (in the absence of any other signs or symptoms), as well as faintness in infants.\*
- EI-4.** The combined use of proton pump inhibitors and NSAIDs, for a short period of time, in patients without risk factors.\*
- EI-5.** Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube).\*
- EI-6.** The use of type H2 antihistamines for long periods of treatment.\* °
- EI-7.** Erythromycin as a prokinetic agent.\*
- EI-8.** The use of setrons (5-HT3 antagonists) for chemotherapy-associated nausea and vomiting.\*

**Omissions**

- EO-1.** Oral rehydration solution in the event of vomiting.\*

**F- DIARRHEA****Inappropriate prescriptions**

- FI-1.** Loperamide before 3 years of age.\*°
- FI-2.** Loperamide in the case of invasive diarrhea.\*
- FI-3.** The use of Diosmectite (Smecta®) in combination with another medication.\*°
- FI-4.** The use of Saccharomyces boulardii (Ultralevure) in powder form, or in a capsule that has to be opened prior to ingestion, to treat patients with a central venous catheter or an immunodeficiency.\*
- FI-5.** Intestinal antiseptics.\*°

**Omissions**

- FO-1.** Oral rehydration solution in the event of diarrhea.\*

**G- COUGH****Inappropriate prescriptions**

- GI-1.** Pholcodine.\* °
- GI-2.** Mucolytic drugs, mucokinetic drugs, or helcidine before two years of age.\* °
- GI-3.** Alimemazine (Theralene®), oxomemazine (Toplexil®), promethazine (Phenergan®), and other types.\* °
- GI-4.** Terpene-based suppositories.\* °

**Omissions**

- GO-1.** Failure to propose a whooping cough booster vaccine for adults who are likely to become parents in the coming months or years (only applicable if the previous vaccination was more than 10 years ago). This booster vaccination should also be proposed to the family and entourage of expectant parents (parents, grandparents, nannies/child minders).

**H- BRONCHIOLITIS IN INFANTS****Inappropriate prescriptions**

- HI-1.** Beta2 agonists, corticosteroids to treat an infant's first case of bronchiolitis.\*
- HI-2.** H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis.\*
- HI-3.** Antibiotics in the absence of signs indicating a bacterial infection (acute otitis media, fever, etc.).\*

**Omissions**

- HO-1.** 0.9% NaCl to relieve nasal congestion (not applicable if nasal congestion is already being treated with 3% NaCl delivered by a nebulizer).\*
- HO-2.** Palivizumab in the following cases:
- (1) babies born both at less than 35 weeks of gestation and less than six months prior to the onset of a seasonal RSV epidemic;
  - (2) children less than two years old who have received treatment for bronchopulmonary dysplasia in the past six months;
  - (3) children less than two years old suffering from congenital heart disease with hemodynamic abnormalities.

DIGESTIVE PROBLEMS

ENT-PULMONARY PROBLEMS

**I- ENT INFECTIONS****Inappropriate prescriptions**

- II-1.** An antibiotic other than amoxicillin as a first-line treatment for acute otitis media, strep throat, or sinusitis (provided that the patient is not allergic to amoxicillin). An effective dose of amoxicillin for an pneumococcal infection is 80–90 mg/kg/day and an effective dose for a streptococcal infection is 50 mg/kg/day.\*
- II-2.** Antibiotic treatment for a sore throat, without a positive rapid diagnostic test result, in children more than three years old.\*
- II-3.** Antibiotics for nasopharyngitis, congestive otitis, sore throat before three years of age, or laryngitis; antibiotics as a first-line treatment for acute otitis media showing few symptoms, after two years of age.\*
- II-4.** Antibiotics to treat otitis media with effusion (OME), except in the case of hearing loss or if OME lasts for more than three months.\*
- II-5.** Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat.\*
- II-6.** Nasal or oral decongestant (oxymetazoline (Aturgyl®), pseudoephedrine (Sudafed®), naphazoline (Derinox®), ephedrine (Rhinamide®), tuaminoheptane (Rhinofluimicil®), phenylephrine (Humoxal®)).\*
- II-7.** H1-antagonists with sedative or atropine-like effects (pheniramine, chlorpheniramine), or camphor; inhalers, nasal sprays, or suppositories containing menthol (or any terpene derivatives) before 30 months of age.\*
- II-8.** Ethanalamine tenoate (Rhinotrophyl®) and other nasal antiseptics.\* °
- II-9.** Ear drops in the case of acute otitis media.\*

**Omissions**

- IO-1.** Doses in mg for drinkable (solutions of) amoxicillin or josamycin.\*
- IO-2.** Paracetamol combined with antibiotic treatment for ear infections to relieve pain.\*

**J- ASTHMA****Inappropriate prescriptions**

- JI-1.** Ketotifen and other H1-antagonists, sodium cromoglycate.\*
- JI-2.** Cough suppressants.\*

**Omissions**

- JO-1.** Asthma inhaler appropriate for the child's age.
- JO-2.** Preventative treatment (inhaled corticosteroids) in the case of persistent asthma.\*

**K-ACNE VULGARIS****Inappropriate prescriptions**

- KI-1.** Minocycline.\* °
- KI-2.** Isotretinoin in combination with a member of the tetracycline family of antibiotics.\* °
- KI-3.** The combined use of an oral and a local antibiotic.\*
- KI-4.** Oral or local antibiotics as a monotherapy (not in combination with another drug).\*
- KI-5.** Cyproterone+ethinylestradiol (Diane 35®) as a contraceptive to allow isotretinoin per os.\* °
- KI-6.** Androgenic progestins (levonorgestrel, norgestrel, norethisterone, lynestrenol, dienogest, contraceptive implants or vaginal rings).\*

**Omissions**

- KO-1.** Contraception (provided with a logbook/diary) for menstruating girls taking isotretinoin.
- KO-2.** Topical treatment (benzoyl peroxide, retinoids, or both) in combination with antibiotic therapy.\*

**L- SCABIES****Omissions**

**LO-1.** A second dose of ivermectin two weeks after the first.\*

**LO-2.** Decontamination of household linen and clothes and treatment for other family members.

**M- LICE****Inappropriate prescriptions**

**MI-1.** The use of aerosols for infants, children with asthma, or children showing asthma-like symptoms such as dyspnea.

**N- RINGWORM****Inappropriate prescriptions****Omissions**

**NI-1.** Treatment other than griseofulvin for *Microsporum*.\*

**NO-1.** Topical treatment combined with an orally administered treatment.\*

**NO-2.** Griseofulvin taken during a meal containing a moderate amount of fat.\* °

**O-IMPETIGO****Inappropriate prescriptions**

**OI-1.** The combination of locally applied and orally administered antibiotic.\*

**OI-2.** Fewer than two applications per day for topical antibiotics.\*

**OI-3.** Any antibiotic other than mupirocin as a first-line treatment (except in cases of hypersensitivity to mupirocin).\*

**P- HERPES SIMPLEX****Inappropriate prescriptions****Omissions**

**PI-1.** Topical agents containing corticosteroids.\*

**PO-1.** Paracetamol during an outbreak of herpes.\*

**PI-2.** Topical agents containing acyclovir before six years of age.\* °

**PO-2.** Orally administered acyclovir to treat primary herpetic gingivostomatitis.\*

**Q-DERMATITE ATOPIQUE****Inappropriate prescriptions**

**QI-1.** A strong dermocorticoid (clobetasol propionate 0.05% Dermoval, betamethasone dipropionate Diprosone) applied to the face, the armpits or groin, and the backside of babies or young children.\*

More than one application per day of a dermocorticoid, except in cases of severe lichenification.\*

**QI-2.** Local or systemic antihistamine during the treatment of outbreaks.\*

**QI-3.** Topically applied 0.03% tacrolimus before two years of age.\*

Topically applied 0.1% tacrolimus before 16 years of age.

**QI-4.** Oral corticosteroids to treat outbreaks.\*

**R- EPILEPSY****Inappropriate prescriptions**

**RI-1.** Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of myoclonic epilepsy.\*

**RI-2.** Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of epilepsy with absence seizures (especially for childhood absence epilepsy or juvenile absence epilepsy).\*

**RI-3.** Levetiracetam, oxcarbamazepine in mL or in mg without systematically writing XX mg per Y mL.\* °

**S-DEPRESSION****Inappropriate prescriptions**

**SI-1.** An SSRI antidepressant other than fluoxetine as a first-line treatment (in the case of pharmacotherapy).\*

**SI-2.** Tricyclic antidepressants to treat depression.\*

**T- NOCTURNAL ENURESIS****Inappropriate prescriptions**

**TI-1.** Desmopressin administered by a nasal spray.\*

Desmopressin in the case of daytime symptoms.

**TI-2.** An anticholinergic agent used as a monotherapy in the absence of daytime symptoms.\*

**TI-3.** Tricyclic agents in combination with anticholinergic agents.\* °

**TI-4.** Tricyclic agents as a first-line treatment.\*

## **U- ANOREXIA**

### **Inappropriate prescriptions**

**UI-1.** Cyproheptadine (Periactin®), clonidine \* °

## **V- ATTENTION DEFICIT DISORDER WITH OR WITHOUT HYPERACTIVITY**

### **Inappropriate prescriptions**

### **Omissions**

**VI-1.** Pharmacological treatment before age six (before school), except in severe cases.\*

**VO-1.** Recording a growth chart (height and weight) if the patient is taking methylphenidate.\*

**VI-2.** Antipsychotic drugs to treat attention deficit disorder without hyperactivity.\*

**VI-3.** Slow release methylphenidate as two doses per day, rather than only one dose.\*°

# BMJ Open

**Retrospective study of irrational prescribing in French pediatric hospital: prevalence of inappropriate prescription detected by POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) in the emergency unit and in the ambulatory setting.**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019186.R1
Article Type:	Research
Date Submitted by the Author:	21-Nov-2017
Complete List of Authors:	Berthe-Aucejo, Aurore; Hopital Universitaire Robert Debre, Pharmacy department Nguyen, Phuong Khanh Hoang; Hopital Universitaire Robert Debre, Department of Pharmacy Angoulvant, François; Hopital universitaire Necker-Enfants malades, Emergency unit; INSERM, UMR-S1123, ECEVE; Inserm U1123 Bellettre, Xavier; Hopital Universitaire Robert Debre, Emergency unit Albaret, Patrick; Albaret Pharmacy Weil, Thomas; Hopital Universitaire Robert Debre, Department of Pharmacy Boulkedid, Rym; Hopital Universitaire Robert Debre, Clinical Epidemiology unit; INSERM, UMR-S1123, ECEVE; Inserm U1123 Bourdon, Olivier; Hopital Universitaire Robert Debre, Department of pharmacy; Universite Paris Descartes, Clinical Pharmacy Prot-Labarthe, Sonia; Hopital Universitaire Robert Debre, Department of Pharmacy; INSERM, UMR-S1123, ECEVE; Inserm U1123
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	General practice / Family practice
Keywords:	inappropriate prescription, omission, tool, detection

SCHOLARONE™  
Manuscripts

1  
2  
3 **Retrospective study of irrational prescribing in French pediatric hospital: prevalence of**  
4 **inappropriate prescription detected by POPI (Pediatrics: Omission of Prescription and**  
5 **Inappropriate prescription) in the emergency unit and in the ambulatory setting.**  
6  
7

8 A. Berthe-Aucejo<sup>1</sup>, H.P.K Nguyen<sup>1</sup>, F. Angoulvant<sup>2,3</sup>, X. Bellettre<sup>4</sup>, P. Albaret<sup>5,6</sup>, T. Weil<sup>1</sup>, R.  
9 Boulkedid<sup>3,7,8</sup>, O. Bourdon<sup>1,6,9,10</sup>, S.Prot-Labarthe<sup>1,3,10</sup>  
10  
11  
12  
13  
14  
15

16 <sup>1</sup> Department of Pharmacy, Robert-Debré Hospital, Paris, France  
17

18 <sup>2</sup> Emergency unit, Necker Hospital, Paris, France  
19

20 <sup>3</sup> UMR-S1123, ECEVE; Inserm U1123, Paris, France  
21

22 <sup>4</sup> Emergency unit AP-HP, Robert-Debré Hospital, Paris, France  
23

24 <sup>5</sup> Albaret Pharmacy, Cesson, France  
25

26 <sup>6</sup> Clinical Pharmacy, Paris Descartes University, Paris, France  
27

28 <sup>7</sup> Assistance publique-Hôpitaux de Paris, Hôpital Robert Debré, Clinical Epidemiology Unit,  
29 75 019 Paris, France  
30

31 <sup>8</sup> CIC-EC 1426, 75019 Paris, France  
32

33 <sup>9</sup> Laboratoire Educations et Pratiques de Santé, Paris XIII University, Bobigny, France  
34

35 <sup>10</sup> Groupe Pédiatrie de la Société Française de Pharmacie Clinique, Paris, France  
36  
37  
38

39 **Word count:** 2628  
40  
41

42 **Corresponding author**  
43  
44  
45

46 Dr Aurore Berthe-Aucejo, Service Pharmacie, AP-HP Hôpital Robert-Debré, 48 Boulevard  
47 Sérurier, 75019 Paris, Fax: 01-40-03-24-81, Tel: 01-40-03-57-41, Email:  
48 [aurore.berthe@aphp.fr](mailto:aurore.berthe@aphp.fr)  
49  
50  
51

## Keywords

Inappropriate prescription, omission, tool, detection

## ABSTRACT

**Background and Objective:** POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) is the first tool of detection for potentially inappropriate medicines (PIM) and potentially prescribing omissions (PPO) in pediatrics. The aim of this study was to evaluate the prevalence of PIM and PPO detected by POPI regarding issuing of prescription in hospital and outpatient care. The second objective is to determine the risk factors related to PIM.

**Design:** A retrospective and descriptive study was conducted in the emergency department (ED) and community pharmacy (CP) during 6 months. POPI was used to identify PIM and PPO.

**Setting:** Robert-Debré Hospital (AP-HP, France) and Albaret community pharmacy (Seine and Marne).

**Participants:** Inclusion criteria included patients who were under 18 years old and who had one medicine prescription. Exclusion criteria consisted of inaccessible medical records for patients consulted in ED and prescription without drugs for outpatients.

**Primary and secondary outcome measures:** PIM and PPO rate, PIM risk factors

**Results:** At ED, 18,562 prescriptions for 15,973 patients and 4,780 prescriptions for 2,225 patients at the CP were analyzed. The PIM rate and PPO rate were respectively 3.3% and 2.6% at the ED and 26.4% and 13.2% at the CP. Respiratory and digestive diseases had the highest rate of PIM. Multivariate logistic regression model showed that children aged between 0 and 12 years (OR=1.3 CI<sub>95%</sub> [1.0-1.6] p=0.03 for 0-2 years, OR=2.4 CI<sub>95%</sub> [1.9-2.9] p<0.001 for 2-6 years, OR=1.9 CI<sub>95%</sub> [1.5-2.3] p<0.001 for 6-12 years) and prescriptions issued from outpatient care (OR= 5.7 CI<sub>95%</sub> [5.0-6.4] p<0.001) were significantly associated with a higher risk of PIM.

**Conclusion:** This study is the first that assesses the prevalence of PIM and PPO detecting by POPI in a pediatric population. A prospective and multicenter study should be conducted to evaluate its impact and benefit in clinical practice.



### Strengths and limitations of this study

- This study is the first to observe the prevalence of PIM and PPO in a pediatric population.

- It is a retrospective and monocentric study. The prevalence of PIM and PPO may be underestimated (large number of prescriptions, absence of specific pathology). Some criteria could be analyzed only in a prospective study. A lack of clinical information is the main limitation in detection in a community setting.

- Many omissions and inappropriate prescriptions can be easily detected with POPI despite limited clinical information.

## INTRODUCTION

Inappropriate prescribing is a known preventable cause of adverse drug events (ADE) and has an important impact on public health and cost of care.[1,2] ADE included adverse drug reaction, harm from use of the treatment. Incidence of hospitalization due to ADE was 42.8% according to a French survey in 2009.[3] In the paediatric population, incidence of adverse drug reaction responsible for hospital admission was estimated from 0.4% to 10.3%.[4] Many drugs were concerned in commonly used medication.[5–7] The World Health Organization estimated that 50% of medications are prescribed and utilized inappropriately.[8] The most recent definition of inappropriate prescription (IP) encompasses potentially inappropriate medicines (PIM) and prescribing omissions (PPO).[9] In a report from the French National Authority for Health, PIMs are defined as “drugs being used in a situation in which the risks involved in treatment potentially outweigh the benefits, lack of demonstrated indication, high risk of ADE, and an unfavorable cost-effect or risk-benefit ratio exists”. PPO or underuse of appropriate medication is defined as the absence of initiation of an effective treatment in subjects with a condition for which one or several drug classes have demonstrated their efficacy. In an elderly population, which presents with age-related physiological changes and high prevalence of polypharmacy, various measures have been developed to detect PIM such as: Beers’ criteria, the Inappropriate Prescribing in the Elderly Tool, The Medication Appropriate Index, and STOPP/START (Screening Tool of Older Person’s prescriptions/Screening Tool to Alert doctor to Right Treatment).[10–15]

Only the STOPP/START enables us to detect under-prescribing.[9] Using these tools, many studies have been carried out which have detected that inappropriate prescriptions are issued to between 35% and 51% of this population.[16–20]

1  
2  
3 Omission prescriptions in geriatric population detected by START tool concerned between  
4 58%-61% of patients.[9,21] Negative outcomes related to an IP such as side effects,  
5 hospitalization, mortality and utilization of resources were also demonstrated.[1,15,22,23]  
6  
7  
8  
9

10 Prescribing in a pediatric population is always a challenge for physician. It is often empirical  
11 and primarily based on safety and pharmacology information obtained in adults.[24] This is a  
12 worry not only in a hospital or general practitioner setting but also for the community  
13 pharmacists. They may only be able to check information and resources or even dispense  
14 infrequently for this vulnerable population.[25] Medication errors were identical in adults and  
15 children but side effects were three time more common in the pediatric population. This  
16 frequency was explained by the vulnerability of young people, pharmacokinetic changes  
17 during childhood and pediatric off-label drug used.[26–28]  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Large differences relating to treatment were seen within and between the countries.[28,29]  
29 Question about rational of prescription could be asked.[30] Optimizing children's care is  
30 based on rational prescribing and allowing a decrease in side effects.[29,30] In order to  
31 improve the correct drug use and optimize practice, the first tool of detection for PIM and  
32 PPO was created by Prot-Labarthe *et al.* in 2013. The tool was named POPI (Pediatrics:  
33 Omission of Prescriptions and Inappropriate prescriptions) (Appendix1).[31,32] Presently, the  
34 complete tool has not been tested in actual practice and the prevalence of PIM and OP is not  
35 known.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Our aim is to evaluate the prevalence of PIM and PPO detected by POPI. This was its first  
47 application, regarding issuing of prescriptions in hospital and outpatient care. The second  
48 objective is to determine the risk factors related to PIM.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS

### Population

A retrospective and descriptive study was conducted in the emergency department (ED) of AP-HP Robert-Debré hospital (Paris) - the largest French pediatric hospital - and the Albaret community pharmacy (Seine and Marne). Inclusion criteria included patients who were under 18 years old and who had one medicine prescription between 1<sup>st</sup> October 2014 and 31<sup>st</sup> March 2015. Exclusion criteria consisted of inaccessible medical records for patients consulted in ED and prescription without drugs for outpatients. POPI contains 102 criteria (76 PIMs, 25 PPO). A literature review was done to obtain criteria. Criteria were categorized according to the main physiological systems (gastroenterology, respiratory infections, pain, neurology, dermatology and miscellaneous). Criteria were validated by 2-round-Delphi consensus technique.[32]

### Data collection

The prescriptions given on leaving the emergency department were extracted from the software Urqual V5<sup>®</sup> (\*) (McKesson Corp, Paris, France). Urqual<sup>®</sup> is an emergency prescription software which is used in many French hospitals. Patient information including age, sex, weight, medicine prescription and current diagnosis was collected. Medical histories and clinical examinations were consulted individually when necessary. Due to the significant amount of data, clinical files of ED were analyzed, based on primary diagnosis. Assessable criteria in the retrospective study in hospital were identified by the symbol “\*” in appendix 1 (82 criteria).

Data from the community pharmacy were obtained from the pharmacy management software OPUS<sup>®</sup> (Computer PG, France). Patient’s age and drugs prescribed were collected. Clinical

1  
2  
3 case records and sex were not available in pharmacy as this was a retrospective analysis, so  
4  
5 only drugs that did not require assessment of diagnosis (for example domperidone,  
6  
7 metoclopramide etc.) were analyzed. These criteria were denoted by the symbol “○” in  
8  
9 appendix 1 (28 criteria).

10  
11  
12 Criteria including analgesics and antipyretics were not evaluated because of the large number  
13  
14 of prescriptions and association with many diseases.

15  
16  
17 Pathologies analyzed by POPI were the same in emergency department and in community.

### 21 **Statistical analysis**

22  
23  
24  
25 Data were presented as continuous variables (age, number of prescriptions by patient, number  
26  
27 of medications per prescription) and were presented as median and interquartile range (25th-  
28  
29 75th percentiles) or mean (standard deviation), minimum and maximum depending on normal  
30  
31 distribution.

32  
33  
34  
35 Logistic regression models were used to identify factors associated with risk of PIM (yes/no)  
36  
37 in hospital, community setting and in hospital and community grouped.

38  
39  
40 Univariate models were performed using different candidate factors as:

- 41  
42  
43 - For model performed with hospital data: sex and age (0 days - 2 years, 2 - 6 years, 6 -  
44  
45 12 years, 12 - 18 years);
- 46  
47 - For model performed with community data: age (0 days - 2 years, 2 - 6 years, 6 - 12  
48  
49 years, 12 - 18 years) and number of medications per prescription;
- 50  
51  
52 - For model performed with hospital and community data: age (0 days - 2 years, 2 - 6  
53  
54 years, 6 - 12 years, 12 - 18 years) and setting of prescription (hospital or community  
55  
56 setting).

The multivariate logistic regression model was constructed using the parameters of the univariate analysis, which showed at least a trend toward significance, with a cut-off of  $p=0.2$ . Backward elimination will start with all candidates in the model and run a sequence of statistical tests to remove them from or keep them in the model based on a nominal  $p$ -value  $<0.05$ . Odds ratios (OR) with 95% confidence intervals (CI) were estimated. Statistical significance was established at  $p<0.05$ . SPSS-22<sup>®</sup> software (SPSS Inc., Chicago, IL, USA) was used for analysis.

This project was approved by the local research ethics committee (n°2015/218).

## RESULTS

In the emergency department, 18,562 prescriptions for 15,973 patients consulted were analyzed. Among them, 29% had at least two visits in 6 months. In the community pharmacy, 4,780 prescriptions for 2,225 patients were evaluated (Figure 1). In ED and CP, 53% of patients had been issued with one prescription, 21% with two and 26% with three or more prescriptions. The population's characteristics and the frequency of pathologies were presented in table 1. Distribution of number of prescriptions by age category was described in the figure 2.

**Table 1. Characteristics of the study population**

<b>Population characteristics</b>	<b>Hospital (N=15,973)</b>	<b>Community (N=2,225)</b>
Age (years) mean (SD)	4.9 (4.5)	7.9 (5.3)
Min, Max	0-18	0-18
Female gender N(%)	8,769 (54.9)	NA

Number of prescriptions/patient mean (SD)	1.4 (0.9)	2.2 (1.9)
Min, Max	1-12	1-16
Number of medications per prescription mean (SD)	NA	2.4 (1.6)
Min, Max		1-22
Number of prescriptions by pathology N(%)		
Digestive disorders	2,728 (14.7)	NA
ENT-Pulmonary disorders	8,397 (45.2)	NA
Dermatological disorders	604 (3.3)	NA
Neuropsychiatric disorders	242 (1.3)	NA
Other illnesses <sup>#</sup>	6,591 (35.5)	NA

NA: Not available; ENT: ear, nose and throat

<sup>#</sup> For example, traumatic injury, pain, sickle cell disease

In hospital, POPI tools identified 541 PIM in 2.9% of the prescriptions analyzed. They were detected in 3.3% of the patients (n=530). In the community, PIM represented 12.3% of all prescriptions, affecting 26.4% patients (Table 2).

**Table 2. Potentially inappropriate medications (PIMs) identified by POPI**

	Hospital N (%)	Community N (%)
PIM identified per prescription *		
1	519 (2.8%)	551 (11.5%)
2	11 (0.1%)	37 (0.8%)

Prescriptions with at least one PIM *	530 (2.9%)	588 (12.3%)
Patients with at least one PIM °	530 (3.3%)	588 (26.4%)

\* Percentage calculated from 18,562 prescriptions at hospital and 4,780 prescriptions in the community.

° Percentage calculated from 15,793 patients at hospital and 2,225 patients in the community.

Details of PIM detected were presented in Table 3 for ED and in Table 4 for community pharmacy. Respiratory and digestive diseases had the highest rate of PIM in hospital and community pharmacy. For various illnesses, we removed one criterion involving medicines containing codeine because of their new contraindication in children under 12 years old.[33] However, the prescription of codeine was observed in 18 cases. According to our comparison of PIMs detectable in both settings, out-of-hospital medication always presents with a higher prevalence of PIMs (Figure 3).

**Table 3. Prevalence of PIMs and PPO identified by POPI in hospital**

Criteria		No. of PIMs and PPO	No. of case analyzed*	%
<b>Potentially inappropriate medications (PIMs)</b>		<b>541</b>	<b>7,304</b>	<b>7.4%</b>
<b>Various illnesses</b>		<b>3</b>	<b>64</b>	<b>4.6%</b>
AI-6	Opiates to treat migraine attacks	3	64	4.6%
<b>Digestive disorders</b>		<b>56</b>	<b>1,977</b>	<b>2.8%</b>
EI-2	Domperidone	28	1,956	1.4%
FI-3	The use of Diosmectite (Smecta®) in combination with another medication	27	1,956	1.4%
EI-1	Metoclopramide	1	1,956	0.05%
<b>ENT-Pulmonary disorders</b>		<b>472</b>	<b>5,163</b>	<b>9.1%</b>
II-4	Antibiotics to treat acute suppurative otitis media etc.	2	7	28.6%
II-2	Antibiotic treatment for a sore throat, without a positive RDT.	23	160	14.4%
II-9	Ear drops in the event of acute otitis media	86	1,083	7.9%
HI-1	Beta2 agonist, corticosteroids to treat an infant's first case of bronchiolitis	25	386	6.4%
II-5	Corticosteroids to treat acute suppurative otitis media etc.	190	3,616	5.2%
II-1	An antibiotic other than amoxicillin as a first-line treatment.	59	1,259	4.7%
JI-1	H1-antagonist to treat asthma	9	802	1.1%



II-8	Tenoate Etanolamine (Rhinotrophyll <sup>®</sup> ) and other nasal antiseptics	21	2,455	0.8%
II-3	Antibiotics for nasopharyngitis	26	3,444	0.7%
GI-3	Alimemazine (Theralene <sup>®</sup> ), oxomemazine (Toplexil <sup>®</sup> ) etc.	18	2,585	0.7%
JI-2	Cough suppressants to treat asthma	5	802	0.6%
HI-2	H1-antagonists, cough suppressants etc. to treat bronchiolitis	2	386	0.5%
II-7	H1-antagonists with sedative or atropine-like effects.	4	2,585	0.2%
GI-2	Mucolytics drugs, mucokinetics drugs or helcidine before 2 years of age	1	2,585	< 0.1%
II-6	Nasal or oral decongestant etc.	1	2,455	< 0.1%
<b>Dermatological disorders</b>		<b>10</b>	<b>100</b>	<b>10%</b>
OI-1	A combination of locally applied and orally administered antibiotics	9	32	28.1%
PI-2	Topical agents containing acyclovir administered to a child under six years of age	1	68	1.5%
<b>Potentially Prescribing Omissions (PPO)</b>		<b>425</b>	<b>4,508</b>	<b>9.4%</b>
<b>Digestive disorders</b>		<b>372</b>	<b>1,956</b>	<b>19.0%</b>
EO-1	Oral rehydration solution in the event of vomiting	135	313	43.1%
FO-1	Oral rehydration solution in the event of diarrhea	237	1,643	14.4%
<b>ENT-Pulmonary disorders</b>		<b>52</b>	<b>1,469</b>	<b>3.5%</b>
HO-1	0.9% NaCl to relieve nasal congestion etc.	38	386	9.8%
IO-2	Paracetamol combined with antibiotic treatment for ear infections etc.	14	1,083	1.3%
<b>Dermatological disorders</b>		<b>1</b>	<b>3</b>	<b>33.3%</b>
NO-2	Griseofulvin taken during a meal containing a moderate amount of fat	1	3	33.3%

ENT: ear, nose and throat; No: Number; RDT: Rapid diagnostic test.

% Percentage calculated by the number of PIMs or PPO detected from the total number of analyzable cases

\*number of cases analyzed corresponded with situation of inappropriate prescription or omission

**Table 4. Most frequently occurring PIMs and PPOs identified by POPI in community setting**

Criteria		N	%
<b>Potentially inappropriate medications (PIMs) N= 591</b>			
<b>Various illnesses</b>		<b>15</b>	<b>2.5%</b>
AI-5	Oral solutions of ibuprofen administered in more than 3 doses etc.	7	1.2%
CI-1	Fluoride supplements prescribed to infants under six months of age	5	0.8%
AI-4	The combined use of two NSAIDs	3	0.5%
<b>Digestive disorders</b>		<b>201</b>	<b>34%</b>

EI-2	Domperidone	152	25.7%
FI-3	The use of Diosmectite (Smecta <sup>®</sup> ) in combination with another medication	35	5.9%
FI-5	Intestinal antiseptics	9	1.5%
EI-1	Metoclopramide	2	0.3%
EI-6	The use of type H2 antihistamines for long periods of treatment	2	0.3%
FI-1	Loperamide before 3 years of age	1	0.2%
<b>ENT-Pulmonary disorders</b>		<b>369</b>	<b>62.4%</b>
GI-3	Alimemazine (Theralene <sup>®</sup> ), oxomemazine (Toplexil <sup>®</sup> )...	202	34.2%
GI-1	Pholcodine	81	13.7%
II-8	Tenoate etanolamine (Rhinotrophy <sup>®</sup> ) and other nasal antiseptics	62	10.5%
II-6	Nasal or oral decongestant etc.	20	3.4%
GI-2	Mucolytic drugs, mucokinetic drugs or helicidine prescribed to a child under 2 years of age	3	0.5%
GI-4	Terpene-based suppositories	1	0.2%
<b>Dermatological disorders</b>		<b>1</b>	<b>0.2%</b>
PI-2	Topical agents containing acyclovir prescribed to a child under six years of age	1	0.2%
<b>Neuropsychiatric disorders</b>		<b>5</b>	<b>0.8%</b>
RI-3	Levetiracetam in mL or in mg prescribed without systematically indicating XX mg per Y mL	5	0.8%
<b>Potentially Prescribing Omissions (PPO)</b>		<b>293</b>	
IO-1	Dose in mg for oral (solution of) amoxicillin etc.	293	100%

*NSAIDs: Non-steroidal anti-inflammatory drugs; ENT: ear, nose and throat  
% Percentage calculated from the total number of PIMs or PPO detected*

Omissions were identified in 425 prescriptions from our hospital (Table 3). The criterion on prescribing amoxicillin in mg (IO-1) was not analyzable due to the fact that this drug is prescribed in great quantity. Among 100 prescriptions randomly assessed in hospital extractions, 97 prescriptions were inappropriate. Nonetheless, one analysis on acute otitis media alone identified a rate of 99.5% (807/811) of prescriptions issued without specification of the doses in mg for oral amoxicillin. In community care, this was observed in 97% of prescriptions, in 13.2% of patients (Table 4).

PIMs classed by age were presented in the figure 4. Potential factors associated with PIM are presented in Table 5. On univariate analysis, only different age categories were associated with risk of PIM in hospital setting. In community setting, the number of medications per prescription and different age categories were found to be significantly associated with risk of PIM on univariate analysis. In the multivariable logistic regression model, the same results were obtained. When data from hospital and community were grouped, univariate analysis showed that different age categories and prescription setting were associated with risk of PIM. In the multivariable logistic regression model, prescription issued from outpatient care was significantly associated with a higher risk of PIM (OR: 5.7 [5.0; 6.4] 95%CI,  $p < 0.001$ ). In addition, patients aged 0-12 years are more at risk of having a PIM than patients aged between 12-18 years (OR: 1.3 [1.0-1.6] 95%CI,  $p = 0.03$  for 0-2 years; OR 2.4 [1.9-2.9]  $p < 0.001$  for 2-6 years; OR 1.9 [1.5-2.3]  $p < 0.001$ ).

**Table 5. Univariate and multivariate analysis to determine factors associated with PIM according to POPI criteria**

Variable	Univariate analysis		Multivariate analysis	
	OR* [CI 95%]	p-value	OR* [CI 95%]	p-value
<b><u>Model 1: Hospital prescription</u></b>				
<b><i>Sex</i></b>				
Male	1			
Female	1.0 [0.9-1.3]	0.3		
<b><i>Age category</i></b>				
0 - 2 years	2.4 [1.5-3.8]	< 0.001	2.4 [1.5-3.8]	< 0.001
2 - 6 years	3.8 [2.3-6.0]	< 0.001	3.8 [2.3-6.0]	< 0.001
6 - 12 years	2.1 [1.2-3.4]	0.005	2.1 [1.2-3.4]	0.005
12 - 18 years	1		1	
<b><u>Model 2: Community prescription</u></b>				
<b><i>Age category</i></b>				

0 - 2 years	0.8 [0.6-1.1]	0.2	0.8 [0.6-1.1]	0.1
2 - 6 years	2.1 [1.6-2.6]	< 0.001	2.0 [1.5-2.5]	< 0.001
6 - 12 years	1.9 [1.5-2.5]	< 0.001	2.0 [1.6-2.6]	< 0.001
12 - 18 years	1		1	
<b>Number of medications per prescription</b>	1.4 [1.3-1.4]	< 0.001	1.4 [1.3-1.4]	< 0.001
<b>Model 3: Hospital and Community prescription</b>				
<b>Age category</b>				
0 - 2 years	0.7 [0.6-0.8]	<0.001	1.3 [1.0-1.6]	0.03
2 - 6 years	1.4 [1.1-1.7]	0.002	2.4 [1.9-2.9]	< 0.001
6 - 12 years	1.4 [1.1-1.7]	0.002	1.9 [1.5-2.3]	< 0.001
12 - 18 years	1		1	
<b>Service</b>				
Hospital	1			
Community	5.3 [4.7-6.0]	< 0.001	5.7 [5.0-6.4]	< 0.001

OR: Odds ratio, CI: Confidence intervals.

## DISCUSSION

This study is the first to observe the prevalence of PIM and PPO in a pediatric population. As expected, the rate of IP detected is lower than in the geriatric population (pediatric: 3.3% in hospital, 26.4% in community vs geriatric: 35% in hospital and 51.3% in community).[9,16,34] Similarly, the incidence of PPO was higher in older people (57.9% and 59.4%) vs (2.6% and 13.2%). This result could be explained by the comorbidities present in elderly patients. Consequently, polypharmacy is the main factor which leads to PIM (2.4 drugs/prescription observed in our study compared with 6 per prescription).[16,34] The majority of PIM are found in respiratory and digestive pathology, in contrast with a geriatric population. Elderly people are frequently concerned by PIM in cardiovascular and nervous

1  
2  
3 central system indications.[16,34] Respiratory and digestive pathologies are typical in  
4  
5 children. These diseases are the most common reasons to be admitted to the ED.[35]  
6  
7

8 Domperidone, which is considered inappropriate by POPI was prescribed more frequently in  
9  
10 outpatient care. In our hospital, considering its modest effectiveness and adverse events  
11  
12 (serious cardiac disorders – QT prolongation and arrhythmia), this drug was no longer  
13  
14 referenced.[36] Loperamide is not recommended, particularly for infants (contraindicated in  
15  
16 France) due to its adverse effects such as ileus or death.[37,38] It is also considered to  
17  
18 produce PIM in a geriatric population. One case of prescription of loperamide was detected in  
19  
20 a young child (2 years) and we therefore made a phone call to the community pharmacist for  
21  
22 intervention. As they hold no recommendation in gastrointestinal disease, metoclopramide  
23  
24 and intestinal antiseptic were rarely observed in hospital prescription.[39] This could also be  
25  
26 explained by the contraindication of metoclopramide in children < 18 years old, except in the  
27  
28 event of nausea or vomiting associated with antimotiletic.[39–41]  
29  
30  
31  
32

33 PIM for diosmectite also occurred frequently. It is important to not administer other drugs at  
34  
35 the same time as diosmectite leaving a time interval to prevent any ADEs via interaction.[42]  
36  
37  
38

39 In respiratory tract infections, PIM was most frequently found in cases of a sore throat (14%).  
40  
41 Lack of rapid test results is common, although this enables us to avoid excessive prescription  
42  
43 of antibiotics and to reduce the emergence of highly resistant bacteria. As we know, the main  
44  
45 cause of sore throat in children is viruses, and streptococcal infection only presents in 25-40%  
46  
47 of cases.[43] We observed that antibiotics were present for 90% of cases of acute otitis media  
48  
49 (AOM). Amoxicillin was not used as the first-line treatment for 145 cases (13%). However,  
50  
51 only 59 cases were considered noncompliant according to criterion II-1. Indeed, in the  
52  
53 management of conjunctivitis-otitis syndrome caused by *Haemophilus influenza*, giving  
54  
55 amoxicillin/clavulanic acid as a first-line treatment is recommended.[44] This antibiotic is  
56  
57  
58  
59  
60

1  
2  
3 also privileged for acute maxillary sinusitis and frontal, ethmoidal and sphenoid sinusitis.[43]  
4  
5 Amoxicillin was used in 77% of cases of AOM, at a higher rate than that observed in a  
6  
7 national study in 2012 (66%). This result shows that the French recommendation for this  
8  
9 course of action in 2011, in order to reduce the rate of bacteria resistance, has had a strong  
10  
11 impact.[43,45] Eardrops are considered inappropriate in cases of AOM without other  
12  
13 symptoms. For chronic otitis with otorrhea, perforation of the eardrum or, antibiotic eardrops  
14  
15 are recommended.[46,47] This application showed that some of our criteria need to be more  
16  
17 detailed, in order to avoid mis-detection of PIM. Prevalence of beta2 agonists or  
18  
19 corticosteroids in an infant's first case of bronchiolitis is 6.4% (25/386 cases), lower than that  
20  
21 observed in a study of another French area in 2012 (41%).[48–50]  
22  
23

24  
25 A high frequency of prescription of antibiotics, corticosteroids or nasal antiseptic medication  
26  
27 was detected in case of nasopharyngitis, although there is no evidence for this.[51] Antiseptics  
28  
29 such as tenoate ethanolamine did not receive a favorable opinion from the ANSM (French  
30  
31 National Agency for Medicines and Health Products Safety) because they exposed patients to  
32  
33 potential nasal irritation and occasionally to serious allergies.[52] Even so, it was frequently  
34  
35 present in prescriptions from outpatient care. Unnecessary exposure to cough suppressants,  
36  
37 pholcodine, nasal or oral decongestants was also observed frequently in this sector.[52]  
38  
39  
40

41  
42 Less PIM were found in dermatological disorders. In the management of scabies, we had  
43  
44 removed the criterion on Ascabiol<sup>®</sup> (Sulfirame and Benzyl Benzoate) as it was out of stock  
45  
46 since 2012.  
47  
48

49  
50 In comparison to PIM, the rate of PPO observed was lower and centred on specific disorders.  
51  
52 In the management of diarrhea caused by gastroenteritis, in hospital, our study found that it  
53  
54 was common to omit prescription of an oral rehydration solution (ORS): 14% (237/1643  
55  
56 case). Even so, this rate is lower than that found in another national study in 2007 (29%).[53]  
57  
58  
59  
60

1  
2  
3 It could be that the recommendation of the European Society for Paediatric Gastroenterology,  
4 Hepatology, and Nutrition (ESPGHAN) in 2008 has had a positive impact.[37,39] Thus, this  
5 criterion serves not only to highlight the importance of ORS for the prescriber but also helps  
6 to increase the frequency of pharmaceutical recommendation of this drug. Another common  
7 omission was identified in the prescription of oral liquid formulation. A precise dosage of oral  
8 amoxicillin is necessary because many errors occurred when using the dosing spoon.[54] In  
9 62/63 cases, oral acyclovir was not prescribed for herpetic gingivostomatitis. In daily practice,  
10 this occurred because a blood test to screen for the primary infection is not performed .  
11 However, the oral treatment can prevent recurrences, which cannot be attained by using  
12 cream.[55] Once again, the role of the community pharmacist is significant in detecting the  
13 omission, intervening or providing education to the patient when necessary.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27  
28 As estimated, the child aged between 0 and 12 years has the highest risk of presenting with a  
29 PIM, according to a multivariate analysis. No inappropriate prescription or omission were  
30 detected for patient aged less 28 days. Certainly, this age group is most frequently affected by  
31 respiratory diseases and is thus exposed to many unnecessary prescriptions such as cough  
32 suppressants or decongestant drugs. As we know, they are also affected by off-label drug  
33 prescriptions, which is consistent with reports from other sources.[56,57] Once again, our  
34 study highlights the importance of appropriate prescription in this age group. As with  
35 geriatrics, an increase in numbers of medications can be associated with PIM.[34]  
36 Prescriptions issued from hospitals elicit fewer IP than those issued by the community. The  
37 main reason for this is that many drugs are not available in this hospital, such as cough  
38 suppressants, Rhinotrophyl<sup>®</sup> (tenoate ethanalamine), domperidone, etc. This shows that many  
39 PIM are preventable in a hospital setting. An efficient method for prevention of PIM could be  
40 to focus on the prescribing habits of physicians and thus have an impact on the selection of  
41 drugs, thereby reducing the rate of PIM.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Our study has several limitations. Firstly, it is a retrospective and monocentric study. Our  
4  
5 result in the hospital could be underestimated. In addition, several criteria could not be  
6  
7 analyzed due to the large number of prescriptions (for example, those for fever or pain which  
8  
9 are associated with many diseases) or absence of a specific pathology (mosquitos, lice,  
10  
11 hyperactivity etc.). Antibiotic prophylaxis, vitamin supplements, proposition of vaccination  
12  
13 etc. can be analyzed in prospective studies. A lack of clinical information is the main  
14  
15 limitation in detection in a community setting. This also constitutes a challenge for  
16  
17 pharmaceutical care review in elderly patients.[58] However, a certain amount of PIM were  
18  
19 identified using POPI. Our study showed that there are many criteria which could be detected  
20  
21 without access to clinical information and are easy to identify. Moreover, community  
22  
23 pharmacists, in their practice, can extrapolate diagnoses from their experience, from common  
24  
25 indications or by interviewing their patient.  
26  
27  
28  
29

30 This is the first study which permits to evaluate prevalence of PIM and PPO in pediatrics  
31  
32 prescription. Hereafter, in order to prove the effectiveness of this tool (decrease of PIM and  
33  
34 PPO), further investigations must be carried out on a larger scale, both in hospital and in  
35  
36 community care. In the next few years, a stepped wedge randomized cluster multicenter study  
37  
38 will be conducted to prove if POPI decreases number of PIM and PPO. It is also necessary to  
39  
40 evaluate the impact of this tool on reducing adverse drugs events, both in consultation or upon  
41  
42 hospitalization. The impact of pharmacists in providing appropriate prescriptions should be  
43  
44 also evaluated. Subsequently, this tool may be proposed to several professional societies such  
45  
46 as the French Society for Pediatricians and the French Society of Clinical Pharmacy to make  
47  
48 its use more widespread. The tool should be regularly updated to reflect recent events and to  
49  
50 specify certain criteria.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 To facilitate its use, this tool can be presented as a mobile app, a small handbook or be  
4 installed into prescription software. In summary, we hope that POPI could be a practical  
5 option used to reduce medication errors and to improve the suitability of prescriptions. It  
6 provides rapid detection of PIM and PPO and can also open up a discussion on the  
7 relationship between the doctor and the pharmacist to remedy the issue at hand.[59]  
8  
9  
10  
11  
12

## 13 14 15 **CONCLUSION**

16  
17  
18 Our study was carried out in in two sectors, hospital and community, and provides a global  
19 view of PIM and PPO in pediatric patients. It highlights the potential role of POPI tools in  
20 improving prescription quality in various sectors. POPI should be applied in different services  
21 to deepen and reinforce its utilization. A prospective and multicenter study should be  
22 conducted to evaluate its impact and benefit in clinical practice.  
23  
24  
25  
26  
27  
28

## 29 30 **ACKNOWLEDGMENTS**

31  
32  
33 We would like to thank the Emergency department of Robert-Debré hospital and the Albaret  
34 pharmacy community for their data support.  
35  
36  
37

38  
39 We would also like to thank the French Society of Clinical Pharmacy (pediatric group) for  
40 their support.  
41  
42  
43

## 44 **ETHICS**

45  
46  
47  
48 This project was approved by the local research ethics committee (n°2015/218).  
49  
50

## 51 **DISCLOSURE OF INTEREST**

52  
53  
54  
55 None Declared  
56  
57  
58  
59  
60

## FUNDING STATEMENT

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

## AUTHOR'S CONTRIBUTION

Sonia Prot-Labarthe, Aurore Berthe-Aucejo conceptualised and designed the study, drafted the initial manuscript, and approved the final manuscript as submitted.

Rym Boulkedid and HPK Nguyen carried out analyses, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Xavier Bellettre, Thomas Weil, Olivier Bourdon reviewed and revised the manuscript and approved the final manuscript as submitted.

François Angoulvant and Patrick Albaret supplied data from hospital and community pharmacy and reviewed and revised the manuscript and approved the final manuscript as submitted.

## DATA SHARING STATEMENT

We have no additional unpublished data

## REFERENCES

- 1 Chrischilles EA, VanGilder R, Wright K, *et al*. Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults. *J Am Geriatr Soc* 2009;**57**:1000–6.
- 2 Lund BC, Carnahan RM, Egge JA, *et al*. Inappropriate prescribing predicts adverse drug events in older adults. *Ann Pharmacother* 2010;**44**:957–63. doi:10.1345/aph.1M657
- 3 Drees - Ministère des Affaires sociales et de la Santé. Enquête Nationale sur les Événements Indésirables graves associés aux Soins. 2011. <http://www.drees.sante.gouv.fr/enquete-nationale-sur-les-evenements-indesirables-graves-associes-aux-soins-description-des-resultats-2009,9499.html> (accessed 5 Mar 2015).

- 1
- 2
- 3
- 4 Smyth RMD, Gargon E, Kirkham J, *et al.* Adverse drug reactions in children--a  
5 systematic review. *PloS One* 2012;**7**:e24061. doi:10.1371/journal.pone.0024061
- 6
- 7 de Vries TW, van Hunsel F. Adverse drug reactions of systemic antihistamines in children  
8 in the Netherlands. *Arch Dis Child* 2016;**101**:968–70. doi:10.1136/archdischild-2015-  
9 310315
- 10
- 11 Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral  
12 corticosteroids in children. *Arch Dis Child* 2016;**101**:365–70. doi:10.1136/archdischild-  
13 2015-309522
- 14
- 15 Cliff-Eribo KO, Sammons H, Choonara I. Systematic review of paediatric studies of  
16 adverse drug reactions from pharmacovigilance databases. *Expert Opin Drug Saf*  
17 2016;**15**:1321–8. doi:10.1080/14740338.2016.1221921
- 18
- 19 Reidenberg MM. Can the selection and use of essential medicines decrease inappropriate  
20 drug use? *Clin Pharmacol Ther* 2009;**85**:581–3. doi:10.1038/clpt.2009.10
- 21
- 22 Barry PJ, Gallagher P, Ryan C, *et al.* START (screening tool to alert doctors to the right  
23 treatment)--an evidence-based screening tool to detect prescribing omissions in elderly  
24 patients. *Age Ageing* 2007;**36**:632–8. doi:10.1093/ageing/afm118
- 25
- 26 Legrain S others. Consommation médicamenteuse chez le sujet âgé. Consommation,  
27 prescription, iatrogénie et observance. 2005. [http://www.has-](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28__16_44_51_580.pdf)  
28 [sante.fr/portail/upload/docs/application/pdf/pmsa\\_synth\\_biblio\\_2006\\_08\\_28\\_\\_16\\_44\\_51\\_](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28__16_44_51_580.pdf)  
29 [580.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28__16_44_51_580.pdf).
- 30
- 31 Beers MH, Ouslander JG, Rollinger I, *et al.* Explicit criteria for determining  
32 inappropriate medication use in nursing home residents. UCLA Division of Geriatric  
33 Medicine. *Arch Intern Med* 1991;**151**:1825–32.
- 34
- 35 Naugler CT, Brymer C, Stolee P, *et al.* Development and validation of an improving  
36 prescribing in the elderly tool. *Can J Clin Pharmacol J Can Pharmacol Clin* 2000;**7**:103–  
37 7.
- 38
- 39 Samsa GP, Hanlon JT, Schmader KE, *et al.* A summated score for the medication  
40 appropriateness index: development and assessment of clinimetric properties including  
41 content validity. *J Clin Epidemiol* 1994;**47**:891–6.
- 42
- 43 Laroche M-L, Bouthier F, Merle L, *et al.* Médicaments potentiellement inappropriés aux  
44 personnes âgées : intérêt d'une liste adaptée à la pratique médicale française. *Rev*  
45 *Médecine Interne* 2009;**30**:592–601. doi:10.1016/j.revmed.2008.08.010
- 46
- 47 Gallagher P, Ryan C, Byrne S, *et al.* STOPP (Screening Tool of Older Person's  
48 Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment).  
49 Consensus validation. *Int J Clin Pharmacol Ther* 2008;**46**:72–83.
- 50
- 51
- 52 Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially  
53 inappropriate Prescriptions): application to acutely ill elderly patients and comparison  
54 with Beers' criteria. *Age Ageing* 2008;**37**:673–9. doi:10.1093/ageing/afn197
- 55
- 56
- 57
- 58
- 59

- 17 Gallagher P, Lang PO, Cherubini A, *et al.* Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. *Eur J Clin Pharmacol* 2011;**67**:1175–88. doi:10.1007/s00228-011-1061-0
- 18 Dalleur O, Boland B, Losseau C, *et al.* Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. *Drugs Aging* 2014;**31**:291–8. doi:10.1007/s40266-014-0157-5
- 19 Ryan C, O'Mahony D, Kennedy J, *et al.* Potentially inappropriate prescribing in an Irish elderly population in primary care. *Br J Clin Pharmacol* 2009;**68**:936–47. doi:10.1111/j.1365-2125.2009.03531.x
- 20 Yayla ME, Bilge U, Binen E, *et al.* The use of START/STOPP criteria for elderly patients in primary care. *ScientificWorldJournal* 2013;**2013**:165873. doi:10.1155/2013/165873
- 21 Borges EP, Morgado M, Macedo AF. Prescribing omissions in elderly patients admitted to a stroke unit: descriptive study using START criteria. *Int J Clin Pharm* 2012;**34**:481–9. doi:10.1007/s11096-012-9635-1
- 22 Dedhiya SD, Hancock E, Craig BA, *et al.* Incident use and outcomes associated with potentially inappropriate medication use in older adults. *Am J Geriatr Pharmacother* 2010;**8**:562–70. doi:10.1016/S1543-5946(10)80005-4
- 23 Lau DT, Kasper JD, Potter DEB, *et al.* Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. *Arch Intern Med* 2005;**165**:68–74. doi:10.1001/archinte.165.1.68
- 24 Hébert G, Prot-Labarthe S, Tremblay M-E, *et al.* La pédiatrie, toujours exclue de l'innovation pharmaceutique? *Arch Pédiatrie* 2014;**21**:245–50. doi:10.1016/j.arcped.2013.12.016
- 25 Benavides S, Huynh D, Morgan J, *et al.* Approach to the pediatric prescription in a community pharmacy. *J Pediatr Pharmacol Ther JPPT Off J PPAG* 2011;**16**:298–307. doi:10.5863/1551-6776-16.4.298
- 26 Kaushal R, Bates DW, Goldmann DA. Medication errors and adverse drug events in pediatric inpatients. *JAMA* 2001;**285**:2114–20.
- 27 Mercier J., Morin L, Prot-Labarthe S. Les erreurs de prescription et leurs conséquences. 2010.
- 28 Clavenna A, Bonati M. Differences in antibiotic prescribing in paediatric outpatients. *Arch Dis Child* 2011;**96**:590–5. doi:10.1136/adc.2010.183541
- 29 Risk R, Naismith H, Burnett A, *et al.* Rational prescribing in paediatrics in a resource-limited setting. *Arch Dis Child* 2013;**98**:503–9. doi:10.1136/archdischild-2012-302987
- 30 Choonara I. Rational prescribing is important in all settings. *Arch Dis Child* 2013;**98**:720. doi:10.1136/archdischild-2013-304559

- 1  
2  
3 31 Prot-Labarthe S, Vercheval C, Angoulvant F, *et al.* «POPI ; pédiatrie : omissions et  
4 prescriptions inappropriées ». Outil d'identification des prescriptions inappropriées chez  
5 l'enfant. *Arch Pédiatrie* 2011;**18**:1231–2. doi:10.1016/j.arcped.2011.08.019  
6  
7 32 Prot-Labarthe S, Weil T, Angoulvant F, *et al.* POPI (Pediatrics: Omission of Prescriptions  
8 and Inappropriate Prescriptions): Development of a Tool to Identify Inappropriate  
9 Prescribing. *PLoS ONE* 2014;**9**:e101171. doi:10.1371/journal.pone.0101171  
10  
11 33 European Medicines Agency. Codeine not to be used in children below 12 years for  
12 cough and cold. 2015.<http://www.ema.europa.eu>  
13  
14 34 Gallagher P, Lang PO, Cherubini A, *et al.* Prevalence of potentially inappropriate  
15 prescribing in an acutely ill population of older patients admitted to six European  
16 hospitals. *Eur J Clin Pharmacol* 2011;**67**:1175–88. doi:10.1007/s00228-011-1061-0  
17  
18 35 Nadège Caillère, Céline Caserio-Schonemann. Réseau OSCOUR® (Organisation de la  
19 surveillance coordonnée des urgences) Résultats nationaux 2004/2011. 2011.  
20  
21 36 European Medicines Agency. PRAC recommends restricting use of domperidone.  
22 2014.<http://www.ema.europa.eu>  
23  
24 37 Guarino A, Albano F, Ashkenazi S, *et al.* European Society for Paediatric  
25 Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious  
26 Diseases evidence-based guidelines for the management of acute gastroenteritis in  
27 children in Europe: executive summary. *J Pediatr Gastroenterol Nutr* 2008;**46**:619–21.  
28 doi:10.1097/MPG.0b013e31816e219e  
29  
30 38 Li S-TT, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children:  
31 systematic review and meta-analysis. *PLoS Med* 2007;**4**:e98.  
32 doi:10.1371/journal.pmed.0040098  
33  
34 39 Guarino A, Ashkenazi S, Gendrel D, *et al.* European Society for Pediatric  
35 Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious  
36 Diseases evidence-based guidelines for the management of acute gastroenteritis in  
37 children in Europe: update 2014. *J Pediatr Gastroenterol Nutr* 2014;**59**:132–52.  
38 doi:10.1097/MPG.0000000000000375  
39  
40 40 Agence national de sécurité du médicament et des produits de santé. Contre-indication des  
41 spécialités à base de métoclopramide (Primpéran® et génériques) chez l'enfant et  
42 l'adolescent et renforcement des informations sur les risques neurologiques et  
43 cardiovasculaires - Lettre aux professionnels de santé. 2012.  
44  
45 41 Agence national de sécurité du médicament et des produits de sant. Spécialités à base de  
46 métoclopramide : actualisation des indications et de la posologie pour diminuer le risque  
47 (principalement neurologique) d'effets indésirables - Lettre aux professionnels de santé.  
48 2014.  
49  
50 42 CNHIM. Diosmectite MYL 3G PDR Oral Sachet-Monographie spécialité.  
51 <http://www.theriaque.org>  
52  
53 43 Société de Pathologie Infectieuse de Langue Française. Antibiothérapie par voie générale  
54 en pratique courante dans les infections respiratoires hautes de l'adulte et l'enfant. 2011.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 44 American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media.  
4 Diagnosis and management of acute otitis media. *Pediatrics* 2004;**113**:1451–65.  
5  
6 45 Levy C, Pereira M, Guedj R, *et al.* Impact of 2011 French guidelines on antibiotic  
7 prescription for acute otitis media in infants. *Médecine Mal Infect* 2014;**44**:102–6.  
8 doi:10.1016/j.medmal.2014.01.005  
9  
10 46 Granath A, Rynnel-Dagöö B, Backheden M, *et al.* Tube associated otorrhea in children  
11 with recurrent acute otitis media; results of a prospective randomized study on  
12 bacteriology and topical treatment with or without systemic antibiotics. *Int J Pediatr*  
13 *Otorhinolaryngol* 2008;**72**:1225–33. doi:10.1016/j.ijporl.2008.04.015  
14  
15 47 Antibiothérapie locale en ORL. Argumentaire. *Médecine Mal Infect* 2004;**34**:573–82.  
16 doi:10.1016/j.medmal.2004.10.004  
17  
18 48 Bronchiolitis in children | 1-recommendations | Guidance and guidelines | NICE.  
19 <http://www.nice.org.uk/guidance/NG9/chapter/1-recommendations> (accessed 22 Jun  
20 2015).  
21  
22 49 Conférence de Consensus sur la prise en charge de la bronchiolite du nourrisson.  
23 2000.<http://www.has-sante.fr>  
24  
25 50 Branchereau E, Branger B, Launay E, *et al.* [Management of bronchiolitis in general  
26 practice and determinants of treatment being discordant with guidelines of the HAS].  
27 *Arch Pédiatrie Organe Off Société Fr Pédiatrie* 2013;**20**:1369–75.  
28 doi:10.1016/j.arcped.2013.09.028  
29  
30 51 Centre for Clinical Practice at NICE (UK). *Respiratory Tract Infections - Antibiotic*  
31 *Prescribing: Prescribing of Antibiotics for Self-Limiting Respiratory Tract Infections in*  
32 *Adults and Children in Primary Care*. London: : National Institute for Health and Clinical  
33 Excellence (UK) 2008. <http://www.ncbi.nlm.nih.gov/books/NBK53632/> (accessed 22 Jun  
34 2015).  
35  
36 52 *La Revue Prescrire*. 2014. <http://www.prescrire.org/fr/>  
37  
38 53 Martinot A, Pruvost I, Aurel M, *et al.* [Improvement in the management of acute  
39 diarrhoea in France?]. *Arch Pédiatrie Organe Off Société Fr Pédiatrie* 2007;**14** **Suppl**  
40 **3**:S181-185.  
41  
42 54 Berthe-Aucejo A, Girard D, Lorrot M, *et al.* Evaluation of frequency of paediatric oral  
43 liquid medication dosing errors by caregivers: amoxicillin and josamycin. *Arch Dis Child*  
44 Published Online First: 4 January 2016. doi:10.1136/archdischild-2015-309426  
45  
46 55 Société Française de Dermatologie. Prise en charge de l'herpès cutanéomuqueux chez le  
47 sujet immuno compétent (manifestations oculaires exclues). 2001.<http://www.has-sante.fr>  
48  
49 56 Joret P, Prot-Labarthe S, Brion F, *et al.* Caractérisation des indications hors AMM en  
50 pédiatrie : analyse descriptive de 327 lignes de prescriptions dans un hôpital pédiatrique.  
51 *Pharm Hosp Clin* 2014;**49**:e151–2. doi:10.1016/j.phclin.2014.04.306  
52  
53 57 Shah SS, Hall M, Goodman DM, *et al.* Off-label drug use in hospitalized children. *Arch*  
54 *Pediatr Adolesc Med* 2007;**161**:282–90. doi:10.1001/archpedi.161.3.282  
55  
56  
57  
58  
59

- 1  
2  
3 58 Ryan C, O'Mahony D, O'Donovan DÓ, *et al.* A comparison of the application of  
4 STOPP/START to patients' drug lists with and without clinical information. *Int J Clin*  
5 *Pharm* 2013;**35**:230–5. doi:10.1007/s11096-012-9733-0  
6  
7 59 Gillespie U, Alassaad A, Hammarlund-Udenaes M, *et al.* Effects of Pharmacists'  
8 Interventions on Appropriateness of Prescribing and Evaluation of the Instruments' (MAI,  
9 STOPP and STARTs') Ability to Predict Hospitalization—Analyses from a Randomized  
10 Controlled Trial. *PLoS ONE* 2013;**8**. doi:10.1371/journal.pone.0062401  
11  
12  
13

14 Figure 1. Flow chart indicating the course of the study  
15

16  
17 \* Prescriptions with only one medical device, dietary supplement or hygiene product, ED:  
18  
19 Emergency department  
20  
21  
22

23 Figure 2. Distribution of number of prescriptions according to age category in hospital and  
24  
25 community settings  
26  
27

28 Figure 3. Comparison of PIMs detected in hospital and in outpatient care  
29  
30

31  
32 Figure 4. Total prescription and PIMs in both hospital and outpatient care: Percentage  
33  
34 distribution by age group  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Flow chart indicating the course of the study† \* Prescriptions with only one medical device, dietary supplement or hygiene product, ED: Emergency department

51x27mm (300 x 300 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Distribution of number of prescriptions according to age category in hospital and community settings

42x26mm (300 x 300 DPI)

view only




Figure 3. Comparison of PIMs detected in hospital and in outpatient care

74x42mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4. Total prescription and PIMs in both hospital and outpatient care: Percentage distribution by age group

90x23mm (300 x 300 DPI)

peer review only

## Appendix 1. POPI - Pediatrics: Omission of Prescriptions &amp; Inappropriate prescriptions

## A- PAIN AND FEVER

## Inappropriate prescriptions

- AI-1.** Prescription of two alternating antipyretics as a first-line treatment. \*
- AI-2.** Prescription of a medication other than paracetamol as a first line treatment (except in the case of migraine).
- AI-3.** Rectal administration of paracetamol as a first-line treatment.
- AI-4.** The combined use of two NSAIDs. \* °
- AI-5.** Oral solutions of ibuprofen administered in more than three doses per day using a graduated pipette of 10mg/kg (other than Advil®). °
- AI-6.** Opiates to treat migraine attacks. \*

## Omissions

- A0-1.** Failure to give sugar solution to new-born babies and infants under four months old two minutes prior to venipuncture.
- A0-2.** Failure to give an osmotic laxative to patients being treated with morphine for a period of more than 48 hours.

## B- URINARY INFECTIONS

## Inappropriate prescriptions

- BI-1.** Nitrofurantoin used as a prophylactic. \*
- BI-2.** Nitrofurantoin used as a curative agent in children under six years of age, or indeed any other antibiotic if avoidable. \*
- BI-3.** Antibiotic prophylaxis following an initial infection without complications (except in the case of uropathy). \*
- BI-4.** Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of uropathy). \*

## C- VITAMIN SUPPLEMENTS AND ANTIBIOTIC PROPHYLAXIS

## Inappropriate prescriptions

- CI-1.** Fluoride supplements prior to six months of age. °\*

## Omissions

- CO-1.** Insufficient intake of vitamin D. Minimum vitamin D intake:
- Breastfed baby = 1 000 to 1 200 IU/day
  - Infant < 18 months of age (milk enriched in vitamin D) = 600 to 800 IU/day
  - Child aged between 18 months and five years, and adolescents aged between 10 and 18 years: two quarterly loading doses of 80 000 to 100 000 IU/day in winter (adolescents can take this dose in one go).
- CO-2.** Antibiotic prophylaxis with phenoxymethylpenicillin (Oracilline) starting from two months of age and lasting until five years of age for children with sickle-cell anemia: 100 000 IU/kg/day (in two doses) for children weighing 10kg or less and 50 000 IU/kg/day for children weighing over 10kg (also in two doses). \*

## D- MOSQUITOS

## Inappropriate prescriptions

- DI-1.** The use of skin repellents in infants less than six months old and picardin in children less than 24 months old.
- DI-2.** Citronella (lemon grass) oil (essential oil).
- DI-3.** Anti-insect bracelets to protect against mosquitos and ticks.
- DI-4.** Ultrasonic pest control devices, vitamin B1, homeopathy, electric bug zappers, sticky tapes without insecticide.

## Omissions

- DO-1. DEET** "30%" (max) before 12 years old  
"50%" (max) after 12 years old.
- DO-2. IR3535** "20%" (max) before 24 months old  
"35%" (max) after 24 months old.
- DO-3.** Mosquito nets and clothes treated with pyrethroids.

**E- NAUSEA, VOMITTING, OR GASTROESOPHAGEAL REFLUX****Inappropriate prescriptions**

- EI-1.** Metoclopramide. \* °
- EI-2.** Domperidone. \* °
- EI-3.** Gastric antisecretory drugs to treat gastroesophageal reflux, dyspepsia, the crying of new-born babies (in the absence of any other signs or symptoms), as well as faintness in infants. \*
- EI-4.** The combined use of proton pump inhibitors and NSAIDs, for a short period of time, in patients without risk factors. \*
- EI-5.** Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube). \*
- EI-6.** The use of type H2 antihistamines for long periods of treatment. \* °
- EI-7.** Erythromycin as a prokinetic agent. \*
- EI-8.** The use of setrons (5-HT3 antagonists) for chemotherapy-associated nausea and vomiting. \*

**Omissions**

- EO-1.** Oral rehydration solution in the event of vomiting.\*

**F- DIARRHEA****Inappropriate prescriptions**

- FI-1.** Loperamide before 3 years of age.\*°
- FI-2.** Loperamide in the case of invasive diarrhea.\*
- FI-3.** The use of Diosmectite (Smecta®) in combination with another medication.\*°
- FI-4.** The use of Saccharomyces boulardii (Ultralevure) in powder form, or in a capsule that has to be opened prior to ingestion, to treat patients with a central venous catheter or an immunodeficiency.\*
- FI-5.** Intestinal antiseptics.\*°

**Omissions**

- FO-1.** Oral rehydration solution in the event of diarrhea.\*

**G- COUGH****Inappropriate prescriptions**

- GI-1.** Pholcodine. \* °
- GI-2.** Mucolytic drugs, mucokinetic drugs, or helcidine before two years of age. \* °
- GI-3.** Alimemazine (Theralene®), oxememazine (Toplexil®), promethazine (Phenergan®), and other types. \* °
- GI-4.** Terpene-based suppositories. \* °

**Omissions**

- GO-1.** Failure to propose a whooping cough booster vaccine for adults who are likely to become parents in the coming months or years (only applicable if the previous vaccination was more than 10 years ago). This booster vaccination should also be proposed to the family and entourage of expectant parents (parents, grandparents, nannies/child minders).

**H- BRONCHIOLITIS IN INFANTS****Inappropriate prescriptions**

- HI-1.** Beta2 agonists, corticosteroids to treat an infant's first case of bronchiolitis. \*
- HI-2.** H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis. \*
- HI-3.** Antibiotics in the absence of signs indicating a bacterial infection (acute otitis media, fever, etc.). \*

**Omissions**

- HO-1.** 0.9% NaCl to relieve nasal congestion (not applicable if nasal congestion is already being treated with 3% NaCl delivered by a nebulizer). \*
- HO-2.** Palivizumab in the following cases:  
 (1) babies born both at less than 35 weeks of gestation and less than six months prior to the onset of a seasonal RSV epidemic;  
 (2) children less than two years old who have received treatment for bronchopulmonary dysplasia in the past six months;  
 (3) children less than two years old suffering from congenital heart disease with hemodynamic abnormalities.

DIGESTIVE PROBLEMS

ENT-PULMONARY PROBLEMS

**I- ENT INFECTIONS****Inappropriate prescriptions**

- II-1.** An antibiotic other than amoxicillin as a first-line treatment for acute otitis media, strep throat, or sinusitis (provided that the patient is not allergic to amoxicillin). An effective dose of amoxicillin for an pneumococcal infection is 80–90 mg/kg/day and an effective dose for a streptococcal infection is 50 mg/kg/day.\*
- II-2.** Antibiotic treatment for a sore throat, without a positive rapid diagnostic test result, in children more than three years old.\*
- II-3.** Antibiotics for nasopharyngitis, congestive otitis, sore throat before three years of age, or laryngitis; antibiotics as a first-line treatment for acute otitis media showing few symptoms, after two years of age.\*
- II-4.** Antibiotics to treat otitis media with effusion (OME), except in the case of hearing loss or if OME lasts for more than three months.\*
- II-5.** Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat.\*
- II-6.** Nasal or oral decongestant (oxymetazoline (Aturgyl®), pseudoephedrine (Sudafed®), naphazoline (Derinox®), ephedrine (Rhinamide®), tuaminoheptane (Rhinofluimicil®), phenylephrine (Humoxal®)).\*°
- II-7.** H1-antagonists with sedative or atropine-like effects (pheniramine, chlorpheniramine), or camphor; inhalers, nasal sprays, or suppositories containing menthol (or any terpene derivatives) before 30 months of age.\* °
- II-8.** Ethanalamine tenoate (Rhinotrophyl®) and other nasal antiseptics.\* °
- II-9.** Ear drops in the case of acute otitis media.\*

**Omissions**

- IO-1.** Doses in mg for drinkable (solutions of) amoxicillin or josamycin.\*°
- IO-2.** Paracetamol combined with antibiotic treatment for ear infections to relieve pain.\*

**J- ASTHMA****Inappropriate prescriptions**

- JI-1.** Ketotifen and other H1-antagonists, sodium cromoglycate.\*
- JI-2.** Cough suppressants.\*

**Omissions**

- JO-1.** Asthma inhaler appropriate for the child's age.
- JO-2.** Preventative treatment (inhaled corticosteroids) in the case of persistent asthma.\*

**K-ACNE VULGARIS****Inappropriate prescriptions**

- KI-1.** Minocycline.\* °
- KI-2.** Isotretinoin in combination with a member of the tetracycline family of antibiotics.\* °
- KI-3.** The combined use of an oral and a local antibiotic.\*
- KI-4.** Oral or local antibiotics as a monotherapy (not in combination with another drug).\*
- KI-5.** Cyproterone+ethinylestradiol (Diane 35®) as a contraceptive to allow isotretinoin per os.\* °
- KI-6.** Androgenic progestins (levonorgestrel, norgestrel, norethisterone, lynestrenol, dienogest, contraceptive implants or vaginal rings).\*

**Omissions**

- KO-1.** Contraception (provided with a logbook/diary) for menstruating girls taking isotretinoin.
- KO-2.** Topical treatment (benzoyl peroxide, retinoids, or both) in combination with antibiotic therapy.\*

**L- SCABIES****Omissions**

**LO-1.** A second dose of ivermectin two weeks after the first. \*

**LO-2.** Decontamination of household linen and clothes and treatment for other family members.

**M- LICE****Inappropriate prescriptions**

**MI-1.** The use of aerosols for infants, children with asthma, or children showing asthma-like symptoms such as dyspnea.

**N- RINGWORM****Inappropriate prescriptions****Omissions**

**NI-1.** Treatment other than griseofulvin for *Microsporum*. \*

**NO-1.** Topical treatment combined with an orally administered treatment. \*

**NO-2.** Griseofulvin taken during a meal containing a moderate amount of fat. \* °

**O-IMPETIGO****Inappropriate prescriptions**

**OI-1.** The combination of locally applied and orally administered antibiotic.\*

**OI-2.** Fewer than two applications per day for topical antibiotics.\*

**OI-3.** Any antibiotic other than mupirocin as a first-line treatment (except in cases of hypersensitivity to mupirocin).\*

**P- HERPES SIMPLEX****Inappropriate prescriptions****Omissions**

**PI-1.** Topical agents containing corticosteroids. \*

**PO-1.** Paracetamol during an outbreak of herpes. \*

**PI-2.** Topical agents containing acyclovir before six years of age. \* °

**PO-2.** Orally administered acyclovir to treat primary herpetic gingivostomatitis. \*

**Q-DERMATITE ATOPIQUE****Inappropriate prescriptions**

**QI-1.** A strong dermocorticoid (clobetasol propionate 0.05% Dermoval, betamethasone dipropionate Diprosone) applied to the face, the armpits or groin, and the backside of babies or young children. \*

More than one application per day of a dermocorticoid, except in cases of severe lichenification. \*

**QI-2.** Local or systemic antihistamine during the treatment of outbreaks. \*

**QI-3.** Topically applied 0.03% tacrolimus before two years of age. \*°

Topically applied 0.1% tacrolimus before 16 years of age.

**QI-4.** Oral corticosteroids to treat outbreaks. \*

**R- EPILEPSY****Inappropriate prescriptions**

**RI-1.** Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of myoclonic epilepsy. \*

**RI-2.** Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of epilepsy with absence seizures (especially for childhood absence epilepsy or juvenile absence epilepsy). \*

**RI-3.** Levetiracetam, oxcarbamazepine in mL or in mg without systematically writing XX mg per Y mL. \* °

**S-DEPRESSION****Inappropriate prescriptions**

**SI-1.** An SSRI antidepressant other than fluoxetine as a first-line treatment (in the case of pharmacotherapy). \*

**SI-2.** Tricyclic antidepressants to treat depression. \*

**T- NOCTURNAL ENURESIS****Inappropriate prescriptions**

1 **TI-1.** Desmopressin administered by a nasal spray. \* °

2 Desmopressin in the case of daytime symptoms.

3 **TI-2.** An anticholinergic agent used as a monotherapy in the absence of daytime symptoms. \*

4 **TI-3.** Tricyclic agents in combination with anticholinergic agents. \* °

5 **TI-4.** Tricyclic agents as a first-line treatment. \*

## 6 **U- ANOREXIA**

### 7 **Inappropriate prescriptions**

8 **UI-1.** Cyproheptadine (Periactin®), clonidine \* °

## 9 **V- ATTENTION DEFICIT DISORDER WITH OR WITHOUT HYPERACTIVITY**

### 10 **Inappropriate prescriptions**

11 **VI-1.** Pharmacological treatment before  
12 age six (before school), except in  
13 severe cases. \*

14 **VI-2.** Antipsychotic drugs to treat  
15 attention deficit disorder without  
16 hyperactivity. \*

17 **VI-3.** Slow release methylphenidate as  
18 two doses per day, rather than only  
19 one dose. \*°

### 10 **Omissions**

11 **VO-1.** Recording a growth chart (height and weight) if  
12 the patient is taking methylphenidate. \*



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Done
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Done
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Done
Objectives	3	State specific objectives, including any prespecified hypotheses	Done
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	Done
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Done
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Done NA
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Done
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Done
Bias	9	Describe any efforts to address potential sources of bias	Done
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Done
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Done
		(b) Describe any methods used to examine subgroups and interactions	Done
		(c) Explain how missing data were addressed	Done
		(d) If applicable, explain how loss to follow-up was addressed	Done
		(e) Describe any sensitivity analyses	Done
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Done
		(b) Give reasons for non-participation at each stage	Done
		(c) Consider use of a flow diagram	Done
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Done
		(b) Indicate number of participants with missing data for each variable of interest	Done
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	NA

		estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Done
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Done
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Done
Generalisability	21	Discuss the generalisability (external validity) of the study results	Done
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Done

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

# BMJ Open

## Retrospective study of irrational prescribing in French pediatric hospital: prevalence of inappropriate prescription detected by POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) in the emergency unit and in the ambulatory setting.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019186.R2
Article Type:	Research
Date Submitted by the Author:	09-Feb-2018
Complete List of Authors:	Berthe-Aucejo, Aurore; Hopital Universitaire Robert Debre, Pharmacy department; INSERM, UMR-S1123, ECEVE; Inserm U1123 Nguyen, Phuong Khanh Hoang; Hopital Universitaire Robert Debre, Department of Pharmacy Angoulvant, François; Hopital universitaire Necker-Enfants malades, Emergency unit; INSERM, UMR-S1123, ECEVE; Inserm U1123 Bellettre, Xavier; Hopital Universitaire Robert Debre, Emergency unit Albaret, Patrick; Albaret Pharmacy Weil, Thomas; Hopital Universitaire Robert Debre, Department of Pharmacy Boulkedid, Rym; Hopital Universitaire Robert Debre, Clinical Epidemiology unit; INSERM, UMR-S1123, ECEVE; Inserm U1123 Bourdon, Olivier; Hopital Universitaire Robert Debre, Department of pharmacy; Universite Paris Descartes, Clinical Pharmacy Prot-Labarthe, Sonia; Hopital Universitaire Robert Debre, Department of Pharmacy; INSERM, UMR-S1123, ECEVE; Inserm U1123
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	General practice / Family practice
Keywords:	inappropriate prescription, omission, tool, detection

SCHOLARONE™  
Manuscripts

1  
2  
3 **Retrospective study of irrational prescribing in French pediatric hospital: prevalence of**  
4 **inappropriate prescription detected by POPI (Pediatrics: Omission of Prescription and**  
5 **Inappropriate prescription) in the emergency unit and in the ambulatory setting.**  
6  
7

8 A. Berthe-Aucejo<sup>1,2</sup>, H.P.K Nguyen<sup>1</sup>, F. Angoulvant<sup>2,3</sup>, X. Bellettre<sup>4</sup>, P. Albaret<sup>5,6</sup>, T. Weil<sup>1</sup>,  
9  
10 R. Boulkedid<sup>2,7,8</sup>, O. Bourdon<sup>1,6,9,10</sup>, S.Prot-Labarthe<sup>1,2,10</sup>  
11  
12  
13  
14  
15

16 <sup>1</sup> Department of Pharmacy, Robert-Debré Hospital, Paris, France  
17

18 <sup>2</sup> UMR-S1123, ECEVE; Inserm U1123, Paris, France  
19

20 <sup>3</sup> Emergency unit, Necker Hospital, Paris, France  
21

22 <sup>4</sup> Emergency unit AP-HP, Robert-Debré Hospital, Paris, France  
23

24 <sup>5</sup> Albaret Pharmacy, Cesson, France  
25

26 <sup>6</sup> Clinical Pharmacy, Paris Descartes University, Paris, France  
27

28 <sup>7</sup> Assistance publique-Hôpitaux de Paris, Hôpital Robert Debré, Clinical Epidemiology Unit,  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
75 019 Paris, France

<sup>8</sup> CIC-EC 1426, 75019 Paris, France

<sup>9</sup> Laboratoire Educations et Pratiques de Santé, Paris XIII University, Bobigny, France

<sup>10</sup> Groupe Pédiatrie de la Société Française de Pharmacie Clinique, Paris, France

**Word count: 2760**

**Corresponding author**

Dr Aurore Berthe-Aucejo, Service Pharmacie, AP-HP Hôpital Robert-Debré, 48 Boulevard  
Sérurier, 75019 Paris, Fax: 01-40-03-24-81, Tel: 01-40-03-57-41, Email:  
[aurore.berthe@aphp.fr](mailto:aurore.berthe@aphp.fr)

## Keywords

Inappropriate prescription, omission, tool, detection

## ABSTRACT

**Background and Objective:** POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) is the first tool of detection for potentially inappropriate medicines (PIM) and potentially prescribing omissions (PPO) in pediatrics. The aim of this study was to evaluate the prevalence of PIM and PPO detected by POPI regarding issuing of prescription in hospital and outpatient care. The second objective is to determine the risk factors related to PIM.

**Design:** A retrospective and descriptive study was conducted in the emergency department (ED) and community pharmacy (CP) during 6 months. POPI was used to identify PIM and PPO.

**Setting:** Robert-Debré Hospital (AP-HP, France) and Albaret community pharmacy (Seine and Marne).

**Participants:** Inclusion criteria included patients who were under 18 years old and who had one medicine prescription. Exclusion criteria consisted of inaccessible medical records for patients consulted in ED and prescription without drugs for outpatients.

**Primary and secondary outcome measures:** PIM and PPO rate, PIM risk factors

**Results:** At ED, 18,562 prescriptions for 15,973 patients and 4,780 prescriptions for 2,225 patients at the CP were analyzed. The PIM rate and PPO rate were respectively 3.3% and 2.6% at the ED and 26.4% and 13.2% at the CP. Respiratory and digestive diseases had the highest rate of PIM. Multivariate logistic regression model showed that prescriptions from community pharmacy were significantly associated with a higher risk of PIM. This study has enable us to describe PIMs or PPOs within a hospital and a community pharmacy. POPI could be used to improve medication use and patient care and to limit hospitalization and adverse drug reaction.

**Conclusion:** This is the first study to assess the prevalence of PIM and PPO detecting by POPI in a pediatric population. A prospective and multicenter study should be conducted to evaluate its impact and benefit in clinical practice.

### Strengths and limitations of this study

- This study is the first to observe the prevalence of PIM and PPO in a pediatric population.
- It is a retrospective and monocentric study. The prevalence of PIM and PPO may be underestimated (large number of prescriptions, absence of specific pathology). Some criteria could be analyzed only in a prospective study. A lack of clinical information is the main limitation in detection in a community setting.
- Many omissions and inappropriate prescriptions can be easily detected with POPI despite limited clinical information.

## INTRODUCTION

Inappropriate prescribing is a known preventable cause of adverse drug events (ADE) and has an important impact on public health and cost of care. [1,2] In the literature, ADE is defined by “an injury resulting from medical intervention related to a drug” (dose error, adverse drug reaction (ADR), misuse of medication such as antibiotics).[3–5] In the pediatric population, ADR during hospitalization was estimated between 0.6% and 33.7% and between 1% and 1.5% for outpatients.[6–9] Incidence of ADR leading to admission was evaluated between 1.8% and 17.7%.[6,7,10] Many drugs were concerned in commonly used medication.[11–13]

The World Health Organization estimated that 50% of medications are prescribed and used inappropriately.[14] The most recent definition of inappropriate prescription (IP) encompasses potentially inappropriate medicines (PIM) and prescribing omissions (PPO).[15]

In a report from the French National Authority for Health, PIMs are defined as “drugs being used in a situation in which the risks involved in treatment potentially outweigh the benefits, lack of demonstrated indication, high risk of ADE, and an unfavorable cost-effect or risk-benefit ratio exists”. PPO or underuse of appropriate medication is defined as the absence of initiation of an effective treatment in subjects with a condition for which one or several drug classes have demonstrated their efficacy. In an elderly population, which presents with age-related physiological changes and high prevalence of polypharmacy, various measures have been developed to detect PIM such as: Beers’ criteria, the Inappropriate Prescribing in the Elderly Tool, The Medication Appropriate Index, and STOPP/START (Screening Tool of Older Person’s prescriptions/Screening Tool to Alert doctor to Right Treatment).[16–21]

Only the STOPP/START enables us to detect under-prescribing.[15] Using these tools, many studies have been carried out which have detected that inappropriate prescriptions are issued to between 35% and 51% of this population.[22–26]

1  
2  
3  
4  
5 Omission prescriptions in geriatric population detected by START tool concerned between  
6 58%-61% of patients.[27,28] Negative outcomes related to an IP such as side effects,  
7 hospitalization, mortality and utilization of resources were also demonstrated.[21,29-31]  
8  
9

10  
11  
12  
13  
14  
15 Prescribing in a pediatric population is always a challenge for physician. It is often empirical  
16 and primarily based on safety and pharmacology information obtained in adults.[32] This is a  
17 worry not only in a hospital or general practitioner setting but also for the community  
18 pharmacists. They may only be able to check information and resources or even dispense  
19 infrequently for this vulnerable population.[33] ADRs were three time higher in the pediatric  
20 population. This frequency was explained by the vulnerability of young people,  
21 pharmacokinetic changes during childhood and pediatric off-label drug used.[4,34] Large  
22 differences relating to treatment were seen within and between the countries.[6,35] Question  
23 about rational of prescription could be asked.[36] Optimizing children's care is based on  
24 rational prescribing and allowing a decrease in side effects.[35,36] In order to improve the  
25 correct drug use and optimize practice, the first tool of detection for PIM and PPO was  
26 created by Prot-Labarthe *et al.* in 2013. The tool was named POPI (Pediatrics: Omission of  
27 Prescriptions and Inappropriate prescriptions) (Appendix1).[37,38] Presently, the complete  
28 tool has not been tested in actual practice and the prevalence of PIM and OP is not known.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 Our aim is to assess the prevalence of PIM and PPO detected using POPI in hospital and  
46 outpatient care. This was its first application, regarding issuing of prescriptions in the  
47 emergency department and the community pharmacy. The second objective is to determine  
48 the risk factors related to PIM.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## METHODS

### Population

A retrospective and descriptive study was conducted in the emergency department (ED) of AP-HP Robert-Debré hospital (Paris) - the largest French pediatric hospital - and the Albaret community pharmacy (CP) (Seine and Marne). Inclusion criteria included patients who were under 18 years old and who had one or more medicine prescriptions between 1<sup>st</sup> October 2014 and 31<sup>st</sup> March 2015. Prescription was defined as one or more lines of drugs prescribed by a physician. Exclusion criteria consisted of inaccessible medical records for patients consulted in ED and prescription without drugs for outpatients. POPI contains 102 criteria (76 PIMs, 25 PPO). A literature review was done to obtain criteria. Criteria were categorized according to the main physiological systems (gastroenterology, respiratory infections, pain, neurology, dermatology and miscellaneous). Criteria were validated by 2-round-Delphi consensus technique.[38]

### Data collection

The prescriptions given on leaving the hospital emergency department were extracted from the Urqual software V5<sup>®</sup> (\*) (McKesson Corp, Paris, France). Urqual<sup>®</sup> is an emergency prescription software which is used in many French hospitals. Patient information including age, sex, weight, medicine prescription and current diagnosis was collected. Medical histories and clinical examinations were consulted individually when necessary. Due to the significant amount of data, clinical files of ED were analyzed, based on primary diagnosis. For this study, 82/102 criteria were analyzed (Table 1). Some criteria could not be used for a hospital setting.

The data extracted from Urqual software give only one line per patient with one diagnosis and the first drug prescribed. Once extracted, the prescription was then analyzed as a whole.

Consequently, the number of medications per prescription was not included. However, all prescriptions have been manually reviewed. For each targeted disorder, the prescription was analyzed to detect PIMs or PPOs.

**Table 1.** POPI - Pediatrics: Omission of Prescriptions & Inappropriate prescriptions

<b>A- PAIN AND FEVER</b>	
<b>Inappropriate prescriptions</b>	<b>Omissions</b>
<b>AI-1.</b> Prescription of two alternating antipyretics as a first-line treatment.	<b>A0-1.</b> Failure to give sugar solution to new-born babies and infants under four months old two minutes prior to venipuncture.
<b>AI-2.</b> Prescription of a medication other than paracetamol as a first line treatment (except in the case of migraine).	<b>A0-2.</b> Failure to give an osmotic laxative to patients being treated with morphine for a period of more than 48 hours.
<b>AI-3.</b> Rectal administration of paracetamol as a first-line treatment.	
<b>AI-4.</b> The combined use of two NSAIDs. * °	
<b>AI-5.</b> Oral solutions of ibuprofen administered in more than three doses per day using a graduated pipette of 10mg/kg (other than Advil®). °	
<b>AI-6.</b> Opiates to treat migraine attacks. *	
<b>B- URINARY INFECTIONS</b>	
<b>Inappropriate prescriptions</b>	
<b>BI-1.</b> Nitrofurantoin used as a prophylactic. *	
<b>BI-2.</b> Nitrofurantoin used as a curative agent in children under six years of age, or indeed any other antibiotic if avoidable. *	
<b>BI-3.</b> Antibiotic prophylaxis following an initial infection without complications (except in the case of uropathy). *	
<b>BI-4.</b> Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of uropathy). *	
<b>C- VITAMIN SUPPLEMENTS AND ANTIBIOTIC PROPHYLAXIS</b>	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Inappropriate prescriptions	Omissions
<p><b>CI-1.</b> Fluoride supplements prior to six months of age. °*</p>	<p><b>CO-1.</b> Insufficient intake of vitamin D. Minimum vitamin D intake:</p> <ul style="list-style-type: none"> <li>▪ Breastfed baby = 1,000 to 1,200 IU/day</li> <li>▪ Infant &lt; 18 months of age (milk enriched with vitamin D) = 600 to 800 IU/day</li> <li>▪ Child aged between 18 months and five years, and adolescents aged between 10 and 18 years: two quarterly loading doses of 80,000 to 100,000 IU/day in winter (adolescents can take this as one dose).</li> </ul> <p><b>CO-2.</b> Antibiotic prophylaxis with phenoxymethylpenicillin (Oracilline) starting from two months of age and lasting until five years of age for children with sickle-cell anemia: 100,000 IU/kg/day (in two doses) for children weighing 10kg or less and 50,000 IU/kg/day for children weighing over 10kg (also in two doses). *</p>

**D- MOSQUITOS**

Inappropriate prescriptions	Omissions
<p><b>DI-1.</b> The use of skin repellents in infants less than six months old and picardin in children less than 24 months old.</p> <p><b>DI-2.</b> Citronella (lemon grass) oil (essential oil).</p> <p><b>DI-3.</b> Anti-insect bracelets to protect against mosquitos and ticks.</p> <p><b>DI-4.</b> Ultrasonic pest control devices, vitamin B1, homeopathy, electric bug zappers, sticky tapes without insecticide.</p>	<p><b>DO-1.</b> DEET “30%” (max) before 12 years old “50%” (max) after 12 years old.</p> <p><b>DO-2.</b> IR3535 “20%” (max) before 24 months old “35%” (max) after 24 months old.</p> <p><b>DO-3.</b> Mosquito nets and clothes treated with pyrethroids.</p>

**E- NAUSEA, VOMITTING, OR GASTROESOPHAGEAL REFLUX**

**PROBLEMS**

Inappropriate prescriptions	Omissions
<p><b>EI-1.</b> Metoclopramide. * °</p> <p><b>EI-2.</b> Domperidone. * °</p> <p><b>EI-3.</b> Gastric antisecretory drugs to treat gastroesophageal reflux, dyspepsia, the crying of new-born babies (in the absence of</p>	<p><b>EO-1.</b> Oral rehydration solution in the event of vomiting.*</p>

any other signs or symptoms), as well as faintness in infants. \*

**EI-4.** The combined use of proton pump inhibitors and NSAIDs, for a short period of time, in patients without risk factors. \*

**EI-5.** Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube). \*

**EI-6.** The use of type H2 antihistamines for long periods of treatment. \* °

**EI-7.** Erythromycin as a prokinetic agent. \*

**EI-8.** The use of setrons (5-HT3 antagonists) for chemotherapy-associated nausea and vomiting. \*

## F- DIARRHEA

### Inappropriate prescriptions

### Omissions

**FI-1.** Loperamide before 3 years of age. \*°

**FI-2.** Loperamide in the case of invasive diarrhea. \*

**FI-3.** The use of Diosmectite (Smecta®) in combination with another medication. \*°

**FI-4.** The use of *Saccharomyces boulardii* (Ultralevure) in powder form, or in a capsule that has to be opened prior to ingestion, to treat patients with a central venous catheter or an immunodeficiency. \*

**FI-5.** Intestinal antiseptics. \*°

**FO-1.** Oral rehydration solution in the event of diarrhea. \*

## G- COUGH

### Inappropriate prescriptions

### Omissions

**GI-1.** Pholcodine. \* °

**GI-2.** Mucolytic drugs, mucokinetic drugs, or helcidine before two years of age. \* °

**GI-3.** Alimemazine (Theralene®), oxomemazine (Toplexil®), promethazine (Phenergan®), and other types. \* °

**GI-4.** Terpene-based suppositories. \* °

**GO-1.** Failure to propose a whooping cough booster vaccine for adults who are likely to become parents in the coming months or years (only applicable if the previous vaccination was more than 10 years ago). This booster vaccination should also be proposed to the family of expectant parents and those in contact with them (parents, grand-parents, nannies/child minders).

## H- BRONCHIOLITIS IN INFANTS

**Inappropriate prescriptions****Omissions**

**HI-1.** Beta2 agonists, corticosteroids to treat an infant's first case of bronchiolitis.\*

**HI-2.** H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis.\*

**HI-3.** Antibiotics in the absence of signs indicating a bacterial infection (acute otitis media, fever, etc.).\*

**HO-1.** 0.9% NaCl to relieve nasal congestion (not applicable if nasal congestion is already being treated with 3% NaCl delivered by a nebulizer).\*

**HO-2.** Palivizumab in the following cases:

- (1) babies born both at less than 35 weeks of gestation and less than six months prior to the onset of a seasonal RSV epidemic;
- (2) children less than two years old who have received treatment for bronchopulmonary dysplasia in the past six months;
- (3) children less than two years old suffering from congenital heart disease with hemodynamic abnormalities.

**I- ENT INFECTIONS****Inappropriate prescriptions****Omissions**

**II-1.** An antibiotic other than amoxicillin as a first-line treatment for acute otitis media, strep throat, or sinusitis (provided that the patient is not allergic to amoxicillin). An effective dose of amoxicillin for an pneumococcal infection is 80–90 mg/kg/day and an effective dose for a streptococcal infection is 50 mg/kg/day.\*

**II-2.** Antibiotic treatment for a sore throat, without a positive rapid diagnostic test result, in children more than three years old.\*

**II-3.** Antibiotics for nasopharyngitis, congestive otitis, sore throat before three years of age, or laryngitis; antibiotics as a first-line treatment for acute otitis media showing few symptoms, after two years of age.\*

**II-4.** Antibiotics to treat otitis media with effusion (OME), except in the case of hearing loss or if OME lasts for more than three months.\*

**II-5.** Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat.\*

**II-6.** Nasal or oral decongestant (oxymetazoline

**IO-1.** Doses in mg for drinkable (solutions of) amoxicillin or josamycin.\*°

**IO-2.** Paracetamol combined with antibiotic treatment for ear infections to relieve pain.\*

(Aturgyl<sup>®</sup>), pseudoephedrine (Sudafed<sup>®</sup>), naphazoline (Derinox<sup>®</sup>), ephedrine (Rhinamide<sup>®</sup>), tuaminoheptane (Rhinofluimicil<sup>®</sup>), phenylephrine (Humoxal<sup>®</sup>)).\*<sup>o</sup>

**II-7.** H1-antagonists with sedative or atropine-like effects (pheniramine, chlorpheniramine), or camphor; inhalers, nasal sprays, or suppositories containing menthol (or any terpene derivatives) before 30 months of age.\*<sup>o</sup>

**II-8.** Ethanolamine tenoate (Rhinotrophyl<sup>®</sup>) and other nasal antiseptics.\*<sup>o</sup>

**II-9.** Ear drops in the case of acute otitis media.\*

## J- ASTHMA

### Inappropriate prescriptions

### Omissions

**JI-1.** Ketotifen and other H1-antagonists, sodium cromoglycate.\*

**JO-1.** Asthma inhaler appropriate for the child's age.

**JI-2.** Cough suppressants.\*

**JO-2.** Preventative treatment (inhaled corticosteroids) in the case of persistent asthma.\*

## K-ACNE VULGARIS

### Inappropriate prescriptions

### Omissions

**KI-1.** Minocycline.\*<sup>o</sup>

**KI-2.** Isotretinoin in combination with a member of the tetracycline family of antibiotics.\*<sup>o</sup>

**KI-3.** The combined use of an oral and a local antibiotic.\*

**KI-4.** Oral or local antibiotics as a monotherapy (not in combination with another drug).\*

**KI-5.** Cyproterone+ethinylestradiol (Diane 35<sup>®</sup>) as a contraceptive to allow isotretinoin per os.\*<sup>o</sup>

**KI-6.** Androgenic progestins (levonorgestrel, norgestrel, norethisterone, lynestrenol, dienogest, contraceptive implants or vaginal rings).\*

**KO-1.** Contraception (provided with a logbook/diary) for menstruating girls taking isotretinoin.

**KO-2.** Topical treatment (benzoyl peroxide, retinoids, or both) in combination with antibiotic therapy.\*

## L- SCABIES

## Omissions

**LO-1.** A second dose of ivermectin two weeks after the first. \*

**LO-2.** Decontamination of household linen and clothes and treatment for other family members.

## M- LICE

### Inappropriate prescriptions

**MI-1.** The use of aerosols for infants, children with asthma, or children showing asthma-like symptoms such as dyspnea.

## N- RINGWORM

### Inappropriate prescriptions

### Omissions

**NI-1.** Treatment other than griseofulvin for Microsporium. \*

**NO-1.** Topical treatment combined with an orally-administered treatment. \*

**NO-2.** Griseofulvin taken during a meal containing a moderate amount of fat. \* °

## O-IMPETIGO

### Inappropriate prescriptions

**OI-1.** The combination of locally applied and orally administered antibiotics.\*

**OI-2.** Fewer than two applications per day for topical antibiotics.\*

**OI-3.** Any antibiotic other than mupirocin as a first-line treatment (except in cases of hypersensitivity to mupirocin).\*

## P- HERPES SIMPLEX

### Inappropriate prescriptions

### Omissions

**PI-1.** Topical agents containing corticosteroids. \*

**PO-1.** Paracetamol during an outbreak of herpes. \*

**PI-2.** Topical agents containing acyclovir before six years of age. \* °

**PO-2.** Orally administered acyclovir to treat primary herpetic gingivostomatitis. \*

## Q-ATOPIC DERMATITIS

### Inappropriate prescriptions

QI-1. A strong topic steroid (clobetasol propionate 0.05% Dermoval, betamethasone dipropionate Diprosone) applied to the face, armpits or groin, and to the backside of babies or young children. \*

More than one application per day of a topical steroid, except in cases of severe lichenification. \*

QI-2. Local or systemic antihistamine during the treatment of outbreaks. \*

QI-3. Topically applied 0.03% tacrolimus before two years of age. \*°

Topically applied 0.1% tacrolimus before 16 years of age.

QI-4. Oral corticosteroids to treat outbreaks. \*

## R- EPILEPSY

### Inappropriate prescriptions

RI-1. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of myoclonic epilepsy. \*

RI-2. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of epilepsy with absence seizures (especially for childhood absence epilepsy or juvenile absence epilepsy). \*

RI-3. Levetiracetam, oxcarbamazepine in mL or in mg without systematically writing XX mg per Y mL. \* °

## S-DEPRESSION

### Inappropriate prescriptions

SI-1. An SSRI antidepressant other than fluoxetine as a first-line treatment (in the case of pharmacotherapy). \*

SI-2. Tricyclic antidepressants to treat depression. \*

## T- NOCTURNAL ENURESIS

### Inappropriate prescriptions

TI-1. Desmopressin administered by a nasal spray. \* °



Desmopressin in the case of daytime symptoms.

**TI-2.** An anticholinergic agent used as a monotherapy in the absence of daytime symptoms. \*

**TI-3.** Tricyclic agents in combination with anticholinergic agents. \* °

**TI-4.** Tricyclic agents as a first-line treatment. \*

## U- ANOREXIA

### Inappropriate prescriptions

**UI-1.** Cyproheptadine (Periactin®), clonidine \* °

## V- ATTENTION DEFICIT DISORDER WITH OR WITHOUT HYPERACTIVITY

### Inappropriate prescriptions

### Omissions

**VI-1.** Pharmacological treatment before age six (before school), except in severe cases. \*

**VI-2.** Antipsychotic drugs to treat attention deficit disorder without hyperactivity. \*

**VI-3.** Slow release methylphenidate as two doses per day, rather than only one dose. \*°

**VO-1.** Recording a growth chart (height and weight) if the patient is taking methylphenidate. \*

\* Criteria analyzed in emergency department

° Criteria analyzed in community pharmacy

Data from the community pharmacy were obtained from the pharmacy management software OPUS® (Computer PG, France). Patient's age and drugs prescribed were collected. Current diagnosis and sex were not available, in the OPUS software, so the number of patients per pathology and the number of prescriptions per pathology were missed. Only drugs that did not require assessment of diagnosis (for example domperidone, metoclopramide etc.) were analyzed (Table 1) (28 criteria/102).

1  
2  
3 Of 5 criteria including analgesics and antipyretics, only three of them were evaluated due to a  
4 large number of prescriptions and their association with many diseases.  
5  
6

7  
8 Pathologies analyzed by POPI were the same in emergency department and in community.  
9

## 10 11 **Statistical analysis**

12  
13  
14  
15 Data were presented as continuous variables (age, number of prescriptions by patient, number  
16 of medications per prescription) and were presented as median and interquartile range (25th-  
17 75th percentiles) or mean (standard deviation), minimum and maximum depending on normal  
18 distribution.  
19  
20  
21  
22

23  
24  
25 Mixed effects logistic regression modelling for repeated measurements was applied to identify  
26 factors associated with PIM (yes/no) in the hospital and community settings. PIM was  
27 identified by prescription, even if the prescription contained several medications.  
28  
29  
30

31  
32  
33 Univariate models were performed using different candidate factors as:

- 34  
35 - For model performed with hospital data: sex and age (0 days - 2 years, 2 - 6 years, 6 -  
36 12 years, 12 - 18 years);
- 37  
38 - For model performed with community data: age (0 days - 2 years, 2 - 6 years, 6 - 12  
39 years, 12 - 18 years) and number of medications per prescription;
- 40  
41  
42 - For model performed with hospital and community data: Age (0 days - 2 years, 2 - 6  
43 years, 6 - 12 years, 12 - 18 years) and setting of prescription (hospital or community  
44 setting)  
45  
46  
47  
48  
49

50  
51 The model was constructed using the parameters of the univariate analysis, which showed at  
52 least a trend toward significance, with a cut-off of  $p=0.2$ . Odds ratios (OR) with 95%  
53  
54  
55

confidence intervals (CI) were estimated. Statistical significance was established at  $p < 0.05$ .

SPSS-22<sup>®</sup> software (SPSS Inc., Chicago, IL, USA) and SAS 9.4 were used for analysis.

This project was approved by the local research ethics committee (n<sup>o</sup>2015/218).

## RESULTS

In the emergency department, 18,562 prescriptions for 15,973 patients consulted were analyzed. Among them, 29% had at least two visits in 6 months. In the community pharmacy, 4,780 prescriptions for 2,225 patients were evaluated (Figure 1). In ED and CP, 53% of patients had been issued with one prescription, 21% with two and 26% with three or more prescriptions. The population's characteristics and the frequency of pathologies were presented in Table 2. Distribution of number of prescriptions by age category was described in the figure 2.

**Table 2. Characteristics of the study population**

<b>Population characteristics</b>	<b>Hospital (N=15,973)</b>	<b>Community (N=2,225)</b>
Age (years) mean (SD)	4.9 (4.5)	7.9 (5.3)
Min, Max	0-18	0-18
Female gender N(%)	8,769 (54.9)	NA
Number of prescriptions/patient mean (SD)	1.4 (0.9)	2.2 (1.9)
Min, Max	1-12	1-16
Number of medications per prescription mean (SD)	NA	2.4 (1.6)
Min, Max		1-22

Number of prescriptions by pathology N(%)		
Digestive disorders	2,728 (14.7)	NA
ENT-Pulmonary disorders	8,397 (45.2)	NA
Dermatological disorders	604 (3.3)	NA
Neuropsychiatric disorders	242 (1.3)	NA
Other illnesses <sup>#</sup>	6,591 (35.5)	NA

NA: Not available; ENT: ear, nose and throat

<sup>#</sup> For example, traumatic injury, pain, sickle cell disease

In hospital, POPI tools identified 541 PIMs in 2.9% of the prescriptions analyzed. They were detected in 3.3% of the patients (n=530). PPOs were detected in 0.1% of prescriptions for 0.1% of patients. In the community, PIMs and PPOs represented 12.3% and 0.9% of all prescriptions, affecting 26.4% and 1.9% patients respectively (Table 3).

**Table 3. Potentially Inappropriate Medications (PIMs) and Potential Prescription Omission (PPOs) identified by POPI**

	Hospital N (%)	Community N (%)
<b>Number of prescriptions (N)</b>	<b>18,562</b>	<b>4,780</b>
PIMs identified per prescription		
1	519 (2.8%)	551 (11.5%)
2	11 (0.1%)	37 (0.8%)
Prescriptions with at least one PIM	530 (2.9%)	588 (12.3%)
PPOs identified per prescription		
1	0 (0%)	0 (0%)

2	20 (0.1%)	44 (0.9%)
3	1 (0.01%)	1 (0.02%)
Prescriptions with at least one PPO	21 (0.1%)	45 (0.9%)
<b>Number of patients (N)</b>	<b>15,793</b>	<b>2,225</b>
Patients with at least one PIM °	530 (3.3%)	588 (26.4%)
Patients with at least one PPO	21 (0.1%)	43 (1.9%)

Table 4 presents the prevalence of PIMs (or PPOs) in the ED in patients with the targeted disorders. Patients with the targeted disorders represent the individuals who were at risk of each PIM/PPO. Table 5, however, presents the proportion of PIMs per disorder (or PPO) according to the total number of PIMs (or PPOs) in the community pharmacy. Respiratory and digestive diseases had the highest rate of PIM in hospital and community pharmacy. For various illnesses, we removed one criterion involving medicines containing codeine because of their new contraindication in children under 12 years old.[39] However, the prescription of codeine was observed in 18 cases. According to our comparison of PIMs detectable in both settings, out-of-hospital medication always presents with a higher prevalence of PIMs (Figure 3).

**Table 4. Prevalence of PIMs and PPOs identified by POPI in hospital**

Criteria	No. of PIMs	No. of patients with the targeted disorders	% of PIMs in patients with the targeted disorders
<b>Potentially inappropriate medications (PIMs)</b>	<b>541</b>	<b>7,304</b>	<b>7.4%</b>
<b>Various illnesses</b>	<b>3</b>	<b>64</b>	<b>4.6%</b>
AI-6   Opiates to treat migraine attacks	3	64	4.6%
<b>Digestive disorders</b>	<b>56</b>	<b>1,956</b>	<b>2.8%</b>

EI-2	Domperidone	28	1,956	1.4%
FI-3	The use of Diosmectite (Smecta <sup>®</sup> ) in combination with another medication	27	1,956	1.4%
EI-1	Metoclopramide	1	1,956	0.05%
<b>ENT-Pulmonary disorders</b>		<b>472</b>	<b>5,163</b>	<b>9.1%</b>
II-4	Antibiotics to treat acute suppurative otitis media etc.	2	7	28.6%
II-2	Antibiotic treatment for a sore throat, without a positive RDT.	23	160	14.4%
II-9	Ear drops in the event of acute otitis media	86	1,083	7.9%
HI-1	Beta2 agonist, corticosteroids to treat an infant's first case of bronchiolitis	25	386	6.4%
II-5	Corticosteroids to treat acute suppurative otitis media etc.	190	3,616	5.2%
II-1	An antibiotic other than amoxicillin as a first-line treatment.	59	1,259	4.7%
JI-1	H1-antagonist to treat asthma	9	802	1.1%
II-8	Tenoate Etanolamine (Rhinotrophyl <sup>®</sup> ) and other nasal antiseptics	21	2,455	0.8%
II-3	Antibiotics for nasopharyngitis	26	3,444	0.7%
GI-3	Alimemazine (Theralene <sup>®</sup> ), oxomemazine (Toplexil <sup>®</sup> ) etc.	18	2,585	0.7%
JI-2	Cough suppressants to treat asthma	5	802	0.6%
HI-2	H1-antagonists, cough suppressants etc. to treat bronchiolitis	2	386	0.5%
II-7	H1-antagonists with sedative or atropine-like effects.	4	2,585	0.2%
GI-2	Mucolytics drugs, mucokinetics drugs or helicidine before 2 years of age	1	2,585	< 0.1%
II-6	Nasal or oral decongestant etc.	1	2,455	< 0.1%
<b>Dermatological disorders</b>		<b>10</b>	<b>100</b>	<b>10%</b>
OI-1	A combination of locally applied and orally administered antibiotics	9	32	28.1%
PI-2	Topical agents containing acyclovir administered to a child under six years of age	1	68	1.5%
		<b>No. of PPO</b>	<b>No. of patients with the targeted disorders</b>	<b>% of PIMs in patients with the targeted disorders</b>
<b>Potentially Prescribing Omissions (PPO)</b>		<b>425</b>	<b>4,508</b>	<b>9.4%</b>
<b>Digestive disorders</b>		<b>372</b>	<b>1,956</b>	<b>19.0%</b>
EO-1	Oral rehydration solution in the event of vomiting	135	313	43.1%
FO-1	Oral rehydration solution in the event of diarrhea	237	1,643	14.4%
<b>ENT-Pulmonary disorders</b>		<b>52</b>	<b>1,469</b>	<b>3.5%</b>

HO-1	0.9% NaCl to relieve nasal congestion etc.	38	386	9.8%
IO-2	Acetaminophen combined with antibiotic treatment for ear infections etc.	14	1,083	1.3%
<b>Dermatological disorders</b>		<b>1</b>	<b>3</b>	<b>33.3%</b>
NO-2	Griseofulvin taken during a meal containing a moderate amount of fat	1	3	33.3%

ENT: ear, nose and throat; No: Number; RDT: Rapid diagnostic test.

% Percentage calculated by the number of PIMs or PPO detected from the total number of analyzable cases

\*the number of patients with the targeted disorder corresponds to patients with clinical situations at risk of PIM or PPO

**Table 5. Most frequently occurring PIMs and PPOs identified by POPI in community setting**

<b>Criteria</b>	<b>Proportion of PIMs per disorder according to total number of PIMs N(%)</b>
<b>Total number of Potentially Inappropriate Medications (PIMs) N= 591</b>	
<b>Various illnesses</b>	<b>15 (2.5)</b>
AI-5 Oral solutions of ibuprofen administered in more than 3 doses etc.	7 (1.2)
CI-1 Fluoride supplements prescribed to infants under six months of age	5 (0.8)
AI-4 The combined use of two NSAIDs	3 (0.5)
<b>Digestive disorders</b>	<b>201 (34)</b>
EI-2 Domperidone	152 (25.7)
FI-3 The use of Diosmectite (Smecta®) in combination with another medication	35 (5.9)
FI-5 Intestinal antiseptics	9 (1.5)
EI-1 Metoclopramide	2 (0.3)
EI-6 The use of type H2 antihistamines for long periods of treatment	2 (0.3)
FI-1 Loperamide before 3 years of age	1 (0.2)
<b>ENT-Pulmonary disorders</b>	<b>369 (62.4)</b>
GI-3 Alimemazine (Theralene®), oxomemazine (Toplexil®), etc.	202 (34.2)
GI-1 Pholcodine	81 (13.7)
II-8 Etanolamine tenoate (Rhinotrophyl®) and other nasal antiseptics	62(10.5)
II-6 Nasal or oral decongestant etc.	20 (3.4)
GI-2 Mucolytic drugs, mucokinetic drugs or helcidine prescribed to a child under 2 years of age	3(0.5)

GI-4 Terpene-based suppositories	1(0.2)
<b>Dermatological disorders</b>	<b>1(0.2)</b>
PI-2 Topical agents containing acyclovir prescribed to a child under six years of age	1(0.2)
<b>Neuropsychiatric disorders</b>	<b>5 (0.8)</b>
RI-3 Levetiracetam in mL or in mg prescribed without systematically indicating XX mg per Y mL	5(0.8)
	<b>Proportion of PIM per disorder according to total number of PIM N(%)</b>
<b>Potential Prescribing Omissions (PPOs) N= 293</b>	
IO-1 Dose in mg for oral (solution of) amoxicillin etc. N (%)	293 (100%)

NSAIDs: Non-steroidal anti-inflammatory drugs; ENT: ear, nose and throat  
 % Percentage of PIMs or PPOs calculated from the total number of PIMs or PPO detected

The criterion on prescribing amoxicillin in mg (IO-1) was not analyzable due to the fact that this drug is prescribed in great quantity. Among 100 prescriptions randomly assessed in hospital extractions, 97 prescriptions were inappropriate. Nonetheless, one analysis on acute otitis media alone identified a rate of 99.5% (807/811) of prescriptions issued without specification of the doses in mg for oral amoxicillin. In community care, this was observed in 97% of prescriptions, in 13.2% of patients (Table 5).

PIMs classed by age were presented in the figure 4. Potential factors associated with PIM are presented in Appendix 1. On univariate analysis, only different age categories were associated with risk of PIM in hospital setting. In community setting, the number of medications per prescription and different age categories were found to be significantly associated with risk of PIM on univariate analysis. In the multivariable logistic regression model, the same results were obtained. When data from hospital and community were grouped, univariate analysis showed that different age categories and prescription setting were associated with risk of PIM. In the multivariable logistic regression model, prescription issued from outpatient care was significantly associated with a higher risk of PIM (OR: 5.4 [4.8; 6.2] 95%CI, p<0.0001). In



1  
2  
3 addition, patients aged 0-12 years are more at risk of having a PIM than patients aged between  
4  
5 12-18 years (OR: 1.3 [1.0-1.6] 95%CI, p=0.01 for 0-2 years; OR 2.4 [1.9-2.9] p< 0.0001 for  
6  
7 2-6 years; OR 1.8 [1.5-2.3] p< 0.0001). In the community pharmacy, only one PPO was  
8  
9 detected (dose in mg for oral solution of amoxicillin etc.). So we cannot compare this with the  
10  
11 hospital setting. In the ED, this criterion can be evaluated due to a larger number of  
12  
13 prescriptions.  
14  
15

## 16 17 **DISCUSSION**

18  
19 This is the first study to observe the prevalence of PIMs and PPOs in a pediatric population.  
20  
21 In the literature, the tool detected PIMs/PPOs in a geriatric population. [22,40–42] The two  
22  
23 populations are not comparable. Respiratory and digestive pathologies are typical in children  
24  
25 and not so in a geriatric population, which is concerned by cardiovascular and nervous  
26  
27 central system diseases.[22,40,43].  
28  
29  
30

31  
32 Domperidone was frequently prescribed in a community setting, yet this drug is responsible  
33  
34 for cardiac adverse effects such as QT prolongation. This side effect is described in the  
35  
36 literature in adult populations and pediatric populations. Detecting of this prescription will  
37  
38 enable us to avoid cardiac risks. [44–49]  
39  
40

41  
42 Prevalence of beta2 agonists or corticosteroids in an infant's first case of bronchiolitis is 6.4%  
43  
44 (25/386 cases), lower than that observed in a study of another French area in 2012 (41%).[50–  
45  
46 52] Use of beta2 agonists in a first case of bronchiolitis has no impact on oxygen saturation,  
47  
48 length of hospitalization or length of illness. They concurrently cause side effects as  
49  
50 tachycardia, oxygen saturation, and tremors. [53]  
51

52  
53 Unnecessary exposure to cough suppressants, pholcodine, nasal or oral decongestants was  
54  
55 also observed frequently in this sector.[54] In Norway, all drugs containing pholcodine have  
56  
57  
58  
59  
60

1  
2  
3 been refused marketing authorization for March 2007. As of this date, a decrease in  
4 sensitization to suxamethonium used in anesthesia and a decrease of 30-40% cases of  
5 anaphylaxis were identified. [55]  
6  
7

8  
9 Our tool enabled us to detect rare PIMs but with a major impact, such as opioid use for  
10 migraines. The use of opioids for this disease induces a transition from episodic to chronic  
11 headaches and an increase of sensitivity to pain.[56–58] Overuse of medication overuse, in  
12 particular opioids, could contribute to the chronicity of headaches in 20–30% of children and  
13 adolescents with chronic daily headaches.[59]  
14  
15

16  
17 In the management of diarrhea caused by gastroenteritis, in hospital, our study found that it  
18 was common to omit prescription of an oral rehydration solution (ORS): 14% (237/1643  
19 case). Even so, this rate is lower than that found in another national study in 2007 (29%).[60]  
20  
21 However, ORSs prevent hospitalization in cases of acute gastroenteritis. In the United  
22 Kingdom, the use of ORSs has enabled a decrease from 300 deaths/year in 1970s to 25  
23 deaths/year in 1980s. [61,62]. The need for ORS prescriptions was confirmed by the  
24 recommendation of the European Society for Paediatric Gastroenterology, Hepatology, and  
25 Nutrition (ESPGHAN) in 2014.[63]  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 As estimated, the child aged between 0 and 12 years has the highest risk of presenting with a  
41 PIM, according to a multivariate analysis. No inappropriate prescriptions or omissions were  
42 detected for patients aged less than 28 days. As we know, they are also affected by off-label  
43 drug prescriptions, which is consistent with reports from other sources.[64,65] As with  
44 geriatrics, an increase in numbers of medications can be associated with PIM.[40]  
45  
46 Prescriptions issued from hospitals elicit fewer PIMs than those issued by the community.  
47  
48 The main reason for this is that many drugs are not available in this hospital, such as cough  
49 suppressants, Rhinotrophyl<sup>®</sup> (tenoate ethanalamine), domperidone, etc. This shows that many  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 PIM are preventable in a hospital setting. An efficient method for prevention of PIM could be  
4  
5 to focus on the prescribing habits of physicians and thus have an impact on the selection of  
6  
7 drugs, thereby reducing the rate of PIM.  
8  
9

10  
11 Our study has several limitations. Firstly, it is a retrospective and monocentric study. Our  
12  
13 result in the hospital could be underestimated. In addition, several criteria could not be  
14  
15 analyzed due to the large number of prescriptions (for example, those for fever or pain which  
16  
17 are associated with many diseases) or absence of a specific pathology (mosquitos, lice,  
18  
19 hyperactivity etc.). Antibiotic prophylaxis, vitamin supplements, proposition of vaccination  
20  
21 etc. can be analyzed in prospective studies. A lack of clinical information is the main  
22  
23 limitation in detection in a community setting. This also constitutes a challenge for  
24  
25 pharmaceutical care review in elderly patients.[66] However, a certain amount of PIM was  
26  
27 identified using POPI. Our study showed that there are many criteria which could be detected  
28  
29 without access to clinical information and are easy to identify. Moreover, community  
30  
31 pharmacists, in their practice, can extrapolate diagnoses from their experience, from common  
32  
33 indications or by interviewing their patient. The study presents a limitation regarding the  
34  
35 URQUAL software, from which the number of medications per prescription could not be  
36  
37 extracted.  
38  
39  
40

41  
42 This is the first study which permits to evaluate prevalence of PIM and PPO in pediatrics  
43  
44 prescription. Detecting of PIMs/PPOs would improve patient care, and prevent hospitalization  
45  
46 and adverse drug reactions. A stepped wedge randomized cluster multicenter study will be  
47  
48 conducted to prove if POPI decreases number of PIM and PPO. It is also necessary to  
49  
50 evaluate the impact of this tool on reducing adverse drugs events, both in consultation or upon  
51  
52 hospitalization. The impact of pharmacists in providing appropriate prescriptions should be  
53  
54 also evaluated. Subsequently, this tool may be proposed to several professional societies such  
55  
56  
57  
58  
59  
60

1  
2  
3 as the French Society for Pediatricians and the French Society of Clinical Pharmacy to make  
4  
5 its use more widespread. The tool should be regularly updated to reflect recent events and to  
6  
7 specify certain criteria.  
8  
9

10 To facilitate its use, this tool can be presented as a mobile app, a small handbook or be  
11  
12 installed into prescription software. In summary, we hope that POPI could be a practical  
13  
14 option used to reduce medication errors and to improve the suitability of prescriptions. It  
15  
16 provides rapid detection of PIM and PPO and can also open up a discussion on the  
17  
18 relationship between the doctor and the pharmacist to remedy the issue at hand.[67]  
19  
20  
21  
22

## 23 **CONCLUSION**

24  
25  
26 Our study was carried out in in two sectors, hospital and community, and provides a global  
27  
28 view of PIM and PPO in pediatric patients. POPI has a clinical impact and plays a role in  
29  
30 improving prescription quality in various sectors and patient care. POPI should be applied in  
31  
32 different services to deepen and reinforce its utilization. A prospective and multicenter study  
33  
34 should be conducted to evaluate its impact and benefit in clinical practice.  
35  
36  
37

## 38 **ACKNOWLEDGMENTS**

39  
40  
41 We would like to thank the Emergency department of Robert-Debré hospital and the Albaret  
42  
43 pharmacy community for their data support.  
44  
45

46  
47 We would also like to thank the French Society of Clinical Pharmacy (pediatric group) for  
48  
49 their support.  
50  
51

## 52 **ETHICS**

53  
54  
55  
56 This project was approved by the local research ethics committee (n°2015/218).  
57  
58  
59

## DISCLOSURE OF INTEREST

None Declared

## FUNDING STATEMENT

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

## AUTHOR'S CONTRIBUTION

Sonia Prot-Labarthe, Aurore Berthe-Aucejo conceptualised and designed the study, drafted the initial manuscript, and approved the final manuscript as submitted.

Rym Boulkedid and HPK Nguyen carried out analyses, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Xavier Bellettre, Thomas Weil, Olivier Bourdon reviewed and revised the manuscript and approved the final manuscript as submitted.

François Angoulvant and Patrick Albaret supplied data from hospital and community pharmacy and reviewed and revised the manuscript and approved the final manuscript as submitted.

## DATA SHARING STATEMENT

We have no additional unpublished data

## REFERENCES

- 1 Lund BC, Carnahan RM, Egge JA, *et al*. Inappropriate prescribing predicts adverse drug events in older adults. *Ann Pharmacother* 2010;**44**:957–63. doi:10.1345/aph.1M657
- 2 Chrischilles EA, VanGilder R, Wright K, *et al*. Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults. *J Am Geriatr Soc* 2009;**57**:1000–6.

- 3 Bates DW, Cullen DJ, Laird N, *et al*. Incidence of adverse drug events and potential  
4 adverse drug events. Implications for prevention. ADE Prevention Study Group. *JAMA*  
5 1995;**274**:29–34.
- 6
- 7 4 Kaushal R, Bates DW, Goldmann DA. Medication errors and adverse drug events in  
8 pediatric inpatients. *JAMA* 2001;**285**:2114–20.
- 9
- 10 5 Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to  
11 terminology, documentation, and reporting. *Ann Intern Med* 2004;**140**:795–801.
- 12
- 13 6 Clavenna A, Bonati M. Differences in antibiotic prescribing in paediatric outpatients.  
14 *Arch Dis Child* 2011;**96**:590–5. doi:10.1136/adc.2010.183541
- 15
- 16 7 Impicciatore P, Choonara I, Clarkson A, *et al*. Incidence of adverse drug reactions in  
17 paediatric in/out-patients: a systematic review and meta-analysis of prospective studies.  
18 *Br J Clin Pharmacol* 2001;**52**:77–83. doi:10.1046/j.0306-5251.2001.01407.x
- 19
- 20 8 dos Santos DB, Coelho HLL. Adverse drug reactions in hospitalized children in Fortaleza,  
21 Brazil. *Pharmacoepidemiol Drug Saf* 2006;**15**:635–40. doi:10.1002/pds.1187
- 22
- 23 9 Rashed AN, Wong ICK, Cranswick N, *et al*. Risk factors associated with adverse drug  
24 reactions in hospitalised children: international multicentre study. *Eur J Clin Pharmacol*  
25 2012;**68**:801–10. doi:10.1007/s00228-011-1183-4
- 26
- 27 10 Thiesen S, Conroy EJ, Bellis JR, *et al*. Incidence, characteristics and risk factors of  
28 adverse drug reactions in hospitalized children - a prospective observational cohort study  
29 of 6,601 admissions. *BMC Med* 2013;**11**:237. doi:10.1186/1741-7015-11-237
- 30
- 31 11 de Vries TW, van Hunsel F. Adverse drug reactions of systemic antihistamines in children  
32 in the Netherlands. *Arch Dis Child* 2016;**101**:968–70. doi:10.1136/archdischild-2015-  
33 310315
- 34
- 35 12 Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral  
36 corticosteroids in children. *Arch Dis Child* 2016;**101**:365–70. doi:10.1136/archdischild-  
37 2015-309522
- 38
- 39 13 Cliff-Eribo KO, Sammons H, Choonara I. Systematic review of paediatric studies of  
40 adverse drug reactions from pharmacovigilance databases. *Expert Opin Drug Saf*  
41 2016;**15**:1321–8. doi:10.1080/14740338.2016.1221921
- 42
- 43 14 Reidenberg MM. Can the selection and use of essential medicines decrease inappropriate  
44 drug use? *Clin Pharmacol Ther* 2009;**85**:581–3. doi:10.1038/clpt.2009.10
- 45
- 46 15 Barry PJ, Gallagher P, Ryan C, *et al*. START (screening tool to alert doctors to the right  
47 treatment)--an evidence-based screening tool to detect prescribing omissions in elderly  
48 patients. *Age Ageing* 2007;**36**:632–8. doi:10.1093/ageing/afm118
- 49
- 50 16 Legrain S others. Consommation médicamenteuse chez le sujet âgé. Consommation,  
51 prescription, iatrogénie et observance. 2005. [http://www.has-](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28__16_44_51_580.pdf)  
52 [sante.fr/portail/upload/docs/application/pdf/pmsa\\_synth\\_biblio\\_2006\\_08\\_28\\_\\_16\\_44\\_51\\_](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28__16_44_51_580.pdf)  
53 [580.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28__16_44_51_580.pdf).
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 17 Beers MH, Ouslander JG, Rollinger I, *et al.* Explicit criteria for determining  
4 inappropriate medication use in nursing home residents. UCLA Division of Geriatric  
5 Medicine. *Arch Intern Med* 1991;**151**:1825–32.  
6  
7 18 Naugler CT, Brymer C, Stolee P, *et al.* Development and validation of an improving  
8 prescribing in the elderly tool. *Can J Clin Pharmacol J Can Pharmacol Clin* 2000;**7**:103–  
9 7.  
10  
11 19 Samsa GP, Hanlon JT, Schmader KE, *et al.* A summated score for the medication  
12 appropriateness index: development and assessment of clinimetric properties including  
13 content validity. *J Clin Epidemiol* 1994;**47**:891–6.  
14  
15 20 Laroche M-L, Bouthier F, Merle L, *et al.* Médicaments potentiellement inappropriés aux  
16 personnes âgées: intérêt d'une liste adaptée à la pratique médicale française. *Rev*  
17 *Médecine Interne* 2009;**30**:592–601. doi:10.1016/j.revmed.2008.08.010  
18  
19 21 Gallagher P, Ryan C, Byrne S, *et al.* STOPP (Screening Tool of Older Person's  
20 Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment).  
21 Consensus validation. *Int J Clin Pharmacol Ther* 2008;**46**:72–83.  
22  
23 22 Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially  
24 inappropriate Prescriptions): application to acutely ill elderly patients and comparison  
25 with Beers' criteria. *Age Ageing* 2008;**37**:673–9. doi:10.1093/ageing/afn197  
26  
27 23 Gallagher P, Lang PO, Cherubini A, *et al.* Prevalence of potentially inappropriate  
28 prescribing in an acutely ill population of older patients admitted to six European  
29 hospitals. *Eur J Clin Pharmacol* 2011;**67**:1175–88. doi:10.1007/s00228-011-1061-0  
30  
31 24 Dalleur O, Boland B, Losseau C, *et al.* Reduction of potentially inappropriate medications  
32 using the STOPP criteria in frail older inpatients: a randomised controlled study. *Drugs*  
33 *Aging* 2014;**31**:291–8. doi:10.1007/s40266-014-0157-5  
34  
35 25 Ryan C, O'Mahony D, Kennedy J, *et al.* Potentially inappropriate prescribing in an Irish  
36 elderly population in primary care. *Br J Clin Pharmacol* 2009;**68**:936–47.  
37 doi:10.1111/j.1365-2125.2009.03531.x  
38  
39 26 Yayla ME, Bilge U, Binen E, *et al.* The use of START/STOPP criteria for elderly patients  
40 in primary care. *ScientificWorldJournal* 2013;**2013**:165873. doi:10.1155/2013/165873  
41  
42 27 Borges EP, Morgado M, Macedo AF. Prescribing omissions in elderly patients admitted  
43 to a stroke unit: descriptive study using START criteria. *Int J Clin Pharm* 2012;**34**:481–9.  
44 doi:10.1007/s11096-012-9635-1  
45  
46 28 Barry PJ, Gallagher P, Ryan C, *et al.* START (screening tool to alert doctors to the right  
47 treatment)--an evidence-based screening tool to detect prescribing omissions in elderly  
48 patients. *Age Ageing* 2007;**36**:632–8. doi:10.1093/ageing/afm118  
49  
50 29 Chrischilles EA, VanGilder R, Wright K, *et al.* Inappropriate medication use as a risk  
51 factor for self-reported adverse drug effects in older adults. *J Am Geriatr Soc*  
52 2009;**57**:1000–6.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 30 Dedhiya SD, Hancock E, Craig BA, *et al.* Incident use and outcomes associated with  
4 potentially inappropriate medication use in older adults. *Am J Geriatr Pharmacother*  
5 2010;**8**:562–70. doi:10.1016/S1543-5946(10)80005-4  
6  
7 31 Lau DT, Kasper JD, Potter DEB, *et al.* Hospitalization and death associated with  
8 potentially inappropriate medication prescriptions among elderly nursing home residents.  
9 *Arch Intern Med* 2005;**165**:68–74. doi:10.1001/archinte.165.1.68  
10  
11 32 Hébert G, Prot-Labarthe S, Tremblay M-E, *et al.* La pédiatrie, toujours exclue de  
12 l'innovation pharmaceutique? *Arch Pédiatrie* 2014;**21**:245–50.  
13 doi:10.1016/j.arcped.2013.12.016  
14  
15 33 Benavides S, Huynh D, Morgan J, *et al.* Approach to the pediatric prescription in a  
16 community pharmacy. *J Pediatr Pharmacol Ther JPPT Off J PPAG* 2011;**16**:298–307.  
17 doi:10.5863/1551-6776-16.4.298  
18  
19 34 Mercier J., Morin L, Prot-Labarthe S. Les erreurs de prescription et leurs conséquences.  
20 2010.  
21  
22 35 Risk R, Naismith H, Burnett A, *et al.* Rational prescribing in paediatrics in a resource-  
23 limited setting. *Arch Dis Child* 2013;**98**:503–9. doi:10.1136/archdischild-2012-302987  
24  
25 36 Choonara I. Rational prescribing is important in all settings. *Arch Dis Child* 2013;**98**:720.  
26 doi:10.1136/archdischild-2013-304559  
27  
28 37 Prot-Labarthe S, Vercheval C, Angoulvant F, *et al.* « POPI ; pédiatrie : omissions et  
29 prescriptions inappropriées ». Outil d'identification des prescriptions inappropriées chez  
30 l'enfant. *Arch Pédiatrie* 2011;**18**:1231–2. doi:10.1016/j.arcped.2011.08.019  
31  
32 38 Prot-Labarthe S, Weil T, Angoulvant F, *et al.* POPI (Pediatrics: Omission of Prescriptions  
33 and Inappropriate Prescriptions): Development of a Tool to Identify Inappropriate  
34 Prescribing. *PLoS ONE* 2014;**9**:e101171. doi:10.1371/journal.pone.0101171  
35  
36 39 European Medicines Agency. Codeine not to be used in children below 12 years for  
37 cough and cold. 2015. <http://www.ema.europa.eu>  
38  
39 40 Gallagher P, Lang PO, Cherubini A, *et al.* Prevalence of potentially inappropriate  
40 prescribing in an acutely ill population of older patients admitted to six European  
41 hospitals. *Eur J Clin Pharmacol* 2011;**67**:1175–88. doi:10.1007/s00228-011-1061-0  
42  
43 41 Beers MH. Explicit criteria for determining potentially inappropriate medication use by  
44 the elderly. An update. *Arch Intern Med* 1997;**157**:1531–6.  
45  
46 42 O'Mahony D, O'Sullivan D, Byrne S, *et al.* STOPP/START criteria for potentially  
47 inappropriate prescribing in older people: version 2. *Age Ageing* 2015;**44**:213–8.  
48 doi:10.1093/ageing/afu145  
49  
50 43 Nadège Caillère, Céline Caserio-Schonemann. Réseau OSCOUR® (Organisation de la  
51 surveillance coordonnée des urgences) Résultats nationaux 2004/2011. 2011.  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 44 Rocha CMG, Barbosa MM. QT interval prolongation associated with the oral use of  
4 domperidone in an infant. *Pediatr Cardiol* 2005;**26**:720–3. doi:10.1007/s00246-004-  
5 0922-z
- 6  
7 45 Rossi M, Giorgi G. Domperidone and long QT syndrome. *Curr Drug Saf* 2010;**5**:257–62.
- 8  
9 46 Djeddi D, Kongolo G, Lefaix C, *et al.* Effect of domperidone on QT interval in neonates.  
10 *J Pediatr* 2008;**153**:663–6. doi:10.1016/j.jpeds.2008.05.013
- 11  
12 47 Domperidone: QT prolongation in infants. *Prescrire Int* 2011;**20**:14.
- 13  
14 48 Caraballo L, Molina G, Weitz D, *et al.* [Proarrhythmic effects of domperidone in infants:  
15 a systematic review]. *Farm Hosp Organo Of Expresion Cient Soc Espanola Farm Hosp*  
16 2014;**38**:438–44. doi:10.7399/fh.2014.38.5.7957
- 17  
18 49 Rochoy M, Auffret M, Béné J, *et al.* [Antiemetics and cardiac effects potentially linked to  
19 prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance  
20 database]. *Rev Epidemiol Sante Publique* 2017;**65**:1–8. doi:10.1016/j.respe.2016.06.335
- 21  
22 50 Branchereau E, Branger B, Launay E, *et al.* [Management of bronchiolitis in general  
23 practice and determinants of treatment being discordant with guidelines of the HAS].  
24 *Arch Pédiatrie Organe Off Société Fr Pédiatrie* 2013;**20**:1369–75.  
25 doi:10.1016/j.arcped.2013.09.028
- 26  
27 51 Bronchiolitis in children | 1-recommendations | Guidance and guidelines | NICE.  
28 <http://www.nice.org.uk/guidance/NG9/chapter/1-recommendations> (accessed 22 Jun  
29 2015).
- 30  
31 52 Conférence de Consensus sur la prise en charge de la bronchiolite du nourrisson.  
32 2000.<http://www.has-sante.fr>
- 33  
34 53 Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. *Cochrane Database Syst*  
35 *Rev* 2014;:CD001266. doi:10.1002/14651858.CD001266.pub4
- 36  
37 54 *La Revue Prescrire*. 2014. <http://www.prescrire.org/fr/>
- 38  
39 55 de Pater GH, Florvaag E, Johansson SGO, *et al.* Six years without pholcodine;  
40 Norwegians are significantly less IgE-sensitized and clinically more tolerant to  
41 neuromuscular blocking agents. *Allergy* 2017;**72**:813–9. doi:10.1111/all.13081
- 42  
43 56 Loder E, Weizenbaum E, Frishberg B, *et al.* Choosing wisely in headache medicine: the  
44 American Headache Society’s list of five things physicians and patients should question.  
45 *Headache* 2013;**53**:1651–9. doi:10.1111/head.12233
- 46  
47 57 Casucci G, Cevoli S. Controversies in migraine treatment: opioids should be avoided.  
48 *Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol* 2013;**34 Suppl 1**:S125-128.  
49 doi:10.1007/s10072-013-1395-8
- 50  
51 58 Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine.  
52 *PAIN®* 2009;**142**:179–82. doi:10.1016/j.pain.2009.01.013
- 53  
54  
55  
56  
57  
58  
59

- 1  
2  
3 59 Piazza F, Chiappedi M, Maffioletti E, *et al.* Medication overuse headache in school-aged  
4 children: more common than expected? *Headache* 2012;**52**:1506–10. doi:10.1111/j.1526-  
5 4610.2012.02221.x
- 6  
7 60 Martinot A, Pruvost I, Aurel M, *et al.* [Improvement in the management of acute  
8 diarrhoea in France?]. *Arch Pédiatrie Organe Off Société Fr Pédiatrie* 2007;**14 Suppl**  
9 **3**:S181-185.
- 10  
11 61 Walker-Smith JA. Management of infantile gastroenteritis. *Arch Dis Child* 1990;**65**:917–  
12 8.
- 13  
14 62 Murphy MS. Guidelines for managing acute gastroenteritis based on a systematic review  
15 of published research. *Arch Dis Child* 1998;**79**:279–84.
- 16  
17 63 Guarino A, Ashkenazi S, Gendrel D, *et al.* European Society for Pediatric  
18 Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious  
19 Diseases evidence-based guidelines for the management of acute gastroenteritis in  
20 children in Europe: update 2014. *J Pediatr Gastroenterol Nutr* 2014;**59**:132–52.  
21 doi:10.1097/MPG.0000000000000375
- 22  
23 64 Joret P, Prot-Labarthe S, Brion F, *et al.* Caractérisation des indications hors AMM en  
24 pédiatrie : analyse descriptive de 327 lignes de prescriptions dans un hôpital pédiatrique.  
25 *Pharm Hosp Clin* 2014;**49**:e151–2. doi:10.1016/j.phclin.2014.04.306
- 26  
27 65 Shah SS, Hall M, Goodman DM, *et al.* Off-label drug use in hospitalized children. *Arch*  
28 *Pediatr Adolesc Med* 2007;**161**:282–90. doi:10.1001/archpedi.161.3.282
- 29  
30 66 Ryan C, O'Mahony D, O'Donovan DÓ, *et al.* A comparison of the application of  
31 STOPP/START to patients' drug lists with and without clinical information. *Int J Clin*  
32 *Pharm* 2013;**35**:230–5. doi:10.1007/s11096-012-9733-0
- 33  
34 67 Gillespie U, Alassaad A, Hammarlund-Udenaes M, *et al.* Effects of Pharmacists'  
35 Interventions on Appropriateness of Prescribing and Evaluation of the Instruments' (MAI,  
36 STOPP and STARTs') Ability to Predict Hospitalization—Analyses from a Randomized  
37 Controlled Trial. *PLoS ONE* 2013;**8**. doi:10.1371/journal.pone.0062401
- 38  
39  
40  
41

42 Figure 1. Flow chart indicating the course of the study

43  
44

45 \* Prescriptions with only one medical device, dietary supplement or hygiene product, ED:  
46  
47  
48 Emergency department

49  
50


51 Figure 2. Distribution of number of prescriptions according to age category in hospital and  
52  
53 community settings

54  
55  
56  
57  
58  
59

1  
2  
3 Figure 3. Comparison of PIMs detected in hospital and in outpatient care  
4  
5

6 Figure 4. Total prescription and PIMs in both hospital and outpatient care: Percentage  
7  
8 distribution by age group  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. Flow chart indicating the course of the study† \* Prescriptions with only one medical device, dietary supplement or hygiene product, ED: Emergency department

51x27mm (300 x 300 DPI)




Figure 2. Distribution of number of prescriptions according to age category in hospital and community settings

42x26mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3. Comparison of PIMs detected in hospital and in outpatient care

74x42mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4. Total prescription and PIMs in both hospital and outpatient care: Percentage distribution by age group

90x23mm (300 x 300 DPI)

peer review only

**Appendix 1. Univariate and multivariate analysis to determine factors associated with PIM according to POPI criteria**

Variable	Univariate analysis		Multivariate analysis	
	OR* [CI 95%]	p-value	OR* [CI 95%]	p-value
<b><u>Model 1: Hospital prescription</u></b>				
<i>Sex</i>				
Male	1			
Female	1.1 [0.9-1.3]	0.3		
<i>Age category</i>				
0 - 2 years	2.5 [1.6-3.9]	0.0001	2.4 [1.6-3.8]	< 0.001
2 - 6 years	4.0 [2.5-6.3]	< 0.0001	4.0 [2.5-6.3]	< 0.0001
6 - 12 years	2.2 [1.4-3.6]	0.0016	2.2 [1.4-3.6]	0.0016
12 - 18 years	1		1	
<b><u>Model 2: Community prescription</u></b>				
<i>Age category</i>				
0 - 2 years	0.8 [0.6-1.1]	0.1	0.7 [0.5-1.0]	0.06
2 - 6 years	2.0 [1.5-2.6]	< 0.0001	1.85 [1.4-2.4]	< 0.0001
6 - 12 years	1.9 [1.5-2.4]	< 0.0001	1.9 [1.5-2.5]	< 0.0001
12 - 18 years	1		1	
<i>Number of medications per prescription</i>	1.4 [1.3-1.6]	< 0.001	1.4 [1.3-1.6]	< 0.0001
<b><u>Model 3: Hospital and Community prescription</u></b>				
<i>Age category</i>				
0 - 2 years	0.7 [0.6- 0.9]	0.002	1.3 [1.0-1.6]	0.01
2 - 6 years	1.4 [1.1-1.7]	0.0006	2.4 [1.9-2.9]	< 0.0001
6 - 12 years	1.4 [1.1-1.7]	0.002	1.8 [1.5-2.3]	< 0.0001
12 - 18 years	1		1	
<i>Service</i>				
Hospital	1			
Community	5.1 [4.5-5.8]	< 0.001	5.4 [4.8-6.2]	< 0.0001

OR: Odds ratio, CI: Confidence intervals.



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	p1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	p2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	p4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	p5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	p6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	P6 NA
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	p6-7-14
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	p15
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	p15-16
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P16+figure 1
		(b) Give reasons for non-participation at each stage	Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 2
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	p17

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
2			(b) Report category boundaries when continuous variables were categorized	NA
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Appendix 1
5	<b>Discussion</b>			
6	Key results	18	Summarise key results with reference to study objectives	p18
7	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p22
8	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	p22 to 24
9	Generalisability	21	Discuss the generalisability (external validity) of the study results	p24-25
10	<b>Other information</b>			
11	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	p24

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

# BMJ Open

**Retrospective study of irrational prescribing in French pediatric hospital: prevalence of inappropriate prescription detected by POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) in the emergency unit and in the ambulatory setting.**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019186.R3
Article Type:	Research
Date Submitted by the Author:	27-Mar-2018
Complete List of Authors:	Berthe-Aucejo, Aurore; Hopital Universitaire Robert Debre, Pharmacy department; INSERM, UMR-S1123, ECEVE; Inserm U1123 Nguyen, Phuong Khanh Hoang; Hopital Universitaire Robert Debre, Department of Pharmacy Angoulvant, François; Hopital universitaire Necker-Enfants malades, Emergency unit; INSERM, UMR-S1123, ECEVE; Inserm U1123 Bellettre, Xavier; Hopital Universitaire Robert Debre, Emergency unit Albaret, Patrick; Albaret Pharmacy Weil, Thomas; Hopital Universitaire Robert Debre, Department of Pharmacy Boulkedid, Rym; Hopital Universitaire Robert Debre, Clinical Epidemiology unit; INSERM, UMR-S1123, ECEVE; Inserm U1123 Bourdon, Olivier; Hopital Universitaire Robert Debre, Department of pharmacy; Universite Paris Descartes, Clinical Pharmacy Prot-Labarthe, Sonia; Hopital Universitaire Robert Debre, Department of Pharmacy; INSERM, UMR-S1123, ECEVE; Inserm U1123
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	General practice / Family practice
Keywords:	inappropriate prescription, omission, tool, detection

SCHOLARONE™  
Manuscripts

1  
2  
3 **Retrospective study of irrational prescribing in French pediatric hospital: prevalence of**  
4 **inappropriate prescription detected by POPI (Pediatrics: Omission of Prescription and**  
5 **Inappropriate prescription) in the emergency unit and in the ambulatory setting.**  
6  
7

8 A. Berthe-Aucejo<sup>1,2</sup>, H.P.K Nguyen<sup>1</sup>, F. Angoulvant<sup>2,3</sup>, X. Bellettre<sup>4</sup>, P. Albaret<sup>5,6</sup>, T. Weil<sup>1</sup>,  
9  
10 R. Boulkedid<sup>2,7,8</sup>, O. Bourdon<sup>1,6,9,10</sup>, S.Prot-Labarthe<sup>1,2,10</sup>  
11  
12  
13  
14  
15

16 <sup>1</sup> Department of Pharmacy, Robert-Debré Hospital, Paris, France  
17

18 <sup>2</sup> UMR-S1123, ECEVE; Inserm U1123, Paris, France  
19

20 <sup>3</sup> Emergency unit, Necker Hospital, Paris, France  
21

22 <sup>4</sup> Emergency unit AP-HP, Robert-Debré Hospital, Paris, France  
23

24 <sup>5</sup> Albaret Pharmacy, Cesson, France  
25

26 <sup>6</sup> Clinical Pharmacy, Paris Descartes University, Paris, France  
27

28 <sup>7</sup> Assistance publique-Hôpitaux de Paris, Hôpital Robert Debré, Clinical Epidemiology Unit,  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
75 019 Paris, France

<sup>8</sup> CIC-EC 1426, 75019 Paris, France

<sup>9</sup> Laboratoire Educations et Pratiques de Santé, Paris XIII University, Bobigny, France

<sup>10</sup> Groupe Pédiatrie de la Société Française de Pharmacie Clinique, Paris, France

**Word count:** 2639

**Corresponding author**

Dr Aurore Berthe-Aucejo, Service Pharmacie, AP-HP Hôpital Robert-Debré, 48 Boulevard  
Sérurier, 75019 Paris, Fax: 01-40-03-24-81, Tel: 01-40-03-57-41, Email:  
[aurore.berthe@aphp.fr](mailto:aurore.berthe@aphp.fr)

## Keywords

Inappropriate prescription, omission, tool, detection

## ABSTRACT

**Background and Objective:** POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) is the first detection tool for potentially inappropriate medicines (PIM) and potentially prescribing omissions (PPO) in pediatrics. The aim of this study was to evaluate the prevalence of PIM and PPO detected by POPI regarding issuing of prescription in hospital and outpatients . The second objective is to determine the risk factors related to PIM and PPO.

**Design:** A retrospective, descriptive study was conducted in the emergency department (ED) and community pharmacy (CP) during 6 months. POPI was used to identify PIM and PPO.

**Setting:** Robert-Debré Hospital (France) and Albaret community pharmacy (Seine and Marne).

**Participants:** Patients who were under 18 years old and who had one or more medicine prescription were included. Exclusion criteria consisted of inaccessible medical records for patients consulted in ED and prescription without drugs for outpatients.

**Primary and secondary outcome measures:** PIM and PPO rate and risk factors

**Results:** At ED, 18,562 prescriptions for 15,973 patients and 4,780 prescriptions for 2,225 patients at the CP were analyzed. The PIM rate and PPO rate were respectively 3.3% and 2.6% at the ED and 26.4% and 13.2% at the CP. Respiratory and digestive diseases had the highest rate of PIM.

**Conclusion:** This is the first study to assess the prevalence of PIM and PPO detecting by POPI in a pediatric population. This study allowed to describe PIMs or PPOs within a hospital and a community pharmacy. POPI could be used to improve medication use and patient care and to limit hospitalization and adverse drug reaction. A prospective and multicenter study should be conducted to evaluate the impact and benefit of implementing POPI in clinical practice.

### Strengths and limitations of this study

- This study is the first to observe the prevalence of PIM and PPO in a pediatric population.

- It is a retrospective and monocentric study. The prevalence of PIM and PPO may be underestimated (large number of prescriptions, absence of specific pathology). Some criteria could be analyzed only in a prospective study. A lack of clinical information is the main limitation in detection in a community setting.

- Many omissions and inappropriate prescriptions can be easily detected with POPI despite limited clinical information.

## INTRODUCTION

Inappropriate prescribing is a known preventable cause of adverse drug events (ADE) and has an important impact on public health and cost of care. [1,2] In the literature, ADE is defined by “an injury resulting from medical intervention related to a drug” (dose error, adverse drug reaction (ADR), misuse of medication such as antibiotics).[3–5] In the pediatric population, ADR during hospitalization was estimated between 0.6% and 33.7% and between 1% and 1.5% for outpatients.[6–9] Incidence of ADR leading to admission was evaluated between 1.8% and 17.7%.[6,7,10] Many drugs were concerned in commonly used medication.[11–13]

The World Health Organization estimated that 50% of medications are prescribed and used inappropriately.[14] The most recent definition of inappropriate prescription (IP) encompasses potentially inappropriate medicines (PIM) and prescribing omissions (PPO).[15]

In a report from the French National Authority for Health, PIMs are defined as “drugs being used in a situation in which the risks involved in treatment potentially outweigh the benefits, lack of demonstrated indication, high risk of ADE, and an unfavorable cost-effect or risk-benefit ratio exists”. PPO or underuse of appropriate medication is defined as the absence of initiation of an effective treatment in subjects with a condition for which one or several drug classes have demonstrated their efficacy. In an elderly population, which presents with age-related physiological changes and high prevalence of polypharmacy, various measures have been developed to detect PIM such as: Beers’ criteria, the Inappropriate Prescribing in the Elderly Tool, The Medication Appropriate Index, and STOPP/START (Screening Tool of Older Person’s prescriptions/Screening Tool to Alert doctor to Right Treatment).[16–21]

Only the STOPP/START enables us to detect under-prescribing.[15] Using these tools, many studies have been carried out which have detected that inappropriate prescriptions are issued to between 35% and 51% of this population.[22–26]

Omission prescriptions in geriatric population detected by START tool concerned between 58%-61% of patients.[27,28] Negative outcomes related to an IP such as side effects, hospitalization, mortality and utilization of resources were also demonstrated.[21,29–31]

Prescribing in a pediatric population is always a challenge for physician. It is often empirical and primarily based on safety and pharmacology information obtained in adults.[32] This is a worry not only in a hospital or general practitioner setting but also for the community pharmacists. They may only be able to check information and resources or even dispense infrequently for this vulnerable population.[33] ADRs were three time higher in the pediatric population. This frequency was explained by the vulnerability of young people, pharmacokinetic changes during childhood and pediatric off-label drug used.[4,34] Large differences relating to treatment were seen within and between the countries.[6,35] Question about rational of prescription could be asked.[36] Optimizing children's care is based on rational prescribing and allowing a decrease in side effects.[35,36] In order to improve the correct drug use and optimize practice, the first tool of detection for PIM and PPO was created by Prot-Labarthe *et al.* in 2013. The tool was named POPI (Pediatrics: Omission of Prescriptions and Inappropriate prescriptions) (Table 1).[37,38] Presently, the complete tool has not been tested in actual practice and the prevalence of PIM and OP is not known.

Our aim is to assess the prevalence of PIM and PPO detected using POPI in hospital and outpatient care. This was its first application, regarding issuing of prescriptions in the emergency department and the community pharmacy. The second objective is to determine the risk factors related to PIM.

## **METHODS**

### **Population**



1  
2  
3 A retrospective and descriptive study was conducted in the emergency department (ED) of  
4 AP-HP Robert-Debré hospital (Paris) - the largest French pediatric hospital - and the Albaret  
5 community pharmacy (CP) (Seine and Marne). Inclusion criteria included patients who were  
6 under 18 years old and who had one or more medicine prescriptions between 1<sup>st</sup> October 2014  
7 and 31<sup>st</sup> March 2015. Prescription was defined as one or more lines of drugs prescribed by a  
8 physician. Exclusion criteria consisted of inaccessible medical records for patients consulted  
9 in ED and prescription without drugs for outpatients. POPI contains 102 criteria (76 PIMs, 25  
10 PPO). A literature review was done to obtain criteria. Criteria were categorized according to  
11 the main physiological systems (gastroenterology, respiratory infections, pain, neurology,  
12 dermatology and miscellaneous). Criteria were validated by 2-round-Delphi consensus  
13 technique.[38]  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

### 28 **Data collection**

29  
30  
31 The prescriptions given on leaving the hospital emergency department were extracted from  
32 the Urqual software V5<sup>®</sup> (\*) (McKesson Corp, Paris, France). Urqual<sup>®</sup> is an emergency  
33 prescription software which is used in many French hospitals. Patient information including  
34 age, sex, weight, medicine prescription and current diagnosis was collected. Medical histories  
35 and clinical examinations were consulted individually when necessary. Due to the significant  
36 amount of data, clinical files of ED were analyzed, based on primary diagnosis. For this study,  
37 82/102 criteria were analyzed (Table 1). Some criteria could not be used for a hospital setting.  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 The data extracted from Urqual software give only the first drug per prescription for each  
48 diagnosis (no possibility to extract all drugs for all prescriptions). Once extracted, the  
49 prescription was then manually analyzed for each diagnosis. Consequently, the number of  
50 medications per prescription was not included. However, all prescriptions have been manually  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

reviewed directly from medical file by two authors. For each targeted disorder, the prescription was analyzed to detect PIMs or PPOs.

**Table 1.** POPI - Pediatrics: Omission of Prescriptions & Inappropriate prescriptions

<b>A- PAIN AND FEVER</b>	
<b>Inappropriate prescriptions</b>	<b>Omissions</b>
<p><b>AI-1.</b> Prescription of two alternating antipyretics as a first-line treatment.</p> <p><b>AI-2.</b> Prescription of a medication other than paracetamol as a first line treatment (except in the case of migraine).</p> <p><b>AI-3.</b> Rectal administration of paracetamol as a first-line treatment.</p> <p><b>AI-4.</b> The combined use of two NSAIDs. * °</p> <p><b>AI-5.</b> Oral solutions of ibuprofen administered in more than three doses per day using a graduated pipette of 10mg/kg (other than Advil<sup>®</sup>). °</p> <p><b>AI-6.</b> Opiates to treat migraine attacks. *</p>	<p><b>A0-1.</b> Failure to give sugar solution to new-born babies and infants under four months old two minutes prior to venipuncture.</p> <p><b>A0-2.</b> Failure to give an osmotic laxative to patients being treated with morphine for a period of more than 48 hours.</p>
<b>B- URINARY INFECTIONS</b>	
<b>Inappropriate prescriptions</b>	
<p><b>BI-1.</b> Nitrofurantoin used as a prophylactic. *</p> <p><b>BI-2.</b> Nitrofurantoin used as a curative agent in children under six years of age, or indeed any other antibiotic if avoidable. *</p> <p><b>BI-3.</b> Antibiotic prophylaxis following an initial infection without complications (except in the case of uropathy). *</p> <p><b>BI-4.</b> Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of uropathy). *</p>	
<b>C- VITAMIN SUPPLEMENTS AND ANTIBIOTIC PROPHYLAXIS</b>	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Inappropriate prescriptions	Omissions
<p><b>CI-1.</b> Fluoride supplements prior to six months of age. °*</p>	<p><b>CO-1.</b> Insufficient intake of vitamin D. Minimum vitamin D intake:</p> <ul style="list-style-type: none"> <li>▪ Breastfed baby = 1,000 to 1,200 IU/day</li> <li>▪ Infant &lt; 18 months of age (milk enriched with vitamin D) = 600 to 800 IU/day</li> <li>▪ Child aged between 18 months and five years, and adolescents aged between 10 and 18 years: two quarterly loading doses of 80,000 to 100,000 IU/day in winter (adolescents can take this as one dose).</li> </ul> <p><b>CO-2.</b> Antibiotic prophylaxis with phenoxymethylpenicillin (Oracilline) starting from two months of age and lasting until five years of age for children with sickle-cell anemia: 100,000 IU/kg/day (in two doses) for children weighing 10kg or less and 50,000 IU/kg/day for children weighing over 10kg (also in two doses). *</p>

**D- MOSQUITOS**

Inappropriate prescriptions	Omissions
<p><b>DI-1.</b> The use of skin repellents in infants less than six months old and picardin in children less than 24 months old.</p> <p><b>DI-2.</b> Citronella (lemon grass) oil (essential oil).</p> <p><b>DI-3.</b> Anti-insect bracelets to protect against mosquitos and ticks.</p> <p><b>DI-4.</b> Ultrasonic pest control devices, vitamin B1, homeopathy, electric bug zappers, sticky tapes without insecticide.</p>	<p><b>DO-1.</b> DEET “30%” (max) before 12 years old “50%” (max) after 12 years old.</p> <p><b>DO-2.</b> IR3535 “20%” (max) before 24 months old “35%” (max) after 24 months old.</p> <p><b>DO-3.</b> Mosquito nets and clothes treated with pyrethroids.</p>

**E- NAUSEA, VOMITTING, OR GASTROESOPHAGEAL REFLUX**

Inappropriate prescriptions	Omissions
<p><b>EI-1.</b> Metoclopramide. * °</p> <p><b>EI-2.</b> Domperidone. * °</p> <p><b>EI-3.</b> Gastric antisecretory drugs to treat gastroesophageal reflux, dyspepsia, the crying of new-born babies (in the absence of</p>	<p><b>EO-1.</b> Oral rehydration solution in the event of vomiting.*</p>

**PROBLEMS**

any other signs or symptoms), as well as faintness in infants. \*

**EI-4.** The combined use of proton pump inhibitors and NSAIDs, for a short period of time, in patients without risk factors. \*

**EI-5.** Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube). \*

**EI-6.** The use of type H2 antihistamines for long periods of treatment. \* °

**EI-7.** Erythromycin as a prokinetic agent. \*

**EI-8.** The use of setrons (5-HT3 antagonists) for chemotherapy-associated nausea and vomiting. \*

## F- DIARRHEA

### Inappropriate prescriptions

**FI-1.** Loperamide before 3 years of age. \*°

**FI-2.** Loperamide in the case of invasive diarrhea. \*

**FI-3.** The use of Diosmectite (Smecta®) in combination with another medication. \*°

**FI-4.** The use of *Saccharomyces boulardii* (Ultralevure) in powder form, or in a capsule that has to be opened prior to ingestion, to treat patients with a central venous catheter or an immunodeficiency. \*

**FI-5.** Intestinal antiseptics. \*°

### Omissions

**FO-1.** Oral rehydration solution in the event of diarrhea. \*

## G- COUGH

### Inappropriate prescriptions

**GI-1.** Pholcodine. \* °

**GI-2.** Mucolytic drugs, mucokinetic drugs, or helcidine before two years of age. \* °

**GI-3.** Alimemazine (Theralene®), oxememazine (Toplexil®), promethazine (Phenergan®), and other types. \* °

**GI-4.** Terpene-based suppositories. \* °

### Omissions

**GO-1.** Failure to propose a whooping cough booster vaccine for adults who are likely to become parents in the coming months or years (only applicable if the previous vaccination was more than 10 years ago). This booster vaccination should also be proposed to the family of expectant parents and those in contact with them (parents, grand-parents, nannies/child minders).

## H- BRONCHIOLITIS IN INFANTS

**Inappropriate prescriptions****Omissions**

**HI-1.** Beta2 agonists, corticosteroids to treat an infant's first case of bronchiolitis. \*

**HI-2.** H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis. \*

**HI-3.** Antibiotics in the absence of signs indicating a bacterial infection (acute otitis media, fever, etc.). \*

**HO-1.** 0.9% NaCl to relieve nasal congestion (not applicable if nasal congestion is already being treated with 3% NaCl delivered by a nebulizer). \*

**HO-2.** Palivizumab in the following cases:

- (1) babies born both at less than 35 weeks of gestation and less than six months prior to the onset of a seasonal RSV epidemic;
- (2) children less than two years old who have received treatment for bronchopulmonary dysplasia in the past six months;
- (3) children less than two years old suffering from congenital heart disease with hemodynamic abnormalities.

**I- ENT INFECTIONS****Inappropriate prescriptions****Omissions**

**II-1.** An antibiotic other than amoxicillin as a first-line treatment for acute otitis media, strep throat, or sinusitis (provided that the patient is not allergic to amoxicillin). An effective dose of amoxicillin for an pneumococcal infection is 80–90 mg/kg/day and an effective dose for a streptococcal infection is 50 mg/kg/day.\*

**II-2.** Antibiotic treatment for a sore throat, without a positive rapid diagnostic test result, in children more than three years old.\*

**II-3.** Antibiotics for nasopharyngitis, congestive otitis, sore throat before three years of age, or laryngitis; antibiotics as a first-line treatment for acute otitis media showing few symptoms, after two years of age.\*

**II-4.** Antibiotics to treat otitis media with effusion (OME), except in the case of hearing loss or if OME lasts for more than three months.\*

**II-5.** Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat.\*

**II-6.** Nasal or oral decongestant (oxymetazoline

**IO-1.** Doses in mg for drinkable (solutions of) amoxicillin or josamycin. \*°

**IO-2.** Paracetamol combined with antibiotic treatment for ear infections to relieve pain. \*

(Aturgyl<sup>®</sup>), pseudoephedrine (Sudafed<sup>®</sup>), naphazoline (Derinox<sup>®</sup>), ephedrine (Rhinamide<sup>®</sup>), tuaminoheptane (Rhinofluimicil<sup>®</sup>), phenylephrine (Humoxal<sup>®</sup>)).\*<sup>o</sup>

**II-7.** H1-antagonists with sedative or atropine-like effects (pheniramine, chlorpheniramine), or camphor; inhalers, nasal sprays, or suppositories containing menthol (or any terpene derivatives) before 30 months of age.\*<sup>o</sup>

**II-8.** Ethanalamine tenoate (Rhinotrophyl<sup>®</sup>) and other nasal antiseptics.\*<sup>o</sup>

**II-9.** Ear drops in the case of acute otitis media.\*

## J- ASTHMA

### Inappropriate prescriptions

### Omissions

**JI-1.** Ketotifen and other H1-antagonists, sodium cromoglycate.\*

**JO-1.** Asthma inhaler appropriate for the child's age.

**JI-2.** Cough suppressants.\*

**JO-2.** Preventative treatment (inhaled corticosteroids) in the case of persistent asthma.\*

## K-ACNE VULGARIS

### Inappropriate prescriptions

### Omissions

**KI-1.** Minocycline.\*<sup>o</sup>

**KI-2.** Isotretinoin in combination with a member of the tetracycline family of antibiotics.\*<sup>o</sup>

**KI-3.** The combined use of an oral and a local antibiotic.\*

**KI-4.** Oral or local antibiotics as a monotherapy (not in combination with another drug).\*

**KI-5.** Cyproterone+ethinylestradiol (Diane 35<sup>®</sup>) as a contraceptive to allow isotretinoin per os.\*<sup>o</sup>

**KI-6.** Androgenic progestins (levonorgestrel, norgestrel, norethisterone, lynestrenol, dienogest, contraceptive implants or vaginal rings).\*

**KO-1.** Contraception (provided with a logbook/diary) for menstruating girls taking isotretinoin.

**KO-2.** Topical treatment (benzoyl peroxide, retinoids, or both) in combination with antibiotic therapy.\*

## L- SCABIES

## Omissions

**LO-1.** A second dose of ivermectin two weeks after the first. \*

**LO-2.** Decontamination of household linen and clothes and treatment for other family members.

## M- LICE

### Inappropriate prescriptions

**MI-1.** The use of aerosols for infants, children with asthma, or children showing asthma-like symptoms such as dyspnea.

## N- RINGWORM

### Inappropriate prescriptions

### Omissions

**NI-1.** Treatment other than griseofulvin for Microsporium. \*

**NO-1.** Topical treatment combined with an orally-administered treatment. \*

**NO-2.** Griseofulvin taken during a meal containing a moderate amount of fat. \* °

## O-IMPETIGO

### Inappropriate prescriptions

**OI-1.** The combination of locally applied and orally administered antibiotics.\*

**OI-2.** Fewer than two applications per day for topical antibiotics.\*

**OI-3.** Any antibiotic other than mupirocin as a first-line treatment (except in cases of hypersensitivity to mupirocin).\*

## P- HERPES SIMPLEX

### Inappropriate prescriptions

### Omissions

**PI-1.** Topical agents containing corticosteroids. \*

**PO-1.** Paracetamol during an outbreak of herpes. \*

**PI-2.** Topical agents containing acyclovir before six years of age. \* °

**PO-2.** Orally administered acyclovir to treat primary herpetic gingivostomatitis. \*

## Q-ATOPIC DERMATITIS

### Inappropriate prescriptions

QI-1. A strong topic steroid (clobetasol propionate 0.05% Dermoval, betamethasone dipropionate Diprosone) applied to the face, armpits or groin, and to the backside of babies or young children. \*

More than one application per day of a topical steroid, except in cases of severe lichenification. \*

QI-2. Local or systemic antihistamine during the treatment of outbreaks. \*

QI-3. Topically applied 0.03% tacrolimus before two years of age. \*°

Topically applied 0.1% tacrolimus before 16 years of age.

QI-4. Oral corticosteroids to treat outbreaks. \*

## R- EPILEPSY

### Inappropriate prescriptions

RI-1. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of myoclonic epilepsy. \*

RI-2. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of epilepsy with absence seizures (especially for childhood absence epilepsy or juvenile absence epilepsy). \*

RI-3. Levetiracetam, oxcarbamazepine in mL or in mg without systematically writing XX mg per Y mL. \* °

## S-DEPRESSION

### Inappropriate prescriptions

SI-1. An SSRI antidepressant other than fluoxetine as a first-line treatment (in the case of pharmacotherapy). \*

SI-2. Tricyclic antidepressants to treat depression. \*

## T- NOCTURNAL ENURESIS

### Inappropriate prescriptions

TI-1. Desmopressin administered by a nasal spray. \* °



Desmopressin in the case of daytime symptoms.

**TI-2.** An anticholinergic agent used as a monotherapy in the absence of daytime symptoms. \*

**TI-3.** Tricyclic agents in combination with anticholinergic agents. \* °

**TI-4.** Tricyclic agents as a first-line treatment. \*

## U- ANOREXIA

### Inappropriate prescriptions

**UI-1.** Cyproheptadine (Periactin®), clonidine \* °

## V- ATTENTION DEFICIT DISORDER WITH OR WITHOUT HYPERACTIVITY

### Inappropriate prescriptions

### Omissions

**VI-1.** Pharmacological treatment before age six (before school), except in severe cases. \*

**VI-2.** Antipsychotic drugs to treat attention deficit disorder without hyperactivity. \*

**VI-3.** Slow release methylphenidate as two doses per day, rather than only one dose. \*°

**VO-1.** Recording a growth chart (height and weight) if the patient is taking methylphenidate. \*

\* Criteria analyzed in emergency department

° Criteria analyzed in community pharmacy

Data from the community pharmacy were obtained from the pharmacy management software OPUS® (Computer PG, France). Patient's age and drugs prescribed were collected. Current diagnosis and sex were not available, in the OPUS software, so the number of patients per pathology and the number of prescriptions per pathology were missed. Only drugs that did not require assessment of diagnosis (for example domperidone, metoclopramide etc.) were analyzed (Table 1) (28 criteria/102).

1  
2  
3 Among the 5 criteria including analgesics and antipyretics, only three were evaluated due to a  
4 large number of prescriptions and their association with many diseases. Pathologies analyzed  
5 by POPI were the same in emergency department and in community. Summary of data and  
6 inclusion criteria are detailed in Appendix 1.  
7  
8  
9  
10

### 11 12 **Statistical analysis**

13  
14  
15  
16 Data were presented as continuous variables (age, number of prescriptions by patient, number  
17 of medications per prescription) and were presented as median and interquartile range (25th-  
18 75th percentiles) or mean (standard deviation), minimum and maximum depending on normal  
19 distribution.  
20  
21  
22  
23

24  
25  
26 Mixed effects logistic regression modelling for repeated measurements was applied to identify  
27 factors associated with PIM and PPO (yes/no) in the hospital and community settings. Unit of  
28 analysis was “the prescription”.  
29  
30  
31  
32

33  
34 Univariate models were performed using different candidate factors as:

- 35  
36 - For model performed with hospital data: sex and age (0 days - 2 years, 2 - 6 years, 6 -  
37 12 years, 12 - 18 years);
- 38  
39 - For model performed with community data: age (0 days - 2 years, 2 - 6 years, 6 - 12  
40 years, 12 - 18 years) and number of medications (drugs) per prescription;  
41  
42  
43  
44

45  
46 The model was constructed using the parameters of the univariate analysis, which showed at  
47 least a trend toward significance, with a cut-off of  $p=0.2$ . Odds ratios (OR) with 95%  
48 confidence intervals (CI) were estimated. Statistical significance was established at  $p<0.05$ .  
49  
50 SPSS-22<sup>®</sup> software (SPSS Inc., Chicago, IL, USA) and SAS 9.4 were used for analysis.  
51  
52  
53

54  
55 This project was approved by the local research ethics committee (n°2015/218).  
56  
57  
58  
59  
60

## Patient and Public Involvement

No Patient and Public involvement

## RESULTS

In the emergency department, 18,562 prescriptions for 15,973 patients consulted were analyzed. Among them, 29% had at least two visits in 6 months. In the community pharmacy, 4,780 prescriptions for 2,225 patients were evaluated (Figure 1). In ED and CP, 53% of patients had been issued with one prescription, 21% with two and 26% with three or more prescriptions. The population's characteristics and the frequency of pathologies were presented in Table 2. Distribution of number of prescriptions by age category was described in the Figure 2.

**Table 2. Characteristics of the study population**

<b>Population characteristics</b>	<b>Hospital (N=15,973)</b>	<b>Community (N=2,225)</b>
Age (years) mean (SD)	4.9 (4.5)	7.9 (5.3)
Min, Max	0-18	0-18
Female gender N(%)	8,769 (54.9)	NA
Number of prescriptions/patient mean (SD)	1.4 (0.9)	2.2 (1.9)
Min, Max	1-12	1-16
Number of drugs per prescription mean (SD)	NA	2.4 (1.6)
Min, Max		1-22

Number of prescriptions by pathology N(%)		
Digestive disorders	2,728 (14.7)	NA
ENT-Pulmonary disorders	8,397 (45.2)	NA
Dermatological disorders	604 (3.3)	NA
Neuropsychiatric disorders	242 (1.3)	NA
Other illnesses <sup>#</sup>	6,591 (35.5)	NA

NA: Not available; ENT: ear, nose and throat

<sup>#</sup> For example, traumatic injury, pain, sickle cell disease

In hospital, POPI tools identified 541 PIMs in 2.9% of the prescriptions analyzed. They were detected in 3.3% of the patients (n=530). PPOs were detected in 0.1% of prescriptions for 0.1% of patients. In the community, PIMs and PPOs represented 12.3% and 0.9% of all prescriptions, affecting 26.4% and 1.9% patients respectively (Table 3).

**Table 3. Potentially Inappropriate Medications (PIMs) and Potential Prescription Omission (PPOs) identified by POPI**

	Hospital N (%)	Community N (%)
<b>Number of prescriptions (N)</b>	<b>18,562</b>	<b>4,780</b>
PIMs identified per prescription		
1	519 (2.8%)	551 (11.5%)
2	11 (0.1%)	37 (0.8%)
Prescriptions with at least one PIM	530 (2.9%)	588 (12.3%)
PPOs identified per prescription		
1	0 (0%)	0 (0%)

2	20 (0.1%)	44 (0.9%)
3	1 (0.01%)	1 (0.02%)
Prescriptions with at least one PPO	21 (0.1%)	45 (0.9%)
<b>Number of patients (N)</b>	<b>15,793</b>	<b>2,225</b>
Patients with at least one PIM °	530 (3.3%)	588 (26.4%)
Patients with at least one PPO	21 (0.1%)	43 (1.9%)

Table 4 presents the prevalence of PIMs (or PPOs) in the ED in patients with the targeted disorders. Patients with the targeted disorders represent the individuals who were at risk of each PIM/PPO. Table 5, however, presents the PIMs (or PPOs) as a proportion of the total number of PIMs (or PPOs) in the community pharmacy. Respiratory and digestive diseases had the highest rate of PIM in hospital and community pharmacy. For various illnesses, we removed one criterion involving medicines containing codeine because of their new contraindication in children under 12 years old.[39] However, the prescription of codeine was observed in 18 cases. According to our comparison of PIMs detectable in both settings, out-of-hospital medication always presents with a higher prevalence of PIMs (Figure 3).

**Table 4. Prevalence of PIMs and PPOs identified by POPI in hospital**

Criteria		No. of PIMs	No. of patients with the targeted disorders	% of PIMs in patients with the targeted disorders
<b>Potentially inappropriate medications (PIMs)</b>		<b>541</b>	<b>7,304</b>	<b>7.4%</b>
<b>Various illnesses</b>		<b>3</b>	<b>64</b>	<b>4.6%</b>
AI-6	Opiates to treat migraine attacks	3	64	4.6%
<b>Digestive disorders</b>		<b>56</b>	<b>1,956</b>	<b>2.8%</b>
EI-2	Domperidone	28	1,956	1.4%
FI-3	The use of Diosmectite (Smecta®) in	27	1,956	1.4%

	combination with another medication			
EI-1	Metoclopramide	1	1,956	0.05%
<b>ENT-Pulmonary disorders</b>		<b>472</b>	<b>5,163</b>	<b>9.1%</b>
II-4	Antibiotics to treat acute suppurative otitis media etc.	2	7	28.6%
II-2	Antibiotic treatment for a sore throat, without a positive RDT.	23	160	14.4%
II-9	Ear drops in the event of acute otitis media	86	1,083	7.9%
HI-1	Beta2 agonist, corticosteroids to treat an infant's first case of bronchiolitis	25	386	6.4%
II-5	Corticosteroids to treat acute suppurative otitis media etc.	190	3,616	5.2%
II-1	An antibiotic other than amoxicillin as a first-line treatment.	59	1,259	4.7%
JI-1	H1-antagonist to treat asthma	9	802	1.1%
II-8	Tenoate Etanolamine (Rhinotrophyl <sup>®</sup> ) and other nasal antiseptics	21	2,455	0.8%
II-3	Antibiotics for nasopharyngitis	26	3,444	0.7%
GI-3	Alimemazine (Theralene <sup>®</sup> ), oxomemazine (Toplexil <sup>®</sup> ) etc.	18	2,585	0.7%
JI-2	Cough suppressants to treat asthma	5	802	0.6%
HI-2	H1-antagonists, cough suppressants etc. to treat bronchiolitis	2	386	0.5%
II-7	H1-antagonists with sedative or atropine-like effects.	4	2,585	0.2%
GI-2	Mucolytics drugs, mucokinetics drugs or helicidine before 2 years of age	1	2,585	< 0.1%
II-6	Nasal or oral decongestant etc.	1	2,455	< 0.1%
<b>Dermatological disorders</b>		<b>10</b>	<b>100</b>	<b>10%</b>
OI-1	A combination of locally applied and orally administered antibiotics	9	32	28.1%
PI-2	Topical agents containing acyclovir administered to a child under six years of age	1	68	1.5%
		<b>No. of PPO</b>	<b>No. of patients with the targeted disorders</b>	<b>% of PIMs in patients with the targeted disorders</b>
<b>Potentially Prescribing Omissions (PPO)</b>		<b>425</b>	<b>4,508</b>	<b>9.4%</b>
<b>Digestive disorders</b>		<b>372</b>	<b>1,956</b>	<b>19.0%</b>
EO-1	Oral rehydration solution in the event of vomiting	135	313	43.1%
FO-1	Oral rehydration solution in the event of diarrhea	237	1,643	14.4%
<b>ENT-Pulmonary disorders</b>		<b>52</b>	<b>1,469</b>	<b>3.5%</b>
HO-1	0.9% NaCl to relieve nasal congestion etc.	38	386	9.8%
IO-2	Acetaminophen combined with antibiotic	14	1,083	1.3%

	treatment for ear infections etc.			
<b>Dermatological disorders</b>		<b>1</b>	<b>3</b>	<b>33.3%</b>
NO-2	Griseofulvin taken during a meal containing a moderate amount of fat	1	3	33.3%

ENT: ear, nose and throat; No: Number; RDT: Rapid diagnostic test.

% Percentage calculated by the number of PIMs or PPO detected from the total number of analyzable cases

\*the number of patients with the targeted disorder corresponds to patients with clinical situations at risk of PIM or PPO

**Table 5. Most frequently occurring PIMs and PPOs identified by POPI in community setting**

Criteria	Proportion of PIMs per disorder according to total number of PIMs N(%)
<b>Total number of Potentially Inappropriate Medications (PIMs) N= 591</b>	
<b>Various illnesses</b>	<b>15 (2.5)</b>
AI-5 Oral solutions of ibuprofen administered in more than 3 doses etc.	7 (1.2)
CI-1 Fluoride supplements prescribed to infants under six months of age	5 (0.8)
AI-4 The combined use of two NSAIDs	3 (0.5)
<b>Digestive disorders</b>	<b>201 (34)</b>
EI-2 Domperidone	152 (25.7)
FI-3 The use of Diosmectite (Smecta <sup>®</sup> ) in combination with another medication	35 (5.9)
FI-5 Intestinal antiseptics	9 (1.5)
EI-1 Metoclopramide	2 (0.3)
EI-6 The use of type H2 antihistamines for long periods of treatment	2 (0.3)
FI-1 Loperamide before 3 years of age	1 (0.2)
<b>ENT-Pulmonary disorders</b>	<b>369 (62.4)</b>
GI-3 Alimemazine (Theralene <sup>®</sup> ), oxomemazine (Toplexil <sup>®</sup> ), etc.	202 (34.2)
GI-1 Pholcodine	81 (13.7)
II-8 Etanolamine tenoate (Rhinotrophy <sup>®</sup> ) and other nasal antiseptics	62(10.5)
II-6 Nasal or oral decongestant etc.	20 (3.4)
GI-2 Mucolytic drugs, mucokinetic drugs or helicidine prescribed to a child under 2 years of age	3(0.5)
GI-4 Terpene-based suppositories	1(0.2)
<b>Dermatological disorders</b>	<b>1(0.2)</b>

<b>PI-2</b> Topical agents containing acyclovir prescribed to a child under six years of age	1(0.2)
<b>Neuropsychiatric disorders</b>	<b>5 (0.8)</b>
<b>RI-3</b> Levetiracetam in mL or in mg prescribed without systematically indicating XX mg per Y mL	5(0.8)
	<b>Proportion of PIM per disorder according to total number of PIM N(%)</b>
<b>Potential Prescribing Omissions (PPOs) N= 293</b>	
<b>IO-1</b> Dose in mg for oral (solution of) amoxicillin etc. N (%)	293 (100%)

*NSAIDs: Non-steroidal anti-inflammatory drugs; ENT: ear, nose and throat  
% Percentage of PIMs or PPOs calculated from the total number of PIMs or PPO detected*

The criterion on prescribing amoxicillin in mg (IO-1) was not analyzable due to the fact that this drug is prescribed in great quantity. Among 100 prescriptions randomly assessed in hospital extractions, 97 prescriptions were inappropriate. Nonetheless, one analysis on acute otitis media alone identified a rate of 99.5% (807/811) of prescriptions issued without specification of the doses in mg for oral amoxicillin. In community care, this was observed in 97% of prescriptions, in 13.2% of patients (Table 5).

PIMs classed by age were presented in the figure 4. Potential factors associated with PIM or PPO are presented in Appendix 2a, b. On univariate analysis, only different age categories were associated with risk of PIM or PPO in hospital setting. In community setting, the number of medications (drugs) per prescription and different age categories were found to be significantly associated with risk of PIM or PPO on univariate analysis. In the multivariable logistic regression model, the same results were obtained.

## DISCUSSION

This is the first study to observe the prevalence of PIMs and PPOs in a pediatric population. In the literature, the tool detected PIMs/PPOs in a geriatric population. [22,40–42] The two



1  
2  
3 populations are not comparable. Respiratory and digestive pathologies are typical in children  
4 and not so in a geriatric population, which is concerned by cardiovascular and nervous  
5 central system diseases.[22,40,43].  
6  
7  
8  
9

10 Domperidone was frequently prescribed in a community setting, yet this drug is responsible  
11 for cardiac adverse effects such as QT prolongation. This side effect is described in the  
12 literature in adult populations and pediatric populations. Detecting of this prescription will  
13 enable us to avoid cardiac risks. [44–49]  
14  
15  
16  
17  
18

19 Prevalence of beta2 agonists or corticosteroids in an infant's first case of bronchiolitis is 6.4%  
20 (25/386 cases), lower than that observed in a study of another French area in 2012 (41%).[50–  
21 52] Use of beta2 agonists in a first case of bronchiolitis has no impact on oxygen saturation,  
22 length of hospitalization or length of illness. They concurrently cause side effects as  
23 tachycardia, oxygen saturation, and tremors. [53] Implementation of guidelines has permitted  
24 to decrease beta2 agonist and corticosteroid use in a French hospital without increase  
25 morbidity. [54]  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 Unnecessary exposure to cough suppressants, pholcodine, nasal or oral decongestants was  
38 also observed frequently in this sector.[55] In Norway, all drugs containing pholcodine have  
39 been refused marketing authorization for March 2007. As of this date, a decrease in  
40 sensitization to suxamethonium used in anesthesia and a decrease of 30-40% cases of  
41 anaphylaxis were identified. [56]  
42  
43  
44  
45  
46  
47

48 Our tool enabled us to detect rare PIMs but with a major impact, such as opioid use for  
49 migraines. The use of opioids for this disease induces a transition from episodic to chronic  
50 headaches and an increase of sensitivity to pain.[57–59]  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Overuse of medication overuse, in particular opioids, could contribute to the chronicity of  
4  
5 headaches in 20–30% of children and adolescents with chronic daily headaches.[59]  
6  
7

8  
9 In the management of diarrhea caused by gastroenteritis, in hospital, our study found that it  
10  
11 was common to omit prescription of an oral rehydration solution (ORS): 14% (237/1643  
12  
13 case). Even so, this rate is lower than that found in another national study in 2007 (29%).[60]  
14  
15 However, ORSs prevent hospitalization in cases of acute gastroenteritis. In the United  
16  
17 Kingdom, the use of ORSs has enabled a decrease from 300 deaths/year in 1970s to 25  
18  
19 deaths/year in 1980s.[61,62]. The need for ORS prescriptions was confirmed by the  
20  
21 recommendation of the European Society for Paediatric Gastroenterology, Hepatology, and  
22  
23 Nutrition (ESPGHAN) in 2014.[63]  
24  
25

26  
27 As estimated, the child aged between 0 and 12 years has the highest risk of presenting with a  
28  
29 PIM, according to a multivariate analysis. No inappropriate prescriptions or omissions were  
30  
31 detected for patients aged less than 28 days. As we know, they are also affected by off-label  
32  
33 drug prescriptions, which is consistent with reports from other sources.[64,65] As with  
34  
35 geriatrics, an increase in numbers of medications can be associated with PIM.[40]  
36  
37 Prescriptions issued from hospitals elicit fewer PIMs than those issued by the community.  
38  
39 The main reason for this is that many drugs are not available in this hospital, such as cough  
40  
41 suppressants, Rhinotrophyl<sup>®</sup> (tenoate ethanolamine), domperidone, etc. This shows that many  
42  
43 PIM are preventable in a hospital setting. An efficient method for prevention of PIM could be  
44  
45 to focus on the prescribing habits of physicians and thus have an impact on the selection of  
46  
47 drugs, thereby reducing the rate of PIM.  
48  
49

50  
51  
52 Our study has several limitations. Firstly, it is a retrospective and monocentric study. Our  
53  
54 result in the hospital could be underestimated. In addition, several criteria could not be  
55  
56 analyzed due to the large number of prescriptions (for example, those for fever or pain which  
57  
58  
59

1  
2  
3 are associated with many diseases) or absence of a specific pathology (mosquitos, lice,  
4 hyperactivity etc.). Antibiotic prophylaxis, vitamin supplements, proposition of vaccination  
5 etc. can be analyzed in prospective studies. A lack of clinical information is the main  
6  
7 limitation in detection in a community setting. This also constitutes a challenge for  
8  
9 pharmaceutical care review in elderly patients.[66] However, a certain amount of PIM was  
10  
11 identified using POPI. Our study showed that there are many criteria which could be detected  
12  
13 without access to clinical information and are easy to identify. Moreover, community  
14  
15 pharmacists, in their practice, can extrapolate diagnoses from their experience, from common  
16  
17 indications or by interviewing their patient. The study presents a limitation regarding the  
18  
19 URQUAL software, from which the number of medications per prescription could not be  
20  
21 extracted.  
22  
23  
24  
25  
26

27  
28 This is the first study which permits to evaluate prevalence of PIM and PPO in pediatrics  
29  
30 prescription. Detecting of PIMs/PPOs would improve patient care, and prevent hospitalization  
31  
32 and adverse drug reactions. A stepped wedge randomized cluster multicenter study will be  
33  
34 conducted to prove if POPI decreases number of PIM and PPO. It is also necessary to  
35  
36 evaluate the impact of this tool on reducing adverse drugs events, both in consultation or upon  
37  
38 hospitalization. The impact of pharmacists in providing appropriate prescriptions should be  
39  
40 also evaluated. Subsequently, this tool may be proposed to several professional societies such  
41  
42 as the French Society for Pediatricians and the French Society of Clinical Pharmacy to make  
43  
44 its use more widespread. The tool should be regularly updated to reflect recent events and to  
45  
46 specify certain criteria.  
47  
48  
49

50  
51 To facilitate its use, this tool can be presented as a mobile app, a small handbook or be  
52  
53 installed into prescription software. In summary, we hope that POPI could be a practical  
54  
55 option used to reduce medication errors and to improve the suitability of prescriptions. It  
56  
57  
58  
59  
60

1  
2  
3 provides rapid detection of PIM and PPO and can also open up a discussion on the  
4 relationship between the doctor and the pharmacist to remedy the issue at hand.[67]  
5  
6  
7

## 8 9 **CONCLUSION**

10  
11 Our study was carried out in in two sectors, hospital and community, and provides a global  
12 view of PIM and PPO in pediatric patients. POPI has a clinical impact and plays a role in  
13 improving prescription quality in various sectors and patient care. POPI should be applied in  
14 different services to deepen and reinforce its utilization. A prospective and multicenter study  
15 should be conducted to evaluate its impact and benefit in clinical practice.  
16  
17  
18  
19  
20  
21  
22

## 23 24 **ACKNOWLEDGMENTS**

25  
26 We would like to thank the Emergency department of Robert-Debré hospital and the Albaret  
27 pharmacy community for their data support.  
28  
29  
30

31  
32 We would also like to thank the French Society of Clinical Pharmacy (pediatric group) for  
33 their support.  
34  
35  
36

## 37 38 **ETHICS**

39  
40 This project was approved by the local research ethics committee (n°2015/218).  
41  
42  
43  
44

## 45 46 **DISCLOSURE OF INTEREST**

47  
48 None Declared  
49  
50

## 51 52 **FUNDING STATEMENT**

53  
54 This research received no specific grant from any funding agency in the public, commercial or  
55 not-for-profit sectors.  
56  
57  
58  
59

## AUTHOR'S CONTRIBUTION

Sonia Prot-Labarthe, Aurore Berthe-Aucejo conceptualised and designed the study, drafted the initial manuscript, and approved the final manuscript as submitted.

Rym Boulkedid and HPK Nguyen carried out analyses, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Xavier Bellettre, Thomas Weil, Olivier Bourdon reviewed and revised the manuscript and approved the final manuscript as submitted.

François Angoulvant and Patrick Albaret supplied data from hospital and community pharmacy and reviewed and revised the manuscript and approved the final manuscript as submitted.

## DATA SHARING STATEMENT

We have no additional unpublished data

## REFERENCES

- 1 Lund BC, Carnahan RM, Egge JA, *et al.* Inappropriate prescribing predicts adverse drug events in older adults. *Ann Pharmacother* 2010;**44**:957–63. doi:10.1345/aph.1M657
- 2 Chrischilles EA, VanGilder R, Wright K, *et al.* Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults. *J Am Geriatr Soc* 2009;**57**:1000–6.
- 3 Bates DW, Cullen DJ, Laird N, *et al.* Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. *JAMA* 1995;**274**:29–34.
- 4 Kaushal R, Bates DW, Goldmann DA. Medication errors and adverse drug events in pediatric inpatients. *JAMA* 2001;**285**:2114–20.
- 5 Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. *Ann Intern Med* 2004;**140**:795–801.
- 6 Clavenna A, Bonati M. Differences in antibiotic prescribing in paediatric outpatients. *Arch Dis Child* 2011;**96**:590–5. doi:10.1136/adc.2010.183541

- 7 Impicciatore P, Choonara I, Clarkson A, *et al.* Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. *Br J Clin Pharmacol* 2001;**52**:77–83. doi:10.1046/j.0306-5251.2001.01407.x
- 8 dos Santos DB, Coelho HLL. Adverse drug reactions in hospitalized children in Fortaleza, Brazil. *Pharmacoepidemiol Drug Saf* 2006;**15**:635–40. doi:10.1002/pds.1187
- 9 Rashed AN, Wong ICK, Cranswick N, *et al.* Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. *Eur J Clin Pharmacol* 2012;**68**:801–10. doi:10.1007/s00228-011-1183-4
- 10 Thiesen S, Conroy EJ, Bellis JR, *et al.* Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions. *BMC Med* 2013;**11**:237. doi:10.1186/1741-7015-11-237
- 11 de Vries TW, van Hunsel F. Adverse drug reactions of systemic antihistamines in children in the Netherlands. *Arch Dis Child* 2016;**101**:968–70. doi:10.1136/archdischild-2015-310315
- 12 Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral corticosteroids in children. *Arch Dis Child* 2016;**101**:365–70. doi:10.1136/archdischild-2015-309522
- 13 Cliff-Eribo KO, Sammons H, Choonara I. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases. *Expert Opin Drug Saf* 2016;**15**:1321–8. doi:10.1080/14740338.2016.1221921
- 14 Reidenberg MM. Can the selection and use of essential medicines decrease inappropriate drug use? *Clin Pharmacol Ther* 2009;**85**:581–3. doi:10.1038/clpt.2009.10
- 15 Barry PJ, Gallagher P, Ryan C, *et al.* START (screening tool to alert doctors to the right treatment)--an evidence-based screening tool to detect prescribing omissions in elderly patients. *Age Ageing* 2007;**36**:632–8. doi:10.1093/ageing/afm118
- 16 Legrain S others. Consommation médicamenteuse chez le sujet âgé. Consommation, prescription, iatrogénie et observance. 2005. [http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa\\_synth\\_biblio\\_2006\\_08\\_28\\_\\_16\\_44\\_51\\_580.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28__16_44_51_580.pdf).
- 17 Beers MH, Ouslander JG, Rollinger I, *et al.* Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. *Arch Intern Med* 1991;**151**:1825–32.
- 18 Naugler CT, Brymer C, Stolee P, *et al.* Development and validation of an improving prescribing in the elderly tool. *Can J Clin Pharmacol J Can Pharmacol Clin* 2000;**7**:103–7.
- 19 Samsa GP, Hanlon JT, Schmader KE, *et al.* A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. *J Clin Epidemiol* 1994;**47**:891–6.

- 1  
2  
3 20 Laroche M-L, Bouthier F, Merle L, *et al.* Médicaments potentiellement inappropriés aux  
4 personnes âgées : intérêt d'une liste adaptée à la pratique médicale française. *Rev*  
5 *Médecine Interne* 2009;**30**:592–601. doi:10.1016/j.revmed.2008.08.010  
6  
7 21 Gallagher P, Ryan C, Byrne S, *et al.* STOPP (Screening Tool of Older Person's  
8 Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment).  
9 Consensus validation. *Int J Clin Pharmacol Ther* 2008;**46**:72–83.  
10  
11 22 Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially  
12 inappropriate Prescriptions): application to acutely ill elderly patients and comparison  
13 with Beers' criteria. *Age Ageing* 2008;**37**:673–9. doi:10.1093/ageing/afn197  
14  
15 23 Gallagher P, Lang PO, Cherubini A, *et al.* Prevalence of potentially inappropriate  
16 prescribing in an acutely ill population of older patients admitted to six European  
17 hospitals. *Eur J Clin Pharmacol* 2011;**67**:1175–88. doi:10.1007/s00228-011-1061-0  
18  
19 24 Dalleur O, Boland B, Losseau C, *et al.* Reduction of potentially inappropriate medications  
20 using the STOPP criteria in frail older inpatients: a randomised controlled study. *Drugs*  
21 *Aging* 2014;**31**:291–8. doi:10.1007/s40266-014-0157-5  
22  
23 25 Ryan C, O'Mahony D, Kennedy J, *et al.* Potentially inappropriate prescribing in an Irish  
24 elderly population in primary care. *Br J Clin Pharmacol* 2009;**68**:936–47.  
25 doi:10.1111/j.1365-2125.2009.03531.x  
26  
27 26 Yayla ME, Bilge U, Binen E, *et al.* The use of START/STOPP criteria for elderly patients  
28 in primary care. *ScientificWorldJournal* 2013;**2013**:165873. doi:10.1155/2013/165873  
29  
30 27 Borges EP, Morgado M, Macedo AF. Prescribing omissions in elderly patients admitted  
31 to a stroke unit: descriptive study using START criteria. *Int J Clin Pharm* 2012;**34**:481–9.  
32 doi:10.1007/s11096-012-9635-1  
33  
34 28 Barry PJ, Gallagher P, Ryan C, *et al.* START (screening tool to alert doctors to the right  
35 treatment)--an evidence-based screening tool to detect prescribing omissions in elderly  
36 patients. *Age Ageing* 2007;**36**:632–8. doi:10.1093/ageing/afm118  
37  
38 29 Chrischilles EA, VanGilder R, Wright K, *et al.* Inappropriate medication use as a risk  
39 factor for self-reported adverse drug effects in older adults. *J Am Geriatr Soc*  
40 2009;**57**:1000–6.  
41  
42 30 Dedhiya SD, Hancock E, Craig BA, *et al.* Incident use and outcomes associated with  
43 potentially inappropriate medication use in older adults. *Am J Geriatr Pharmacother*  
44 2010;**8**:562–70. doi:10.1016/S1543-5946(10)80005-4  
45  
46 31 Lau DT, Kasper JD, Potter DEB, *et al.* Hospitalization and death associated with  
47 potentially inappropriate medication prescriptions among elderly nursing home residents.  
48 *Arch Intern Med* 2005;**165**:68–74. doi:10.1001/archinte.165.1.68  
49  
50 32 Hébert G, Prot-Labarthe S, Tremblay M-E, *et al.* La pédiatrie, toujours exclue de  
51 l'innovation pharmaceutique ? *Arch Pédiatrie* 2014;**21**:245–50.  
52 doi:10.1016/j.arcped.2013.12.016  
53  
54  
55  
56  
57  
58  
59

- 1  
2  
3 33 Benavides S, Huynh D, Morgan J, *et al.* Approach to the pediatric prescription in a  
4 community pharmacy. *J Pediatr Pharmacol Ther JPPT Off J PPAG* 2011;**16**:298–307.  
5 doi:10.5863/1551-6776-16.4.298  
6  
7 34 Mercier J., Morin L, Prot-Labarthe S. Les erreurs de prescription et leurs conséquences.  
8 2010.  
9  
10 35 Risk R, Naismith H, Burnett A, *et al.* Rational prescribing in paediatrics in a resource-  
11 limited setting. *Arch Dis Child* 2013;**98**:503–9. doi:10.1136/archdischild-2012-302987  
12  
13 36 Choonara I. Rational prescribing is important in all settings. *Arch Dis Child* 2013;**98**:720.  
14 doi:10.1136/archdischild-2013-304559  
15  
16 37 Prot-Labarthe S, Vercheval C, Angoulvant F, *et al.* «POPI ; pédiatrie : omissions et  
17 prescriptions inappropriées ». Outil d'identification des prescriptions inappropriées chez  
18 l'enfant. *Arch Pédiatrie* 2011;**18**:1231–2. doi:10.1016/j.arcped.2011.08.019  
19  
20 38 Prot-Labarthe S, Weil T, Angoulvant F, *et al.* POPI (Pediatrics: Omission of Prescriptions  
21 and Inappropriate Prescriptions): Development of a Tool to Identify Inappropriate  
22 Prescribing. *PLoS ONE* 2014;**9**:e101171. doi:10.1371/journal.pone.0101171  
23  
24 39 European Medicines Agency. Codeine not to be used in children below 12 years for  
25 cough and cold. 2015.<http://www.ema.europa.eu>  
26  
27 40 Gallagher P, Lang PO, Cherubini A, *et al.* Prevalence of potentially inappropriate  
28 prescribing in an acutely ill population of older patients admitted to six European  
29 hospitals. *Eur J Clin Pharmacol* 2011;**67**:1175–88. doi:10.1007/s00228-011-1061-0  
30  
31 41 Beers MH. Explicit criteria for determining potentially inappropriate medication use by  
32 the elderly. An update. *Arch Intern Med* 1997;**157**:1531–6.  
33  
34 42 O'Mahony D, O'Sullivan D, Byrne S, *et al.* STOPP/START criteria for potentially  
35 inappropriate prescribing in older people: version 2. *Age Ageing* 2015;**44**:213–8.  
36 doi:10.1093/ageing/afu145  
37  
38 43 Nadège Caillère, Céline Caserio-Schonemann. Réseau OSCOUR® (Organisation de la  
39 surveillance coordonnée des urgences) Résultats nationaux 2004/2011. 2011.  
40  
41 44 Rocha CMG, Barbosa MM. QT interval prolongation associated with the oral use of  
42 domperidone in an infant. *Pediatr Cardiol* 2005;**26**:720–3. doi:10.1007/s00246-004-  
43 0922-z  
44  
45 45 Rossi M, Giorgi G. Domperidone and long QT syndrome. *Curr Drug Saf* 2010;**5**:257–62.  
46  
47 46 Djeddi D, Kongolo G, Lefaix C, *et al.* Effect of domperidone on QT interval in neonates.  
48 *J Pediatr* 2008;**153**:663–6. doi:10.1016/j.jpeds.2008.05.013  
49  
50 47 Domperidone: QT prolongation in infants. *Prescrire Int* 2011;**20**:14.  
51  
52 48 Caraballo L, Molina G, Weitz D, *et al.* [Proarrhythmic effects of domperidone in infants:  
53 a systematic review]. *Farm Hosp Organo Of Expresion Cient Soc Espanola Farm Hosp*  
54 2014;**38**:438–44. doi:10.7399/fh.2014.38.5.7957  
55  
56  
57  
58  
59  
60



- 1  
2  
3 49 Rochoy M, Auffret M, Béné J, *et al.* [Antiemetics and cardiac effects potentially linked to  
4 prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance  
5 database]. *Rev Epidemiol Sante Publique* 2017;**65**:1–8. doi:10.1016/j.respe.2016.06.335  
6  
7 50 Branchereau E, Branger B, Launay E, *et al.* [Management of bronchiolitis in general  
8 practice and determinants of treatment being discordant with guidelines of the HAS].  
9 *Arch Pédiatrie Organe Off Société Fr Pédiatrie* 2013;**20**:1369–75.  
10 doi:10.1016/j.arcped.2013.09.028  
11  
12 51 Bronchiolitis in children | 1-recommendations | Guidance and guidelines | NICE.  
13 <http://www.nice.org.uk/guidance/NG9/chapter/1-recommendations> (accessed 22 Jun  
14 2015).  
15  
16 52 Conférence de Consensus sur la prise en charge de la bronchiolite du nourrisson.  
17 2000.<http://www.has-sante.fr>  
18  
19 53 Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. *Cochrane Database Syst*  
20 *Rev* 2014;:CD001266. doi:10.1002/14651858.CD001266.pub4  
21  
22 54 *La Revue Prescrire*. 2014. <http://www.prescrire.org/fr/>  
23  
24 55 de Pater GH, Florvaag E, Johansson SGO, *et al.* Six years without pholcodine;  
25 Norwegians are significantly less IgE-sensitized and clinically more tolerant to  
26 neuromuscular blocking agents. *Allergy* 2017;**72**:813–9. doi:10.1111/all.13081  
27  
28 56 Loder E, Weizenbaum E, Frishberg B, *et al.* Choosing wisely in headache medicine: the  
29 American Headache Society’s list of five things physicians and patients should question.  
30 *Headache* 2013;**53**:1651–9. doi:10.1111/head.12233  
31  
32 57 Casucci G, Cevoli S. Controversies in migraine treatment: opioids should be avoided.  
33 *Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol* 2013;**34 Suppl 1**:S125-128.  
34 doi:10.1007/s10072-013-1395-8  
35  
36 58 Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine.  
37 *PAIN®* 2009;**142**:179–82. doi:10.1016/j.pain.2009.01.013  
38  
39 59 Piazza F, Chiappedi M, Maffioletti E, *et al.* Medication overuse headache in school-aged  
40 children: more common than expected? *Headache* 2012;**52**:1506–10. doi:10.1111/j.1526-  
41 4610.2012.02221.x  
42  
43 60 Martinot A, Pruvost I, Aurel M, *et al.* [Improvement in the management of acute  
44 diarrhoea in France?]. *Arch Pédiatrie Organe Off Société Fr Pédiatrie* 2007;**14 Suppl**  
45 **3**:S181-185.  
46  
47 61 Walker-Smith JA. Management of infantile gastroenteritis. *Arch Dis Child* 1990;**65**:917–  
48 8.  
49  
50 62 Murphy MS. Guidelines for managing acute gastroenteritis based on a systematic review  
51 of published research. *Arch Dis Child* 1998;**79**:279–84.  
52  
53 63 Guarino A, Ashkenazi S, Gendrel D, *et al.* European Society for Pediatric  
54 Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious  
55  
56  
57  
58  
59  
60

1  
2  
3 Diseases evidence-based guidelines for the management of acute gastroenteritis in  
4 children in Europe: update 2014. *J Pediatr Gastroenterol Nutr* 2014;**59**:132–52.  
5 doi:10.1097/MPG.0000000000000375

6  
7 64 Joret P, Prot-Labarthe S, Brion F, *et al.* Caractérisation des indications hors AMM en  
8 pédiatrie : analyse descriptive de 327 lignes de prescriptions dans un hôpital pédiatrique.  
9 *Pharm Hosp Clin* 2014;**49**:e151–2. doi:10.1016/j.phclin.2014.04.306

10  
11 65 Shah SS, Hall M, Goodman DM, *et al.* Off-label drug use in hospitalized children. *Arch*  
12 *Pediatr Adolesc Med* 2007;**161**:282–90. doi:10.1001/archpedi.161.3.282

13  
14 66 Ryan C, O'Mahony D, O'Donovan DÓ, *et al.* A comparison of the application of  
15 STOPP/START to patients' drug lists with and without clinical information. *Int J Clin*  
16 *Pharm* 2013;**35**:230–5. doi:10.1007/s11096-012-9733-0

17  
18 67 Gillespie U, Alassaad A, Hammarlund-Udenaes M, *et al.* Effects of Pharmacists'  
19 Interventions on Appropriateness of Prescribing and Evaluation of the Instruments' (MAI,  
20 STOPP and STARTs') Ability to Predict Hospitalization—Analyses from a Randomized  
21 Controlled Trial. *PLoS ONE* 2013;**8**. doi:10.1371/journal.pone.0062401  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33  
34 Figure 1. Flow chart indicating the course of the study

35  
36  
37 \* Prescriptions with only one medical device, dietary supplement or hygiene product, ED:  
38  
39 Emergency department

40  
41  
42  
43 Figure 2. Distribution of number of prescriptions according to age category in hospital and  
44  
45 community settings

46  
47  
48 Figure 3. Comparison of PIMs detected in hospital and in outpatient care

49  
50  
51  
52 Figure 4. Total prescription and PIMs in both hospital and outpatient care: Percentage  
53  
54 distribution by age group




Figure 1. Flow chart indicating the course of the study† \* Prescriptions with only one medical device, dietary supplement or hygiene product, ED: Emergency department

51x27mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Distribution of number of prescriptions according to age category in hospital and community settings

42x26mm (300 x 300 DPI)

view only




Figure 3. Comparison of PIMs detected in hospital and in outpatient care

254x190mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4. Total prescription and PIMs in both hospital and outpatient care: Percentage distribution by age group

90x23mm (300 x 300 DPI)

peer review only

**Appendix 1. Description of inclusion/exclusion criteria, data collected and POPI criteria analyzed among the two cohorts**

	Hospital	Community
Inclusion criteria	Patient under 18 years old Patient with one or more medicine prescriptions	Patient under 18 years old Patient with one or more medicine prescriptions
Exclusion criterion	Inaccessible medical records for patients	Prescription without any drug prescribed
Software extracted	Urqual®	Opus®
Data collected	Age Sex Weight Current diagnosis Number of prescriptions	Age  Number of prescriptions Number of drugs per prescription
Number of POPI items analyzed (among the 102 criteria)	82	28 (items usable for retrospective analysis if no diagnostic available)

**Appendix 2a. Univariate and multivariate analysis to determine factors associated with PIM according to POPI criteria**

Variable	Univariate analysis		Multivariate analysis	
	OR* [CI 95%]	p-value	OR* [CI 95%]	p-value
<b><u>Model 1: Hospital prescription</u></b>				
<b>Sex</b>				
Male	1			
Female	1.1 [0.9-1.3]	0.3		
<b>Age category</b>				
0 - 2 years	2.5 [1.6-3.9]	0.0001	2.5 [1.6-3.9]	< 0.001
2 - 6 years	4.0 [2.5-6.3]	< 0.0001	4.0 [2.5-6.3]	< 0.0001
6 - 12 years	2.2 [1.4-3.6]	0.0016	2.2 [1.4-3.6]	0.0016
12 - 18 years	1		1	
<b><u>Model 2: Community prescription</u></b>				
<b>Age category</b>				
0 - 2 years	0.8 [0.6-1.1]	0.1	0.7 [0.5-1.0]	0.06
2 - 6 years	2.0 [1.5-2.6]	< 0.0001	1.9 [1.4-2.4]	< 0.0001
6 - 12 years	1.9 [1.5-2.4]	< 0.0001	1.9 [1.5-2.5]	< 0.0001
12 - 18 years	1		1	
<b>Number of medications per prescription</b>	1.4 [1.3-1.6]	< 0.001	1.4 [1.3-1.6]	< 0.0001

OR: Odds ratio, CI: Confidence intervals.



**Appendix 2b. Univariate and multivariate analysis to determine factors associated with PPO according to POPI criteria**

Variable	Univariate analysis p		Multivariate analysis	
	OR* [CI 95%]	p-value	OR* [CI 95%]	p-value
<b>Model 1: Hospital prescription</b>				
<b>Sex</b>				
Male	1			
Female	1.1 [0.9 ; 1.3]	0.3053		
<b>Age category</b>				
0 - 2 years	1.1 [0.7 ; 1.6]	0.7703	1.1 [0.7 ; 1.6]	0.7703
2 - 6 years	1.4 [0.9 ; 2.1]	0.0761	1.4 [0.9 ; 2.1]	0.0761
6 - 12 years	1.9 [1.3 ; 2.8]	0.0015	1.9 [1.3 ; 2.8]	0.0015
12 - 18 years	1		1	
<b>Model 2: Community prescription</b>				
<b>Age category</b>				
0 - 2 years	6.1 [2.9 ; 12.7]	<0.0001	6.1 [2.9 ; 12.9]	<0.0001
2 - 6 years	22.4 [11.4 ; 44.1]	<0.0001	22.4 [11.3 ; 44.3]	<0.0001
6 - 12 years	9.8 [4.9 ; 19.6]	<0.0001	10.2 [5.1 ; 20.7]	<0.0001
12 - 18 years	1			
<b>Number of medications per prescription</b>	1.2 [1.1 ; 1.3]	<.0001	1.2 [1.2 ; 1.4]	<0.0001

OR: Odds ratio, CI: Confidence intervals.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	p1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	p2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	p4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	p5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	p6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	P6 NA
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	p6-7-14
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	p15
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	p15-16
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P16+figure 1
		(b) Give reasons for non-participation at each stage	Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 2
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	p17

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
2			(b) Report category boundaries when continuous variables were categorized	NA
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Appendix2
5	<b>Discussion</b>			
6	Key results	18	Summarise key results with reference to study objectives	p18
7	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p22
8	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	p22 to 24
9	Generalisability	21	Discuss the generalisability (external validity) of the study results	p24-25
10	<b>Other information</b>			
11	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	p24

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

# BMJ Open

**Retrospective study of irrational prescribing in French pediatric hospital: prevalence of inappropriate prescription detected by POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) in the emergency unit and in the ambulatory setting.**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019186.R4
Article Type:	Research
Date Submitted by the Author:	15-May-2018
Complete List of Authors:	Berthe-Aucejo, Aurore; Hopital Universitaire Robert Debre, Pharmacy department; INSERM, UMR-S1123, ECEVE; Inserm U1123 Nguyen, Phuong Khanh Hoang; Hopital Universitaire Robert Debre, Department of Pharmacy Angoulvant, François; Hopital universitaire Necker-Enfants malades, Emergency unit; INSERM, UMR-S1123, ECEVE; Inserm U1123 Bellettre, Xavier; Hopital Universitaire Robert Debre, Emergency unit Albaret, Patrick; Albaret Pharmacy Weil, Thomas; Hopital Universitaire Robert Debre, Department of Pharmacy Boulkedid, Rym; Hopital Universitaire Robert Debre, Clinical Epidemiology unit; INSERM, UMR-S1123, ECEVE; Inserm U1123 Bourdon, Olivier; Hopital Universitaire Robert Debre, Department of pharmacy; Universite Paris Descartes, Clinical Pharmacy Prot-Labarthe, Sonia; Hopital Universitaire Robert Debre, Department of Pharmacy; INSERM, UMR-S1123, ECEVE; Inserm U1123
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	General practice / Family practice
Keywords:	inappropriate prescription, omission, tool, detection

SCHOLARONE™  
Manuscripts

1  
2  
3 **Retrospective study of irrational prescribing in French pediatric hospital: prevalence of**  
4 **inappropriate prescription detected by POPI (Pediatrics: Omission of Prescription and**  
5 **Inappropriate prescription) in the emergency unit and in the ambulatory setting.**  
6  
7

8 A. Berthe-Aucejo<sup>1,2</sup>, H.P.K Nguyen<sup>1</sup>, F. Angoulvant<sup>2,3</sup>, X. Bellettre<sup>4</sup>, P. Albaret<sup>5,6</sup>, T. Weil<sup>1</sup>,  
9  
10 R. Boulkedid<sup>2,7,8</sup>, O. Bourdon<sup>1,6,9,10</sup>, S.Prot-Labarthe<sup>1,2,10</sup>  
11  
12  
13  
14  
15

16 <sup>1</sup> Department of Pharmacy, Robert-Debré Hospital, Paris, France  
17

18 <sup>2</sup> UMR-S1123, ECEVE; Inserm U1123, Paris, France  
19

20 <sup>3</sup> Emergency unit, Necker Hospital, Paris, France  
21

22 <sup>4</sup> Emergency unit AP-HP, Robert-Debré Hospital, Paris, France  
23

24 <sup>5</sup> Albaret Pharmacy, Cesson, France  
25

26 <sup>6</sup> Clinical Pharmacy, Paris Descartes University, Paris, France  
27

28 <sup>7</sup> Assistance publique-Hôpitaux de Paris, Hôpital Robert Debré, Clinical Epidemiology Unit,  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
75 019 Paris, France

<sup>8</sup> CIC-EC 1426, 75019 Paris, France

<sup>9</sup> Laboratoire Educations et Pratiques de Santé, Paris XIII University, Bobigny, France

<sup>10</sup> Groupe Pédiatrie de la Société Française de Pharmacie Clinique, Paris, France

**Word count:** 2639

**Corresponding author**

Dr Aurore Berthe-Aucejo, Service Pharmacie, AP-HP Hôpital Robert-Debré, 48 Boulevard  
Sérurier, 75019 Paris, Fax: 01-40-03-24-81, Tel: 01-40-03-57-41, Email:  
[aurore.berthe84@gmail.com](mailto:aurore.berthe84@gmail.com)

## Keywords

Inappropriate prescription, omission, tool, detection

## ABSTRACT

**Background and Objective:** POPI (Pediatrics: Omission of Prescription and Inappropriate prescription) is the first detection tool for potentially inappropriate medicines (PIM) and potentially prescribing omissions (PPO) in pediatrics. The aim of this study was to evaluate the prevalence of PIM and PPO detected by POPI regarding prescriptions in hospital and for outpatients. The second objective is to determine the risk factors related to PIM and PPO.

**Design:** A retrospective, descriptive study was conducted in the emergency department (ED) and community pharmacy (CP) during 6 months. POPI was used to identify PIM and PPO.

**Setting:** Robert-Debré Hospital (France) and Albaret community pharmacy (Seine and Marne).

**Participants:** Patients who were under 18 years old and who had one or more drugs prescribed were included. Exclusion criteria consisted of inaccessible medical records for patients consulted in ED and prescription without drugs for outpatients.

**Primary and secondary outcome measures:** PIM and PPO rate and risk factors

**Results:** At the ED, 18,562 prescriptions of 15,973 patients and 4,780 prescriptions of 2,225 patients at the CP were analyzed. The PIM rate and PPO rate were respectively 2.9% and 2.3% at the ED and 12.3% and 6.1% at the CP. Respiratory and digestive diseases had the highest rate of PIM.

**Conclusion:** This is the first study to assess the prevalence of PIM and PPO detected by POPI in a pediatric population. This study assessed PIMs or PPOs within a hospital and a community pharmacy. POPI could be used to improve drug use and patient care, and to limit hospitalization and adverse drug reaction. A prospective multicentric study should be conducted to evaluate the impact and benefit of implementing POPI in clinical practice.

### Strengths and limitations of this study

- This study is the first to observe the prevalence of PIM and PPO in a pediatric population.
- It is a retrospective and monocentric study. The prevalence of PIM and PPO may be underestimated (large number of prescriptions, absence of specific pathology). Some criteria could only be analyzed in a prospective study. The lack of clinical information is the main limit to detection in a community setting.
- Many omissions and inappropriate prescriptions can be easily detected with POPI despite limited clinical information.

## INTRODUCTION

Inappropriate prescribing is a known preventable cause of adverse drug events (ADE) and has an important impact on public health and cost of care. [1,2] In the literature, ADE is defined by “an injury resulting from medical intervention related to a drug” (dose error, adverse drug reaction (ADR), misuse of medication such as antibiotics).[3–5] In the pediatric population, ADR during hospitalization was estimated between 0.6% and 33.7%, and between 1% and 1.5% for outpatients.[6–9] Incidence of ADR leading to admission was evaluated between 1.8% and 17.7%.[6,7,10] Many drugs were concerned in commonly used medication.[11–13]

The World Health Organization estimated that 50% of medications are prescribed and used inappropriately.[14] The most recent definition of inappropriate prescription (IP) encompasses potentially inappropriate medicines (PIM) and prescribing omissions (PPO).[15]

In a report from the French National Authority for Health, PIMs are defined as “drugs being used in a situation in which the risks involved in treatment potentially outweigh the benefits, lack of demonstrated indication, high risk of ADE, or an unfavorable cost-effect or risk-benefit ratio exists”. PPO or underuse of appropriate medication is defined as the absence of initiation of an effective treatment in subjects with a condition for which one or several drug classes have demonstrated their efficacy. In an elderly population, which presents with age-related physiological changes and high prevalence of polypharmacy, various measures have been developed to detect PIM such as: Beers’ criteria, the Inappropriate Prescribing in the Elderly Tool, The Medication Appropriate Index, and STOPP/START (Screening Tool of Older Person’s prescriptions/Screening Tool to Alert doctor to Right Treatment).[16–21]

Only the STOPP/START enables us to detect under-prescription.[15] Using these tools, many studies have been carried out which have detected that inappropriate prescriptions range from 35% to 51% in the above population.[22–26]



1  
2  
3 Omission of prescriptions in geriatric population detected by the START tool concerned 58%-  
4 61% of patients.[27,28] Negative outcomes related to an IP such as side effects,  
5 hospitalization, mortality and utilization of resources were also highlighted.[21,29–31]  
6  
7

8  
9 Prescribing in a pediatric population is always challenging for physicians. It is often empirical  
10 and primarily based on safety and pharmacology information obtained in adults.[32] This is a  
11 worry not only in a hospital or general practitioner setting but also for the community  
12 pharmacists. With many off-label uses, they may be obligated to find alternative information  
13 sources , and might even dispense infrequently for this vulnerable population.[33] ADRs are  
14 three time higher in pediatric populations. This frequency is explained by the vulnerability of  
15 children, pharmacokinetic changes during childhood and pediatric off-label drug used.[4,34]  
16 Large differences relating to treatment were seen within and between countries.[6,35]  
17 Questions about the rationale of prescriptions could be asked.[36] Optimizing children's care  
18 is based on rational prescribing and aims for a decrease in side effects.[35,36] In order to  
19 improve the correct drug use and optimize practice, the first tool of detection for PIM and  
20 PPO was created by Prot-Labarthe *et al.* in 2013. The tool was named POPI (Pediatrics:  
21 Omission of Prescriptions and Inappropriate prescriptions) (Table 1).[37,38] Presently, the  
22 complete tool has yet to be tested in clinical practice and the prevalence of PIM and OP is not  
23 known.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Our first aim is to assess the prevalence of PIM and PPO detected using POPI in hospital and  
43 outpatient care. This is its first application, focusing on prescriptions extracted from the  
44 emergency department and the community pharmacy. Our second objective is to determine  
45 the risk factors related to PIM and PPO.  
46  
47  
48  
49  
50

## 51 52 53 **METHODS**

### 54 55 56 **Population**

1  
2  
3 A retrospective and descriptive study was conducted in the emergency department (ED) of  
4 AP-HP Robert-Debré hospital (Paris) - the largest French pediatric hospital - and the Albaret  
5 community pharmacy (CP) (Seine and Marne). Inclusion criteria included patients who were  
6 under 18 years old and who had one or more drug prescriptions between 1<sup>st</sup> October 2014 and  
7 31<sup>st</sup> March 2015. Prescription was defined as one or more lines of drugs prescribed by a  
8 physician. Exclusion criteria consisted of inaccessible medical records for ED patients and  
9 prescription without drugs for outpatients. POPI contains 101 criteria (76 PIMs, 25 PPO. A  
10 literature review was done to obtain criteria. Criteria were categorized according to  
11 physiological systems (gastroenterology, respiratory infections, pain, neurology, dermatology  
12 and miscellaneous). Criteria were validated by a 2-round-Delphi consensus technique.[38]  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Data collection**

26  
27  
28  
29 The prescriptions given on leaving hospital emergency department were extracted from the  
30 Urqual software V5<sup>®</sup> (\*) (McKesson Corp, Paris, France). Urqual<sup>®</sup> is an emergency  
31 prescription software which is used in many French hospitals. Patient information including  
32 age, sex, weight, medical prescription and current diagnosis was collected. Medical histories  
33 and clinical examinations were consulted individually when necessary. Due to the significant  
34 amount of data, clinical files of the ED were analyzed, based on primary diagnosis.  
35 Prescriptions for secondary diagnosis were not evaluated. For this study, 82/101 criteria were  
36 analyzed (Table 1). Some criteria could not be used for a hospital setting.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 The data extracted from Urqual software give only the first drug per prescription for each  
48 diagnosis (impossibility to extract all drugs for all prescriptions). To have every medications  
49 concerning the primary diagnosis, the prescription was then manually analyzed for each  
50 diagnosis to evaluate presence of PIM/PPO. Consequently, the number of medications per  
51 prescription was not included. However, all prescriptions have been manually reviewed  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 directly from medical files by two authors. For each targeted disorder, the prescription was  
4  
5 analyzed to detect PIMs or PPOs.  
6  
7  
8  
9  
10

11 **Table 1.** POPI - Pediatrics: Omission of Prescriptions & Inappropriate prescriptions  
12

13 <b>A- PAIN AND FEVER</b>	
14 <b>Inappropriate prescriptions</b>	15 <b>Omissions</b>
16	
17 <b>AI-1.</b> Prescription of two alternating antipyretics as a first-	<b>A0-1.</b> Failure to give sugar solution to
18 line treatment.	new-born babies and infants
19 <b>AI-2.</b> Prescription of a medication other than paracetamol	under four months old two
20 as a first line treatment (except in the case of	minutes prior to venipuncture.
21 migraine).	<b>A0-2.</b> Failure to give an osmotic laxative
22 <b>AI-3.</b> Rectal administration of paracetamol as a first-line	to patients being treated with
23 treatment.	morphine for a period of more
24 <b>AI-4.</b> The combined use of two NSAIDs. * °	than 48 hours.
25 <b>AI-5.</b> Oral solutions of ibuprofen administered in more	
26 than three doses per day using a graduated pipette	
27 of 10mg/kg (other than Advil <sup>®</sup> ). °	
28 <b>AI-6.</b> Opiates to treat migraine attacks. *	
29	
30 <b>B- URINARY INFECTIONS</b>	
31 <b>Inappropriate prescriptions</b>	
32	
33 <b>BI-1.</b> Nitrofurantoin used as a prophylactic. *	
34 <b>BI-2.</b> Nitrofurantoin used as a curative agent in children under six years of age, or indeed any other	
35 antibiotic if avoidable. *	
36 <b>BI-3.</b> Antibiotic prophylaxis following an initial infection without complications (except in the case of	
37 uropathy). *	
38 <b>BI-4.</b> Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of	
39 uropathy). *	
40 <b>C- VITAMIN SUPPLEMENTS AND ANTIBIOTIC PROPHYLAXIS</b>	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Inappropriate prescriptions	Omissions
<p><b>CI-1.</b> Fluoride supplements prior to six months of age. °*</p>	<p><b>CO-1.</b> Insufficient intake of vitamin D. Minimum vitamin D intake:</p> <ul style="list-style-type: none"> <li>▪ Breastfed baby = 1,000 to 1,200 IU/day</li> <li>▪ Infant &lt; 18 months of age (milk enriched with vitamin D) = 600 to 800 IU/day</li> <li>▪ Child aged between 18 months and five years, and adolescents aged between 10 and 18 years: two quarterly loading doses of 80,000 to 100,000 IU/day in winter (adolescents can take this as one dose).</li> </ul> <p><b>CO-2.</b> Antibiotic prophylaxis with phenoxymethylpenicillin (Oracilline) starting from two months of age and lasting until five years of age for children with sickle-cell anemia: 100,000 IU/kg/day (in two doses) for children weighing 10kg or less and 50,000 IU/kg/day for children weighing over 10kg (also in two doses). *</p>

**D- MOSQUITOS**

Inappropriate prescriptions	Omissions
<p><b>DI-1.</b> The use of skin repellents in infants less than six months old and picardin in children less than 24 months old.</p> <p><b>DI-2.</b> Citronella (lemon grass) oil (essential oil).</p> <p><b>DI-3.</b> Anti-insect bracelets to protect against mosquitos and ticks.</p> <p><b>DI-4.</b> Ultrasonic pest control devices, vitamin B1, homeopathy, electric bug zappers, sticky tapes without insecticide.</p>	<p><b>DO-1.</b> DEET “30%” (max) before 12 years old “50%” (max) after 12 years old.</p> <p><b>DO-2.</b> IR3535 “20%” (max) before 24 months old “35%” (max) after 24 months old.</p> <p><b>DO-3.</b> Mosquito nets and clothes treated with pyrethroids.</p>

**E- NAUSEA, VOMITTING, OR GASTROESOPHAGEAL REFLUX**

**PROBLEMS**

Inappropriate prescriptions	Omissions
<p><b>EI-1.</b> Metoclopramide. * °</p> <p><b>EI-2.</b> Domperidone. * °</p> <p><b>EI-3.</b> Gastric antisecretory drugs to treat gastroesophageal reflux, dyspepsia, the crying of new-born babies (in the absence of</p>	<p><b>EO-1.</b> Oral rehydration solution in the event of vomiting.*</p>

any other signs or symptoms), as well as faintness in infants. \*

**EI-4.** The combined use of proton pump inhibitors and NSAIDs, for a short period of time, in patients without risk factors. \*

**EI-5.** Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube). \*

**EI-6.** The use of type H2 antihistamines for long periods of treatment. \* °

**EI-7.** Erythromycin as a prokinetic agent. \*

**EI-8.** The use of setrons (5-HT3 antagonists) for chemotherapy-associated nausea and vomiting. \*

## F- DIARRHEA

### Inappropriate prescriptions

**FI-1.** Loperamide before 3 years of age. \*°

**FI-2.** Loperamide in the case of invasive diarrhea.\*

**FI-3.** The use of Diosmectite (Smecta®) in combination with another medication.\*°

**FI-4.** The use of *Saccharomyces boulardii* (Ultralevure) in powder form, or in a capsule that has to be opened prior to ingestion, to treat patients with a central venous catheter or an immunodeficiency.\*

**FI-5.** Intestinal antiseptics.\*°

### Omissions

**FO-1.** Oral rehydration solution in the event of diarrhea.\*

## G- COUGH

### Inappropriate prescriptions

**GI-1.** Pholcodine. \* °

**GI-2.** Mucolytic drugs, mucokinetic drugs, or helcidine before two years of age. \* °

**GI-3.** Alimemazine (Theralene®), oxomemazine (Toplexil®), promethazine (Phenergan®), and other types. \* °

**GI-4.** Terpene-based suppositories. \* °

### Omissions

**GO-1.** Failure to propose a whooping cough booster vaccine for adults who are likely to become parents in the coming months or years (only applicable if the previous vaccination was more than 10 years ago). This booster vaccination should also be proposed to the family of expectant parents and those in contact with them (parents, grand-parents, nannies/child minders).

## H- BRONCHIOLITIS IN INFANTS

**Inappropriate prescriptions****Omissions**

**HI-1.** Beta2 agonists, corticosteroids to treat an infant's first case of bronchiolitis. \*

**HI-2.** H1-antagonists, cough suppressants, mucolytic drugs, or ribavirin to treat bronchiolitis. \*

**HI-3.** Antibiotics in the absence of signs indicating a bacterial infection (acute otitis media, fever, etc.). \*

**HO-1.** 0.9% NaCl to relieve nasal congestion (not applicable if nasal congestion is already being treated with 3% NaCl delivered by a nebulizer). \*

**HO-2.** Palivizumab in the following cases:

- (1) babies born both at less than 35 weeks of gestation and less than six months prior to the onset of a seasonal RSV epidemic;
- (2) children less than two years old who have received treatment for bronchopulmonary dysplasia in the past six months;
- (3) children less than two years old suffering from congenital heart disease with hemodynamic abnormalities.

**I- ENT INFECTIONS****Inappropriate prescriptions****Omissions**

**II-1.** An antibiotic other than amoxicillin as a first-line treatment for acute otitis media, strep throat, or sinusitis (provided that the patient is not allergic to amoxicillin). An effective dose of amoxicillin for an pneumococcal infection is 80–90 mg/kg/day and an effective dose for a streptococcal infection is 50 mg/kg/day.\*

**II-2.** Antibiotic treatment for a sore throat, without a positive rapid diagnostic test result, in children more than three years old.\*

**II-3.** Antibiotics for nasopharyngitis, congestive otitis, sore throat before three years of age, or laryngitis; antibiotics as a first-line treatment for acute otitis media showing few symptoms, after two years of age.\*

**II-4.** Antibiotics to treat otitis media with effusion (OME), except in the case of hearing loss or if OME lasts for more than three months.\*

**II-5.** Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat.\*

**II-6.** Nasal or oral decongestant (oxymetazoline

**IO-1.** Doses in mg for drinkable (solutions of) amoxicillin or josamycin. \*°

**IO-2.** Paracetamol combined with antibiotic treatment for ear infections to relieve pain. \*

(Aturgyl<sup>®</sup>), pseudoephedrine (Sudafed<sup>®</sup>), naphazoline (Derinox<sup>®</sup>), ephedrine (Rhinamide<sup>®</sup>), tuaminoheptane (Rhinofluimicil<sup>®</sup>), phenylephrine (Humoxal<sup>®</sup>)).\*<sup>o</sup>

**II-7.** H1-antagonists with sedative or atropine-like effects (pheniramine, chlorpheniramine), or camphor; inhalers, nasal sprays, or suppositories containing menthol (or any terpene derivatives) before 30 months of age.\*<sup>o</sup>

**II-8.** Ethanalamine tenoate (Rhinotrophyl<sup>®</sup>) and other nasal antiseptics.\*<sup>o</sup>

**II-9.** Ear drops in the case of acute otitis media.\*

## J- ASTHMA

### Inappropriate prescriptions

### Omissions

**JI-1.** Ketotifen and other H1-antagonists, sodium cromoglycate.\*

**JO-1.** Asthma inhaler appropriate for the child's age.

**JI-2.** Cough suppressants.\*

**JO-2.** Preventative treatment (inhaled corticosteroids) in the case of persistent asthma.\*

## K-ACNE VULGARIS

### Inappropriate prescriptions

### Omissions

**KI-1.** Minocycline.\*<sup>o</sup>

**KI-2.** Isotretinoin in combination with a member of the tetracycline family of antibiotics.\*<sup>o</sup>

**KI-3.** The combined use of an oral and a local antibiotic.\*

**KI-4.** Oral or local antibiotics as a monotherapy (not in combination with another drug).\*

**KI-5.** Cyproterone+ethinylestradiol (Diane 35<sup>®</sup>) as a contraceptive to allow isotretinoin per os.\*<sup>o</sup>

**KI-6.** Androgenic progestins (levonorgestrel, norgestrel, norethisterone, lynestrenol, dienogest, contraceptive implants or vaginal rings).\*

**KO-1.** Contraception (provided with a logbook/diary) for menstruating girls taking isotretinoin.

**KO-2.** Topical treatment (benzoyl peroxide, retinoids, or both) in combination with antibiotic therapy.\*

## L- SCABIES

## Omissions

**LO-1.** A second dose of ivermectin two weeks after the first. \*

**LO-2.** Decontamination of household linen and clothes and treatment for other family members.

## M- LICE

### Inappropriate prescriptions

**MI-1.** The use of aerosols for infants, children with asthma, or children showing asthma-like symptoms such as dyspnea.

## N- RINGWORM

### Inappropriate prescriptions

### Omissions

**NI-1.** Treatment other than griseofulvin for Microsporium. \*

**NO-1.** Topical treatment combined with an orally-administered treatment. \*

**NO-2.** Griseofulvin taken during a meal containing a moderate amount of fat. \* °

## O-IMPETIGO

### Inappropriate prescriptions

**OI-1.** The combination of locally applied and orally administered antibiotics.\*

**OI-2.** Fewer than two applications per day for topical antibiotics.\*

**OI-3.** Any antibiotic other than mupirocin as a first-line treatment (except in cases of hypersensitivity to mupirocin).\*

## P- HERPES SIMPLEX

### Inappropriate prescriptions

### Omissions

**PI-1.** Topical agents containing corticosteroids. \*

**PO-1.** Paracetamol during an outbreak of herpes. \*

**PI-2.** Topical agents containing acyclovir before six years of age. \* °

**PO-2.** Orally administered acyclovir to treat primary herpetic gingivostomatitis. \*



## Q-ATOPIC DERMATITIS

### Inappropriate prescriptions

QI-1. A strong topic steroid (clobetasol propionate 0.05% Dermoval, betamethasone dipropionate Diprosone) applied to the face, armpits or groin, and to the backside of babies or young children. \*

More than one application per day of a topical steroid, except in cases of severe lichenification. \*

QI-2. Local or systemic antihistamine during the treatment of outbreaks. \*

QI-3. Topically applied 0.03% tacrolimus before two years of age. \*°

Topically applied 0.1% tacrolimus before 16 years of age.

QI-4. Oral corticosteroids to treat outbreaks. \*

## R- EPILEPSY

### Inappropriate prescriptions

RI-1. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of myoclonic epilepsy. \*

RI-2. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin in the case of epilepsy with absence seizures (especially for childhood absence epilepsy or juvenile absence epilepsy). \*

RI-3. Levetiracetam, oxcarbamazepine in mL or in mg without systematically writing XX mg per Y mL. \* °

## S-DEPRESSION

### Inappropriate prescriptions

SI-1. An SSRI antidepressant other than fluoxetine as a first-line treatment (in the case of pharmacotherapy). \*

SI-2. Tricyclic antidepressants to treat depression. \*

## T- NOCTURNAL ENURESIS

### Inappropriate prescriptions

TI-1. Desmopressin administered by a nasal spray. \* °

Desmopressin in the case of daytime symptoms.

**TI-2.** An anticholinergic agent used as a monotherapy in the absence of daytime symptoms. \*

**TI-3.** Tricyclic agents in combination with anticholinergic agents. \* °

**TI-4.** Tricyclic agents as a first-line treatment. \*

## U- ANOREXIA

### Inappropriate prescriptions

**UI-1.** Cyproheptadine (Periactin®), clonidine \* °

## V- ATTENTION DEFICIT DISORDER WITH OR WITHOUT HYPERACTIVITY

### Inappropriate prescriptions

### Omissions

**VI-1.** Pharmacological treatment before age six (before school), except in severe cases. \*

**VI-2.** Antipsychotic drugs to treat attention deficit disorder without hyperactivity. \*

**VI-3.** Slow release methylphenidate as two doses per day, rather than only one dose. \*°

**VO-1.** Recording a growth chart (height and weight) if the patient is taking methylphenidate. \*

\* Criteria analyzed in emergency department

° Criteria analyzed in community pharmacy

Data from the community pharmacy were obtained from the pharmacy management software OPUS® (Computer PG, France). Patient's age and drugs prescribed were collected. Current diagnosis and sex are not available in the OPUS software, so the number of patients per pathology and the number of prescriptions per pathology were lacking. Only drugs that did not require an assessment of diagnosis (for example domperidone, metoclopramide etc.) were included (Table 1) (28 criteria/101).

1  
2  
3 Among the 5 criteria including analgesics and antipyretics, only three were evaluated due to  
4 an overwhelming number of prescriptions, and their association with many diseases.  
5  
6 Pathologies analyzed by POPI were the same in emergency department and in community.  
7  
8  
9 Summary of data and inclusion criteria are detailed in Appendix 1.  
10

### 11 12 **Statistical analysis**

13  
14  
15  
16 Data were presented as continuous variables (age, number of prescriptions by patient, number  
17 of medications per prescription) and were presented as median and interquartile range (25th-  
18 75th percentiles) or mean (standard deviation), minimum and maximum depending on normal  
19 distribution.  
20  
21  
22  
23

24  
25  
26 Mixed effects logistic regression modelling for repeated measurements was applied to identify  
27 factors associated with PIM and PPO (yes/no) in the hospital and community settings. Unit of  
28 analysis was “the prescription”.  
29  
30  
31

32  
33  
34 Univariate models were performed using different candidate factors as:

- 35  
36 - For model performed with hospital data: sex and age (0 days - 2 years, 2 - 6 years, 6 -  
37 12 years, 12 - 18 years);
- 38  
39 - For model performed with community data: age (0 days - 2 years, 2 - 6 years, 6 - 12  
40 years, 12 - 18 years) and number of medications (drugs) per prescription;  
41  
42  
43  
44

45 The model was constructed using the parameters of the univariate analysis, which showed at  
46 least a trend toward significance, with a cut-off of  $p=0.2$ . Odds ratios (OR) with 95%  
47 confidence intervals (CI) were estimated. Statistical significance was established at  $p<0.05$ .  
48  
49  
50  
51  
52 SPSS-22<sup>®</sup> software (SPSS Inc., Chicago, IL, USA) and SAS 9.4 were used for analysis.  
53

54  
55 This project was approved by the local research ethics committee (n°2015/218).  
56  
57  
58  
59

## Patient and Public Involvement

No Patient and Public involvement

## RESULTS

In the emergency department, 18,562 prescriptions for 15,973 patients were analyzed. Around 11,500 prescriptions were reviewed manually that's 9500 patients. We consulted the software used by the emergency department by searching either: 1/ per drug and by therapeutic class extension; 2 / by main diagnosis for which a POPI item could matched. In each case, if there was a PMI / PPO, the data was collected. Among the patients, 29% had at least two visits in 6 months. In the community pharmacy, 4,780 prescriptions for 2,225 patients were evaluated (Figure 1). In ED and CP, 53% of patients had been issued one prescription, 21% with two and 26% with three or more prescriptions. The population's characteristics and the frequency of pathologies were presented in Table 2. Distribution of number of prescriptions by age category was described in the Figure 2.

**Table 2. Characteristics of the study population**

<b>Population characteristics</b>	<b>Hospital (N=15,973)</b>	<b>Community (N=2,225)</b>
Age (years) mean (SD)	4.9 (4.5)	7.9 (5.3)
Min, Max	0-18	0-18
Female gender N(%)	8,769 (54.9)	NA
Number of prescriptions/patient mean (SD)	1.4 (0.9)	2.2 (1.9)
Min, Max	1-12	1-16

Number of drugs per prescription mean (SD) Min, Max	NA	2.4 (1.6) 1-22
Number of prescriptions by pathology N(%)		
Digestive disorders	2,728 (14.7)	NA
ENT-Pulmonary disorders	8,397 (45.2)	NA
Dermatological disorders	604 (3.3)	NA
Neuropsychiatric disorders	242 (1.3)	NA
Other illnesses <sup>#</sup>	6,591 (35.5)	NA

NA: Not available; ENT: ear, nose and throat

<sup>#</sup> For example, traumatic injury, pain, sickle cell disease

In the hospital, POPI identified 541 PIMs in 2.9% of the prescriptions analyzed. They were detected in 3.3% of the patients (n=530). PPOs were detected in 2.3% of prescriptions for 2.7% of patients. In the community, PIMs and PPOs represented 12.3% and 6.1% of all prescriptions, affecting 26.4% and 11.3% patients respectively (Table 3).

**Table 3. Potentially Inappropriate Medications (PIMs) and Potential Prescription Omission (PPOs) identified by POPI**

	Hospital N (%)	Community N (%)
<b>Number of prescriptions (N)</b>	<b>18,562</b>	<b>4,780</b>
PIMs identified per prescription		
1	519 (2.8%)	551 (11.5%)
2	11 (0.1%)	37 (0.8%)

Prescriptions with at least one PIM	530 (2.9%)	588 (12.3%)
PPOs identified per prescription		
1	424 (2.3 %)	293 (6.1%)
<b>Number of patients (N)</b>	<b>15,793</b>	<b>2,225</b>
Patients with at least one PIM °	530 (3.3%)	588 (26.4%)
Patients with at least one PPO	424 (2.7%)	251 (11.3%)

Table 4 presents the prevalence of PIMs (or PPOs) in the ED in patients with the targeted disorders. Patients with the targeted disorders represent the individuals who were at risk of each PIM/PPO. Table 5, however, presents the PIMs (or PPOs) as a proportion of the total number of PIMs (or PPOs) in the community pharmacy. Respiratory and digestive diseases had the highest rate of PIM in hospital and community pharmacy. For various illnesses, we removed one criterion involving medicines containing codeine because of their new contraindication in children under 12 years old.[39] However, the prescription of codeine was observed in 18 cases. According to our comparison of PIMs detectable in both settings, out-of-hospital medication always presents with higher prevalence of PIMs (Figure 3).

**Table 4. Prevalence of PIMs and PPOs identified by POPI in hospital**

Criteria		No. of PIMs	No. of patients with the targeted disorders	% of PIMs in patients with the targeted disorders
<b>Potentially inappropriate medications (PIMs)</b>		<b>541</b>	<b>7,304</b>	<b>7.4%</b>
<b>Various illnesses</b>		<b>3</b>	<b>64</b>	<b>4.6%</b>
AI-6	Opiates to treat migraine attacks	3	64	4.6%
<b>Digestive disorders</b>		<b>56</b>	<b>1,956</b>	<b>2.8%</b>
EI-2	Domperidone	28	1,956	1.4%
FI-3	The use of Diosmectite (Smecta®) in	27	1,956	1.4%

	combination with another medication			
EI-1	Metoclopramide	1	1,956	0.05%
<b>ENT-Pulmonary disorders</b>		<b>472</b>	<b>5,163</b>	<b>9.1%</b>
II-4	Antibiotics to treat acute suppurative otitis media etc.	2	7	28.6%
II-2	Antibiotic treatment for a sore throat, without a positive RDT.	23	160	14.4%
II-9	Ear drops in the event of acute otitis media	86	1,083	7.9%
HI-1	Beta2 agonist, corticosteroids to treat an infant's first case of bronchiolitis	25	386	6.4%
II-5	Corticosteroids to treat acute suppurative otitis media etc.	190	3,616	5.2%
II-1	An antibiotic other than amoxicillin as a first-line treatment.	59	1,259	4.7%
JI-1	H1-antagonist to treat asthma	9	802	1.1%
II-8	Tenoate Etanolamine (Rhinotrophyl <sup>®</sup> ) and other nasal antiseptics	21	2,455	0.8%
II-3	Antibiotics for nasopharyngitis	26	3,444	0.7%
GI-3	Alimemazine (Theralene <sup>®</sup> ), oxomemazine (Toplexil <sup>®</sup> ) etc.	18	2,585	0.7%
JI-2	Cough suppressants to treat asthma	5	802	0.6%
HI-2	H1-antagonists, cough suppressants etc. to treat bronchiolitis	2	386	0.5%
II-7	H1-antagonists with sedative or atropine-like effects.	4	2,585	0.2%
GI-2	Mucolytics drugs, mucokinetics drugs or helcidine before 2 years of age	1	2,585	< 0.1%
II-6	Nasal or oral decongestant etc.	1	2,455	< 0.1%
<b>Dermatological disorders</b>		<b>10</b>	<b>100</b>	<b>10%</b>
OI-1	A combination of locally applied and orally administered antibiotics	9	32	28.1%
PI-2	Topical agents containing acyclovir administered to a child under six years of age	1	68	1.5%
		<b>No. of PPO</b>	<b>No. of patients with the targeted disorders</b>	<b>% of PIMs in patients with the targeted disorders</b>
<b>Potentially Prescribing Omissions (PPO)</b>		<b>424</b>	<b>4,508</b>	<b>9.4%</b>
<b>Digestive disorders</b>		<b>372</b>	<b>1,956</b>	<b>19.0%</b>
EO-1	Oral rehydration solution in the event of vomiting	135	313	43.1%
FO-1	Oral rehydration solution in the event of diarrhea	237	1,643	14.4%
<b>ENT-Pulmonary disorders</b>		<b>51</b>	<b>1,469</b>	<b>3.5%</b>
HO-1	0.9% NaCl to relieve nasal congestion etc.	38	386	9.8%
IO-2	Acetaminophen combined with antibiotic	13	1,083	1.3%

	treatment for ear infections etc.			
<b>Dermatological disorders</b>		<b>1</b>	<b>3</b>	<b>33.3%</b>
NO-2	Griseofulvin taken during a meal containing a moderate amount of fat	1	3	33.3%

ENT: ear, nose and throat; No: Number; RDT: Rapid diagnostic test.

% Percentage calculated by the number of PIMs or PPO detected from the total number of analyzable cases

\*the number of patients with the targeted disorder corresponds to patients with clinical situations at risk of PIM or PPO

**Table 5. Most frequently occurring PIMs and PPOs identified by POPI in community setting**

Criteria	Proportion of PIMs per disorder according to total number of PIMs N(%)
<b>Total number of Potentially Inappropriate Medications (PIMs) N= 625</b>	
<b>Various illnesses</b>	<b>15 (2.4)</b>
AI-5 Oral solutions of ibuprofen administered in more than 3 doses etc.	7 (1.1)
CI-1 Fluoride supplements prescribed to infants under six months of age	5 (0.8)
AI-4 The combined use of two NSAIDs	3 (0.5)
<b>Digestive disorders</b>	<b>201 (32.2)</b>
EI-2 Domperidone	152 (24.3)
FI-3 The use of Diosmectite (Smecta <sup>®</sup> ) in combination with another medication	35 (5.6)
FI-5 Intestinal antiseptics	9 (1.5)
EI-1 Metoclopramide	2 (0.3)
EI-6 The use of type H2 antihistamines for long periods of treatment	2 (0.3)
FI-1 Loperamide before 3 years of age	1 (0.2)
<b>ENT-Pulmonary disorders</b>	<b>403 (64.4)</b>
GI-3 Alimemazine (Theralene <sup>®</sup> ), oxomemazine (Toplexil <sup>®</sup> ), etc.	202 (32.2)
GI-1 Pholcodine	81 (13.0)
II-8 Etanolamine tenoate (Rhizophyl <sup>®</sup> ) and other nasal antiseptics	96(15.3)
II-6 Nasal or oral decongestant etc.	20 (3.2)
GI-2 Mucolytic drugs, mucokinetic drugs or helicidine prescribed to a child under 2 years of age	3(0.5)
GI-4 Terpene-based suppositories	1(0.2)
<b>Dermatological disorders</b>	<b>1(0.2)</b>



<b>PI-2</b> Topical agents containing acyclovir prescribed to a child under six years of age	1(0.2)
<b>Neuropsychiatric disorders</b>	<b>5 (0.8)</b>
<b>RI-3</b> Levetiracetam in mL or in mg prescribed without systematically indicating XX mg per Y mL	5(0.8)
	<b>Proportion of PIM per disorder according to total number of PIM N(%)</b>
<b>Potential Prescribing Omissions (PPOs) N= 293</b>	
<b>IO-1</b> Dose in mg for oral (solution of) amoxicillin etc. N (%)	293 (100%)

*NSAIDs: Non-steroidal anti-inflammatory drugs; ENT: ear, nose and throat*  
*% Percentage of PIMs or PPOs calculated from the total number of PIMs or PPO detected*

The analysis of criterion regarding the prescription of amoxicillin in mg (IO-1) was not possible due to the fact that this drug is prescribed in great quantity. Among 100 prescriptions randomly assessed in hospital extractions, 97 prescriptions were inappropriate. Nonetheless, one analysis on acute otitis media alone identified a rate of 99.5% (807/811) of prescriptions issued without specification of the doses in mg for oral amoxicillin. In community care, this was observed in 97% of prescriptions, in 13.2% of patients (Table 5).

PIMs classed by age are presented in the figure 4. Potential factors associated with PIM or PPO are presented in Appendix 2a, b. On univariate analysis, only age was associated with risk of PIM or PPO in hospital setting. In a community setting, the number of drugs per prescription and different age categories were found to be significantly associated with a higher risk of PIM or PPO on univariate analysis. With a multivariable logistic regression model, the same results were obtained.

## DISCUSSION

This is the first study to observe the prevalence of PIMs and PPOs in a pediatric population. In the literature, such tools focused on detecting PIMs/PPOs in a geriatric population. [22,40–

1  
2  
3 42] The two populations are not comparable. Respiratory and digestive pathologies are typical  
4  
5 in children and are not so in geriatric populations, which are more concerned by  
6  
7 cardiovascular and nervous central system diseases.[22,40,43].  
8  
9

10 Domperidone was frequently prescribed in a community setting, yet this drug is responsible  
11  
12 for cardiac adverse effects such as QT prolongation. This side effect is described in the  
13  
14 literature in adult populations and pediatric populations. The detection of this prescription will  
15  
16 enable us to avoid cardiac risks. [44–49]  
17  
18

19 Prevalence of beta2 agonists or corticosteroids in an infant's first case of bronchiolitis is 6.4%  
20  
21 (25/386 cases), lower than that observed in a study of another French area in 2012 (41%).[50–  
22  
23 52] The use of beta2 agonists in a first case of bronchiolitis has no impact on oxygen  
24  
25 saturation, length of hospitalization or length of illness. They concurrently cause side effects  
26  
27 as tachycardia, oxygen saturation, and tremors. [53] Implementation of guidelines has  
28  
29 permitted to decrease beta2 agonist and corticosteroid use in a French hospital without  
30  
31 increase morbidity. [54]  
32  
33  
34  
35  
36

37 Unnecessary exposure to cough suppressants, pholcodine, nasal or oral decongestants was  
38  
39 also observed frequently in this sector.[55] In Norway, all drugs containing pholcodine were  
40  
41 refused marketing authorization in March 2007. As of this date, a decrease in sensitization to  
42  
43 suxamethonium used in anesthesia and a decrease of 30-40% cases of anaphylaxis was?  
44  
45 identified. [56]  
46  
47

48 Our tool enabled us to detect rare PIMs that carry heavy consequences, such as opioid use for  
49  
50 migraines. The use of opioids for this disease induces a transition from episodic to chronic  
51  
52 headaches and an increase of sensitivity to pain.[57–59]  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Overuse of medication, in particular opioids, could contribute to the chronicity of headaches  
4 in 20–30% of children and adolescents with chronic daily headaches.[59]  
5  
6

7  
8 In the management of diarrhea caused by gastroenteritis in hospitals, our study found that it  
9 was common to omit to prescribe oral rehydration solution (ORS):14% (237/1643 cases).  
10  
11 Even so, this rate is lower than that found in another national study in 2007 (29%).[60]  
12  
13 However, ORSs prevent hospitalization in cases of acute gastroenteritis. In the United  
14  
15 Kingdom, the use of ORSs has enabled a decrease from 300 deaths/year in 1970s to 25  
16  
17 deaths/year in 1980s.[61,62]. The need for ORS prescriptions was confirmed by the  
18  
19 recommendation of the European Society for Paediatric Gastroenterology, Hepatology, and  
20  
21 Nutrition (ESPGHAN) in 2014.[63]  
22  
23  
24  
25

26  
27 As estimated, children aged between 0 and 12 years have the highest risk of presenting with a  
28  
29 PIM, according to a multivariate analysis. No inappropriate prescriptions or omissions were  
30  
31 detected for patients aged less than 28 days. As we know, they are also affected by off-label  
32  
33 drug prescriptions, which is consistent with reports from other sources.[64,65] As with  
34  
35 geriatrics, an increase in the number of medications used can be associated with PIM.[40]  
36  
37 Prescriptions issued from hospitals elicit fewer PIMs than those issued by the community.  
38  
39 The main reason for this is that many drugs are not available in our hospital, such as cough  
40  
41 suppressants, Rhinotrophyl<sup>®</sup> (tenoate ethanolamine), domperidone, etc. This shows that many  
42  
43 PIM are preventable in a hospital settings. An efficient method for the prevention of PIM  
44  
45 could be to focus on the prescribing habits of physicians and thus have an impact on the  
46  
47 selection of drugs, thereby reducing the rate of PIM.  
48  
49  
50

51  
52 The data was extracted from a community pharmacy and the emergency department of a  
53  
54 mother-child hospital during the winter months. The data focusses on winter epidemics. An  
55  
56 analysis of the year in its entirety would have found other PMI / PPO concerning different  
57  
58  
59

1  
2  
3 pathologies or events related to travel. While the Robert Debré hospital offers sub-specialized  
4 hospitalization services (cardiology, nephrology, hematology, etc.), the emergency  
5 department drains the more general activity. Likewise, the data coming from the community  
6 pharmacy provides a representative image of the pediatric prescriptions that could be found in  
7 other French pharmacies. Concerning a generalization of our data to other countries, a study is  
8 in progress to specify which POPI items could be applicable internationally.  
9  
10  
11  
12  
13  
14  
15

16  
17 Our study has several limitations. Firstly, it is a retrospective and monocentric study, the result  
18 in hospital could be underestimated. In addition, several criteria could not be analyzed due to  
19 the large number of prescriptions (for example, those for fever or pain which are associated  
20 with many diseases) or absence of certain pathologies (mosquitos, lice, hyperactivity etc.). All  
21 drugs were not evaluated. Antibiotic prophylaxis, vitamin supplements, propositions for  
22 vaccination etc. can only be analyzed in prospective studies. The lack of clinical information  
23 is the main limitation in detection in a community setting. This also constitutes a challenge for  
24 pharmaceutical care review in elderly patients.[66] However, a certain amount of PIM were  
25 identified using POPI. Our study showed that there are many criteria that are easily  
26 identifiable, and which could be detected without accessing clinical information. Moreover,  
27 community pharmacists, in their practice, can extrapolate diagnoses from their experience,  
28 from common indications or by interviewing their patients. The study presents a limitation  
29 regarding the URQUAL software, from which the number of medications per prescription  
30 could not be extracted.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 This is the first study which permits an evaluation of the prevalence of PIM and PPO in  
49 pediatrics prescription. The detection of PIMs/PPOs would improve patient care, and prevent  
50 hospitalization and adverse drug reactions. A stepped wedge randomized cluster multicenter  
51 study will be conducted to prove if POPI decreases number of PIM and PPO. It is also  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 necessary to evaluate the impact of this tool on reducing adverse drugs events, both in  
4 consultation or hospitalization. The impact of pharmacists in providing appropriate  
5 prescriptions should be also evaluated. Subsequently, this tool may be offered to several  
6 professional societies such as the French Society for Pediatricians and the French Society of  
7 Clinical Pharmacy to make its use more widespread. The tool should be regularly updated to  
8 reflect recent events and to specify certain criteria.  
9  
10  
11  
12  
13  
14  
15  
16

17 To facilitate its use, this tool can be presented as a mobile app, a small handbook or installed  
18 into prescription software. In summary, we hope that POPI could be a practical option used to  
19 reduce medication errors and to improve the suitability of prescriptions. It provides rapid  
20 detection of PIM and PPO and can also open up discussion on the relationship between doctor  
21 and pharmacist to remedy the issues at hand.[67]  
22  
23  
24  
25  
26  
27  
28  
29

## 30 **CONCLUSION**

31  
32 Our study was carried out in in two sectors, hospital and community, and provides a global  
33 view of PIM and PPO in pediatric patients. POPI has a clinical impact and plays a role in  
34 improving prescription quality in various sectors and patient care. POPI should be applied in  
35 different services to deepen and reinforce its utilization. A prospective and multicenter study  
36 should be conducted to evaluate its impact and benefit in clinical practice.  
37  
38  
39  
40  
41  
42  
43  
44

## 45 **ACKNOWLEDGMENTS**

46  
47 We would like to thank the Emergency department of Robert-Debré hospital and the Albaret  
48 pharmacy community for their data support.  
49  
50  
51

52  
53 We would also like to thank the French Society of Clinical Pharmacy (pediatric group) for  
54 their support.  
55  
56  
57  
58  
59  
60

## **ETHICS**

This project was approved by the local research ethics committee (n°2015/218).

## **DISCLOSURE OF INTEREST**

None Declared

## **FUNDING STATEMENT**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

## **AUTHOR'S CONTRIBUTION**

Sonia Prot-Labarthe, Aurore Berthe-Aucejo conceptualised and designed the study, drafted the initial manuscript, and approved the final manuscript as submitted.

Rym Boulkedid and HPK Nguyen carried out analyses, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Xavier Bellettre, Thomas Weil, Olivier Bourdon reviewed and revised the manuscript and approved the final manuscript as submitted.

François Angoulvant and Patrick Albaret supplied data from hospital and community pharmacy and reviewed and revised the manuscript and approved the final manuscript as submitted.

## **DATA SHARING STATEMENT**

We have no additional unpublished data

## REFERENCES

- 1 Lund BC, Carnahan RM, Egge JA, *et al.* Inappropriate prescribing predicts adverse drug events in older adults. *Ann Pharmacother* 2010;**44**:957–63. doi:10.1345/aph.1M657
- 2 Chrischilles EA, VanGilder R, Wright K, *et al.* Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults. *J Am Geriatr Soc* 2009;**57**:1000–6.
- 3 Bates DW, Cullen DJ, Laird N, *et al.* Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. *JAMA* 1995;**274**:29–34.
- 4 Kaushal R, Bates DW, Goldmann DA. Medication errors and adverse drug events in pediatric inpatients. *JAMA* 2001;**285**:2114–20.
- 5 Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. *Ann Intern Med* 2004;**140**:795–801.
- 6 Clavenna A, Bonati M. Differences in antibiotic prescribing in paediatric outpatients. *Arch Dis Child* 2011;**96**:590–5. doi:10.1136/adc.2010.183541
- 7 Impicciatore P, Choonara I, Clarkson A, *et al.* Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. *Br J Clin Pharmacol* 2001;**52**:77–83. doi:10.1046/j.0306-5251.2001.01407.x
- 8 dos Santos DB, Coelho HLL. Adverse drug reactions in hospitalized children in Fortaleza, Brazil. *Pharmacoepidemiol Drug Saf* 2006;**15**:635–40. doi:10.1002/pds.1187
- 9 Rashed AN, Wong ICK, Cranswick N, *et al.* Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. *Eur J Clin Pharmacol* 2012;**68**:801–10. doi:10.1007/s00228-011-1183-4
- 10 Thiesen S, Conroy EJ, Bellis JR, *et al.* Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions. *BMC Med* 2013;**11**:237. doi:10.1186/1741-7015-11-237
- 11 de Vries TW, van Hunsel F. Adverse drug reactions of systemic antihistamines in children in the Netherlands. *Arch Dis Child* 2016;**101**:968–70. doi:10.1136/archdischild-2015-310315
- 12 Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral corticosteroids in children. *Arch Dis Child* 2016;**101**:365–70. doi:10.1136/archdischild-2015-309522
- 13 Cliff-Eribo KO, Sammons H, Choonara I. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases. *Expert Opin Drug Saf* 2016;**15**:1321–8. doi:10.1080/14740338.2016.1221921
- 14 Reidenberg MM. Can the selection and use of essential medicines decrease inappropriate drug use? *Clin Pharmacol Ther* 2009;**85**:581–3. doi:10.1038/clpt.2009.10

- 15 Barry PJ, Gallagher P, Ryan C, *et al.* START (screening tool to alert doctors to the right treatment)--an evidence-based screening tool to detect prescribing omissions in elderly patients. *Age Ageing* 2007;**36**:632–8. doi:10.1093/ageing/afm118
- 16 Legrain S others. Consommation médicamenteuse chez le sujet âgé. Consommation, prescription, iatrogénie et observance. 2005. [http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa\\_synth\\_biblio\\_2006\\_08\\_28\\_\\_16\\_44\\_51\\_580.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa_synth_biblio_2006_08_28__16_44_51_580.pdf).
- 17 Beers MH, Ouslander JG, Rollinger I, *et al.* Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. *Arch Intern Med* 1991;**151**:1825–32.
- 18 Naugler CT, Brymer C, Stolee P, *et al.* Development and validation of an improving prescribing in the elderly tool. *Can J Clin Pharmacol J Can Pharmacol Clin* 2000;**7**:103–7.
- 19 Samsa GP, Hanlon JT, Schmader KE, *et al.* A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. *J Clin Epidemiol* 1994;**47**:891–6.
- 20 Laroche M-L, Bouthier F, Merle L, *et al.* Médicaments potentiellement inappropriés aux personnes âgées : intérêt d'une liste adaptée à la pratique médicale française. *Rev Médecine Interne* 2009;**30**:592–601. doi:10.1016/j.revmed.2008.08.010
- 21 Gallagher P, Ryan C, Byrne S, *et al.* STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. *Int J Clin Pharmacol Ther* 2008;**46**:72–83.
- 22 Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. *Age Ageing* 2008;**37**:673–9. doi:10.1093/ageing/afn197
- 23 Gallagher P, Lang PO, Cherubini A, *et al.* Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. *Eur J Clin Pharmacol* 2011;**67**:1175–88. doi:10.1007/s00228-011-1061-0
- 24 Dalleur O, Boland B, Losseau C, *et al.* Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. *Drugs Aging* 2014;**31**:291–8. doi:10.1007/s40266-014-0157-5
- 25 Ryan C, O'Mahony D, Kennedy J, *et al.* Potentially inappropriate prescribing in an Irish elderly population in primary care. *Br J Clin Pharmacol* 2009;**68**:936–47. doi:10.1111/j.1365-2125.2009.03531.x
- 26 Yayla ME, Bilge U, Binen E, *et al.* The use of START/STOPP criteria for elderly patients in primary care. *ScientificWorldJournal* 2013;**2013**:165873. doi:10.1155/2013/165873
- 27 Borges EP, Morgado M, Macedo AF. Prescribing omissions in elderly patients admitted to a stroke unit: descriptive study using START criteria. *Int J Clin Pharm* 2012;**34**:481–9. doi:10.1007/s11096-012-9635-1



- 1  
2  
3 28 Barry PJ, Gallagher P, Ryan C, *et al.* START (screening tool to alert doctors to the right  
4 treatment)--an evidence-based screening tool to detect prescribing omissions in elderly  
5 patients. *Age Ageing* 2007;**36**:632–8. doi:10.1093/ageing/afm118  
6  
7 29 Chrischilles EA, VanGilder R, Wright K, *et al.* Inappropriate medication use as a risk  
8 factor for self-reported adverse drug effects in older adults. *J Am Geriatr Soc*  
9 2009;**57**:1000–6.  
10  
11 30 Dedhiya SD, Hancock E, Craig BA, *et al.* Incident use and outcomes associated with  
12 potentially inappropriate medication use in older adults. *Am J Geriatr Pharmacother*  
13 2010;**8**:562–70. doi:10.1016/S1543-5946(10)80005-4  
14  
15 31 Lau DT, Kasper JD, Potter DEB, *et al.* Hospitalization and death associated with  
16 potentially inappropriate medication prescriptions among elderly nursing home residents.  
17 *Arch Intern Med* 2005;**165**:68–74. doi:10.1001/archinte.165.1.68  
18  
19 32 Hébert G, Prot-Labarthe S, Tremblay M-E, *et al.* La pédiatrie, toujours exclue de  
20 l'innovation pharmaceutique ? *Arch Pédiatrie* 2014;**21**:245–50.  
21 doi:10.1016/j.arcped.2013.12.016  
22  
23 33 Benavides S, Huynh D, Morgan J, *et al.* Approach to the pediatric prescription in a  
24 community pharmacy. *J Pediatr Pharmacol Ther JPPT Off J PPAG* 2011;**16**:298–307.  
25 doi:10.5863/1551-6776-16.4.298  
26  
27 34 Mercier J., Morin L, Prot-Labarthe S. Les erreurs de prescription et leurs conséquences.  
28 2010.  
29  
30 35 Risk R, Naismith H, Burnett A, *et al.* Rational prescribing in paediatrics in a resource-  
31 limited setting. *Arch Dis Child* 2013;**98**:503–9. doi:10.1136/archdischild-2012-302987  
32  
33 36 Choonara I. Rational prescribing is important in all settings. *Arch Dis Child* 2013;**98**:720.  
34 doi:10.1136/archdischild-2013-304559  
35  
36 37 Prot-Labarthe S, Vercheval C, Angoulvant F, *et al.* «POPI ; pédiatrie : omissions et  
37 prescriptions inappropriées ». Outil d'identification des prescriptions inappropriées chez  
38 l'enfant. *Arch Pédiatrie* 2011;**18**:1231–2. doi:10.1016/j.arcped.2011.08.019  
39  
40 38 Prot-Labarthe S, Weil T, Angoulvant F, *et al.* POPI (Pediatrics: Omission of Prescriptions  
41 and Inappropriate Prescriptions): Development of a Tool to Identify Inappropriate  
42 Prescribing. *PLoS ONE* 2014;**9**:e101171. doi:10.1371/journal.pone.0101171  
43  
44 39 European Medicines Agency. Codeine not to be used in children below 12 years for  
45 cough and cold. 2015.<http://www.ema.europa.eu>  
46  
47 40 Gallagher P, Lang PO, Cherubini A, *et al.* Prevalence of potentially inappropriate  
48 prescribing in an acutely ill population of older patients admitted to six European  
49 hospitals. *Eur J Clin Pharmacol* 2011;**67**:1175–88. doi:10.1007/s00228-011-1061-0  
50  
51 41 Beers MH. Explicit criteria for determining potentially inappropriate medication use by  
52 the elderly. An update. *Arch Intern Med* 1997;**157**:1531–6.  
53  
54  
55  
56  
57  
58  
59

- 1  
2  
3 42 O'Mahony D, O'Sullivan D, Byrne S, *et al.* STOPP/START criteria for potentially  
4 inappropriate prescribing in older people: version 2. *Age Ageing* 2015;**44**:213–8.  
5 doi:10.1093/ageing/afu145  
6  
7 43 Nadège Caillère, Céline Caserio-Schonemann. Réseau OSCOUR® (Organisation de la  
8 surveillance coordonnée des urgences) Résultats nationaux 2004/2011. 2011.  
9  
10 44 Rocha CMG, Barbosa MM. QT interval prolongation associated with the oral use of  
11 domperidone in an infant. *Pediatr Cardiol* 2005;**26**:720–3. doi:10.1007/s00246-004-  
12 0922-z  
13  
14 45 Rossi M, Giorgi G. Domperidone and long QT syndrome. *Curr Drug Saf* 2010;**5**:257–62.  
15  
16 46 Djeddi D, Kongolo G, Lefaix C, *et al.* Effect of domperidone on QT interval in neonates.  
17 *J Pediatr* 2008;**153**:663–6. doi:10.1016/j.jpeds.2008.05.013  
18  
19 47 Domperidone: QT prolongation in infants. *Prescrire Int* 2011;**20**:14.  
20  
21 48 Caraballo L, Molina G, Weitz D, *et al.* [Proarrhythmic effects of domperidone in infants:  
22 a systematic review]. *Farm Hosp Organo Of Expresion Cient Soc Espanola Farm Hosp*  
23 2014;**38**:438–44. doi:10.7399/fh.2014.38.5.7957  
24  
25 49 Rochoy M, Auffret M, Béné J, *et al.* [Antiemetics and cardiac effects potentially linked to  
26 prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance  
27 database]. *Rev Epidemiol Sante Publique* 2017;**65**:1–8. doi:10.1016/j.respe.2016.06.335  
28  
29 50 Branchereau E, Branger B, Launay E, *et al.* [Management of bronchiolitis in general  
30 practice and determinants of treatment being discordant with guidelines of the HAS].  
31 *Arch Pédiatrie Organe Off Société Fr Pédiatrie* 2013;**20**:1369–75.  
32 doi:10.1016/j.arcped.2013.09.028  
33  
34 51 Bronchiolitis in children | 1-recommendations | Guidance and guidelines | NICE.  
35 <http://www.nice.org.uk/guidance/NG9/chapter/1-recommendations> (accessed 22 Jun  
36 2015).  
37  
38 52 Conférence de Consensus sur la prise en charge de la bronchiolite du nourrisson.  
39 2000.<http://www.has-sante.fr>  
40  
41 53 Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. *Cochrane Database Syst*  
42 *Rev* 2014;:CD001266. doi:10.1002/14651858.CD001266.pub4  
43  
44 54 *La Revue Prescrire*. 2014. <http://www.prescrire.org/fr/>  
45  
46 55 de Pater GH, Florvaag E, Johansson SGO, *et al.* Six years without pholcodine;  
47 Norwegians are significantly less IgE-sensitized and clinically more tolerant to  
48 neuromuscular blocking agents. *Allergy* 2017;**72**:813–9. doi:10.1111/all.13081  
49  
50 56 Loder E, Weizenbaum E, Frishberg B, *et al.* Choosing wisely in headache medicine: the  
51 American Headache Society's list of five things physicians and patients should question.  
52 *Headache* 2013;**53**:1651–9. doi:10.1111/head.12233  
53  
54  
55  
56  
57  
58  
59

- 1  
2  
3 57 Casucci G, Cevoli S. Controversies in migraine treatment: opioids should be avoided. *Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol* 2013;**34 Suppl 1**:S125-128. doi:10.1007/s10072-013-1395-8
- 4  
5  
6  
7 58 Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. *PAIN®* 2009;**142**:179–82. doi:10.1016/j.pain.2009.01.013
- 8  
9  
10 59 Piazza F, Chiappedi M, Maffioletti E, *et al.* Medication overuse headache in school-aged children: more common than expected? *Headache* 2012;**52**:1506–10. doi:10.1111/j.1526-4610.2012.02221.x
- 11  
12  
13  
14 60 Martinot A, Pruvost I, Aurel M, *et al.* [Improvement in the management of acute diarrhoea in France?]. *Arch Pédiatrie Organe Off Société Fr Pédiatrie* 2007;**14 Suppl 3**:S181-185.
- 15  
16  
17  
18 61 Walker-Smith JA. Management of infantile gastroenteritis. *Arch Dis Child* 1990;**65**:917–8.
- 19  
20  
21 62 Murphy MS. Guidelines for managing acute gastroenteritis based on a systematic review of published research. *Arch Dis Child* 1998;**79**:279–84.
- 22  
23  
24 63 Guarino A, Ashkenazi S, Gendrel D, *et al.* European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. *J Pediatr Gastroenterol Nutr* 2014;**59**:132–52. doi:10.1097/MPG.0000000000000375
- 25  
26  
27  
28  
29  
30 64 Joret P, Prot-Labarthe S, Brion F, *et al.* Caractérisation des indications hors AMM en pédiatrie : analyse descriptive de 327 lignes de prescriptions dans un hôpital pédiatrique. *Pharm Hosp Clin* 2014;**49**:e151–2. doi:10.1016/j.phclin.2014.04.306
- 31  
32  
33  
34 65 Shah SS, Hall M, Goodman DM, *et al.* Off-label drug use in hospitalized children. *Arch Pediatr Adolesc Med* 2007;**161**:282–90. doi:10.1001/archpedi.161.3.282
- 35  
36  
37  
38 66 Ryan C, O'Mahony D, O'Donovan DÓ, *et al.* A comparison of the application of STOPP/START to patients' drug lists with and without clinical information. *Int J Clin Pharm* 2013;**35**:230–5. doi:10.1007/s11096-012-9733-0
- 39  
40  
41  
42 67 Gillespie U, Alassaad A, Hammarlund-Udenaes M, *et al.* Effects of Pharmacists' Interventions on Appropriateness of Prescribing and Evaluation of the Instruments' (MAI, STOPP and STARTs') Ability to Predict Hospitalization—Analyses from a Randomized Controlled Trial. *PLoS ONE* 2013;**8**. doi:10.1371/journal.pone.0062401
- 43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


1  
2  
3 Figure 1. Flow chart indicating the course of the study  
4  
5

6 \* Prescriptions with only one medical device, dietary supplement or hygiene product, ED:  
7  
8 Emergency department  
9  
10

11 Figure 2. Distribution of number of prescriptions according to age category in hospital and  
12  
13 community settings  
14  
15

16  
17 Figure 3. Comparison of PIMs detected in hospital and in outpatient care  
18  
19

20  
21 Figure 4. Total prescription and PIMs in both hospital and outpatient care: Percentage  
22  
23 distribution by age group  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. Flow chart indicating the course of the study. \* Prescriptions with only one medical device, dietary supplement or hygiene product, ED: Emergency department

168x90mm (300 x 300 DPI)




Figure 2. Distribution of number of prescriptions according to age category in hospital and community settings

141x90mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3. Comparison of PIMs detected in hospital and in outpatient care

119x90mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4. Total prescription and PIMs in both hospital and outpatient care: Percentage distribution by age group

344x90mm (300 x 300 DPI)

peer review only



**Appendix 1. Description of inclusion/exclusion criteria, data collected and POPI criteria analyzed among the two cohorts**

	Hospital	Community
Inclusion criteria	Patient under 18 years old Patient with one or more medicine prescriptions	Patient under 18 years old Patient with one or more medicine prescriptions
Exclusion criterion	Inaccessible medical records for patients	Prescription without any drug prescribed
Software extracted	Urqual®	Opus®
Data collected	Age Sex Weight Current diagnosis Number of prescriptions	Age  Number of prescriptions Number of drugs per prescription
Number of POPI items analyzed (among the 102 criteria)	82	28 (items usable for retrospective analysis if no diagnostic available)

**Appendix 2a. Univariate and multivariate analysis to determine factors associated with PIM according to POPI criteria**

Variable	Univariate analysis		Multivariate analysis	
	OR* [CI 95%]	p-value	OR* [CI 95%]	p-value
<b><u>Model 1: Hospital prescription</u></b>				
<b>Sex</b>				
Male	1			
Female	1.1 [0.9-1.3]	0.3		
<b>Age category</b>				
0 - 2 years	2.5 [1.6-3.9]	0.0001	2.5 [1.6-3.9]	< 0.001
2 - 6 years	4.0 [2.5-6.3]	< 0.0001	4.0 [2.5-6.3]	< 0.0001
6 - 12 years	2.2 [1.4-3.6]	0.0016	2.2 [1.4-3.6]	0.0016
12 - 18 years	1		1	
<b><u>Model 2: Community prescription</u></b>				
<b>Age category</b>				
0 - 2 years	0.8 [0.6-1.1]	0.1	0.7 [0.5-1.0]	0.06
2 - 6 years	2.0 [1.5-2.6]	< 0.0001	1.9 [1.4-2.4]	< 0.0001
6 - 12 years	1.9 [1.5-2.4]	< 0.0001	1.9 [1.5-2.5]	< 0.0001
12 - 18 years	1		1	
<b>Number of medications per prescription</b>	1.4 [1.3-1.6]	< 0.001	1.4 [1.3-1.6]	< 0.0001

OR: Odds ratio, CI: Confidence intervals.

**Appendix 2b. Univariate and multivariate analysis to determine factors associated with PPO according to POPI criteria**

Variable	Univariate analysis p		Multivariate analysis	
	OR* [CI 95%]	p-value	OR* [CI 95%]	p-value
<b>Model 1: Hospital prescription</b>				
<b>Sex</b>				
Male	1			
Female	1.1 [0.9 ; 1.3]	0.3053		
<b>Age category</b>				
0 - 2 years	1.1 [0.7 ; 1.6]	0.7703	1.1 [0.7 ; 1.6]	0.7703
2 - 6 years	1.4 [0.9 ; 2.1]	0.0761	1.4 [0.9 ; 2.1]	0.0761
6 - 12 years	1.9 [1.3 ; 2.8]	0.0015	1.9 [1.3 ; 2.8]	0.0015
12 - 18 years	1		1	
<b>Model 2: Community prescription</b>				
<b>Age category</b>				
0 - 2 years	6.1 [2.9 ; 12.7]	<0.0001	6.1 [2.9 ; 12.9]	<0.0001
2 - 6 years	22.4 [11.4 ; 44.1]	<0.0001	22.4 [11.3 ; 44.3]	<0.0001
6 - 12 years	9.8 [4.9 ; 19.6]	<0.0001	10.2 [5.1 ; 20.7]	<0.0001
12 - 18 years	1			
<b>Number of medications per prescription</b>	1.2 [1.1 ; 1.3]	<.0001	1.2 [1.2 ; 1.4]	<0.0001

OR: Odds ratio, CI: Confidence intervals.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	p1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	p2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	p4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	p5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	p6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	p6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	P6 NA
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	p7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	p6-7-14
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	p15
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	p15-16
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P16+figure 1
		(b) Give reasons for non-participation at each stage	Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 2
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	p17

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
2			(b) Report category boundaries when continuous variables were categorized	NA
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Appendix2
5	<b>Discussion</b>			
6	Key results	18	Summarise key results with reference to study objectives	p18
7	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p22
8	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	p22 to 24
9	Generalisability	21	Discuss the generalisability (external validity) of the study results	p24
10	<b>Other information</b>			
11	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	p26

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.